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1. PARKINSON’S DISEASE 
Neurodegenerative disease is a term that covers a range of conditions that 
primarily affect the neurons of the central nervous system (CNS). Given that 
neurons normally do not reproduce or replace themselves when they become 
damaged or die, they cannot be easily replaced by the body. 
Neurodegenerative diseases are incurable and debilitating conditions that 
result in progressive degeneration and / or death of nerve cells. This causes 
motor problems (called ataxias) or mental dysfunction (called dementias). In 
the modern world these diseases are increasing in morbidity and mortality. The 
World Health Organization (WHO) has predicted that by year 2030 the 
population suffering dementia will double, representing over 70 million people 
worldwide (Dementia: a public health priority, 2012(Anon 2016)). In the same 
way, the number of cases of Parkinson’s Disease (PD) is expected to continue 
increasing, reaching 8.7 million people by 2030 (doubling the estimated 
number of cases in 2005) (Dorsey et al. 2007). Indeed, 1.2 million people were 
estimated to be affected by PD in 2010 in Europe and 79,000 only in Spain, 
representing a total estimated cost of 14,000 million and 1,800 million euros, 
respectively (Olesen et al. 2012; Parés-Badell et al. 2014). Moreover, Dementia 
with Lewy Bodies (DLB) represents ca. 20% of all the cases of dementia as 
determined by autopsy (McKeith et al. 2003), while Multiple System Atrophy 
(MSA) presents a prevalence of 4-5 cases per 100,000 people in the European 
Union, but about 8-10% of patients with Parkinsonism will eventually develop 
MSA. Therefore, a higher prevalence than that estimated can be assumed 
(Longo et al. 2015). Due to the increased life expectancy and population 
demography changes (i.e. increase in the rate of aging groups) 
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(Brookmeyer et al. 1998; Samii et al. 2004). Therefore, the understanding of the 
mechanisms involved in these disorders is becoming crucial for the 
development of new therapies and approaches to fight with the staggering 
personal, social and economic costs of these diseases. 
From the increasing understanding of the pathophysiology of several of these 
neurodegenerative diseases during the last two decades, a common pathogenic 
mechanism has been pointed out: the accumulation and deposition of specific 
insoluble aggregates of misfolded proteins in particular regions of the brain, 
such as Amyloid-β (Aβ) and tau in Alzheimer Disease’s (AD), Superoxide 
dismutase-1 (SOD1) and TDP-43 in Amyotrophic Lateral Sclerosis (ALS) or 
huntingtin in Huntington’s Disease (HD). In the same way the so called α-
synucleinopathies comprise progressive neurodegenerative diseases, including 
PD, DLB and MSA, with the major pathological hallmark being α-Synuclein 
(aSyn) inclusions in neuronal and/or glial cells. Another shared aspect of these 
diseases is the appearance of microgliosis, i.e. the presence of activated 
microglia and proinflammatory mediators, such as citokines and chemokines, in 
the brain of patients; initially seen in postmortem brains (Imamura et al. 2003; 
Mirza et al. 2000) and now extensively confirmed by Positron Emission 
Tomography (PET) in living patients (Gerhard et al. 2003; Gerhard et al. 2006; 
Iannaccone et al. 2013). Despite all the accumulating knowledge, the exact 
pathogenic mechanisms remain unclear. Indeed, all the accumulated data 
pointing to different -sometimes even opposing - directions, support the 
current view that these diseases are extremely complex disorders with multiple 
pathogenic mechanisms. And maybe that is the reason why we still lack 
effective therapies for these diseases. 
As aforementioned, the synucleinopathies have in common the accumulation 




Outeiro 2012). However, these inclusions appear in different locations and cell 
types depending on the specific disease. Cytoplasmic neuronal inclusions highly 
enriched in aggregated aSyn, known as Lewy bodies (LB) and dendritic or 
axonal Lewy neurites are key features in these diseases. Mainly present in 
Substantia Nigra pars compacta (SNpc) in PD and in cerebral cortex in DLB 
(Ferman & Boeve 2007; Spillantini et al. 1998), while the cytoplasmic aSyn 
filament inclusions in oligodendrocytes are characteristic in MSA (Tu et al. 
1998; Wakabayashi et al. 1998). In addition, extensive aSyn staining has been 
detected in corticospinal axon tract fibers and glia in brain and spinal cord of 
ALS cases (Doherty et al. 2004), while aSyn has also been identified as a 
component of amyloid brain tissues in AD patients (Hamilton 2000; Hansen et 
al. 1990) and higher levels of non-aggregated aSyn have been measured in 
Cerebrospinal Fluid (CSF) of AD patients (Korff et al. 2013) 
The connection between aSyn and the pathology of PD started in the late 90’s 
when a single missense mutation in the aSyn gene, now known as A53T, was 
related with an autosomal dominant form of hereditary PD (Polymeropoulos et 
al. 1997). Soon after, the aSyn was identified as the major component of LB 
(Spillantini et al. 1998). Later on, two other missense mutations were also 
associated with early-onset, familiar cases of PD, A30P and E46K (Kruger et al. 
1998; Zarranz et al. 2004). And more recently, three new missense mutations 
have been also identified: H50Q, G51D and A53E (Appel-Cresswell et al. 2013; 
Proukakis et al. 2013; Fares et al. 2014; Lesage et al. 2013; Pasanen et al. 2014). 
At the same time, the presence of two or three copies of the wild-type aSyn 
gene were linked to early-onset, familiar cases of PD (Chartier-Harlin et al. 
2004; Singleton et al. 2003). Moreover, animal models based on wild-type aSyn 
overexpression (Masliah et al. 2000; Rockenstein et al. 2002) as well as early 
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Neumann et al. 2002) display a wide range of pathological features and motor 
symptoms resembling those observed in human patients (Extensively reviewed 
in Crabtree & Zhang 2012). Accordingly, all these evidences originally pointed 
to a pivotal role of aSyn in the pathophysiology of PD. 
2. ALPHA-SYNUCLEIN 
aSyn (together with β- and γ-synucleins) belongs to the family of the synucleins, 
a group of closely related, brain-enriched proteins. This 140 aa-residue protein 
is largely located in neuronal presynaptic terminals (Kim et al. 2004) and in the 
nucleus (Yu et al. 2007) of dopaminergic neurons, as well as within astrocytes, 
microglia and oligodendroglia (Austin et al. 2006; Mori et al. 2002; Richter-
Landsberg et al. 2000). In particular, it is found in the neocortex, hippocampus 
and SN (Kim et al. 2004) and in other brain regions. ASyn belongs to a group of 
proteins described as natively/intrinsically unfolded proteins (Weinreb et al. 
1996), meaning that it does not adopt a well-defined globular structure, but 
instead a broad ensemble of dynamically interacting and largely disordered 
conformations. This unfolded nature makes aSyn capable of interacting with a 
wide range of proteins (indeed more than 50 proteins have been identified to 
interact with aSyn (Breydo et al. 2012)) as well as with lipid membranes (Jo et 
al. 2000; Pirc & Ulrih 2015; Lai et al. 2014). Indeed, its promiscuous properties 
have made difficult the identification of the certain physiological properties. 
Even though aSyn functions remain to be completely understood, it has been 
found to play a role in the regulation of the synaptic vesicle pool, acting as an 
activity-dependent negative regulator of vesicle release (Murphy et al. 2000; 
Nemani et al. 2010) and, on the other hand, to be a positive regulator of the 
synaptic transmission by modulating the late steps of exocytosis (Chandra et al. 
2005; Burré et al. 2010). Furthermore aSyn regulates brain lipid metabolism 




directly related with the dopaminergic system, aSyn has been found to be 
implicated in the dopamine (DA) metabolism network. First, aSyn interacts and 
has an inhibitory effect on the enzyme Tyrosine hydroxylase (TH), the rate-
limiting enzyme in the DA synthesis chain (Perez et al. 2002). Moreover, aSyn 
interacts with PP2A (a serine phosphatase), thereby promoting its activity and 
changing the balance of the TH from the phosphorylated, highly active form to 
the non-phosphorylated, less active form (Peng et al. 2005). And finally, aSyn 
can inhibit aromatic amino acid descarboxylase wich definitely converts the 
inactive metabolite L-DOPA into the active neurotransmitter DA (Tehranian et 
al. 2006). 
Currently, there is considerable accumulated evidence indicating a principal 
role of aSyn in the etiology of PD, in which the conversion of aSyn from soluble 
monomers to soluble oligomers and, ultimately, into aggregated amyloid-like 
insoluble fibrils is a key event in PD pathogenesis (Chiti & Dobson 2006). Indeed 
the amyloid fibrils, that are the main component of the aforementioned LB and 
Lewy neurites, share physicochemical properties with those found in AD and 
other amyloid related diseases e.g. rich β-sheet structure, specific staining, etc. 
(Reviewed in (Chiti & Dobson 2006)). Firstly the amyloid fibrils were seen as the 
main neurotoxic molecular species. But accumulating evidences showing the 
toxicity of aSyn oligomers shifted this perception (Roodveldt et al. 2012; Kalia & 
Kalia 2015). However, the cellular and molecular mechanisms underlying the 
pathological actions of aSyn are still not completely understood. 
Traditionally, aSyn has been viewed as an exclusively intracellular, cytoplasmic 
protein that is highly expressed in dopaminergic neuronal cells. However later 
studies have shown that aSyn is also normally present in extracellular biological 
fluids, including human CSF(extensively reviewed and analysed in (Gao et al. 
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2016; Shi et al. 2014). Shi and colleagues found that aSyn is actually transported 
from CSF to blood plasma and importantly part of these aSyn is associated with 
CNS specific exosomes; interestingly they found increased levels of these CNS 
exosome associated aSyn in plasma from PD patients relative to controls and 
that these levels correlated with disease severity(Shy et al 2014). Furthermore 
novel techniques have provided tools to better measure total levels of aSyn in 
plasma, in order to solve results heterogeneity; in this way, increased total-
aSyn and phopho-serine 129-aSyn levels have been found in plasma from PD 
patients compared to healthy subjects (Yang et al. 2016; Stewart et al. 2015; 
Wang et al. 2012). Moreover, El-Agnaf and colleagues showed an elevated 
content of oligomeric aSyn species in plasma from PD patients compared to 
controls (El-Agnaf et al. 2006). On the other hand, while lower levels of total 
aSyn than normal have been largely described in CSF from PD patients, other 
studies show increased levels of oligomeric aSyn and consequently oligomeric 
aSyn/total aSyn ratio in the CSF from PD (Gao et al. 2014; Zhou et al. 2015). In 
addition, elevated aSyn staining have been found in several post and ante 
mortem PD patient tissues, including Gastro intestinal tract, Heart , Salivary 
gland  and Vagus nerve (Beach et al. 2013; Ghebremedhin et al. 2009; Del 
Tredici et al. 2010; Cersósimo et al. 2011). All these findings seem to indicate 
that changes in the levels and characteristics of extracellular aSyn are 
associated with the disease progression and prognosis.  
Even though membrane permeability from dying cells was thought to be one 
contributing source, it was recently demonstrated that the main source of 
extracellular aSyn are actually healthy intact cells (Ulusoy et al. 2015). Two 
main mechanisms have been proposed, the principal one thought to be 
through ER/Golgi independent, non-classical exocytosis (Lee 2008; Jang et al. 




associated to vesicles (Emmanouilidou et al. 2011; Kunadt et al. 2015). 
Moreover, the release of aSyn can be enhanced upon exposure to several cell 
stressors, such as oxidative stress (Jang et al. 2010; Tyson et al. 2016). On the 
other hand, extracellular aSyn has been shown to be taken up by neuronal and 
microglial cells in vitro and in vivo (reviewed in (Tyson et al. 2016). Although the 
nature of the mechanism involved is still controversial, aSyn has been shown to 
enter the cells by simple diffusion (Lee et al. 2008) and by active endocytosis 
(Sung et al. 2001; Hansen et al. 2011; Holmes et al. 2013). In addition, recent 
studies have provided strong evidence for a neuron-to-neuron and neuron-to-
non-neuronal cell transmission of aSyn aggregates and their associated 
cytotoxicity, in cellular and mouse models of PD (Dehay et al. 2015; George et 
al. 2013; Vermilyea & Emborg 2015), pointing to a prion-like property of aSyn 
aggregates (Reviewed in (Tyson et al. 2016; Emmanouilidou & Vekrellis 2016)) 
and highlighting the importance of extracellular aSyn in the pathogenic 
mechanism of α-synucleinopathies (Lim et al. 2016).  
Biochemical studies have shown that the ensemble of aSyn conformers is 
perturbed by early-onset related mutations (Lázaro et al. 2014). Conversely, all 
the familiar PD related mutations do not show the same perturbed 
characteristics, while E46K, A53T, A30P and H50Q variants show increased 
oligomer formation rates, A53E and G51D show decreased aggregation rates (Li 
et al. 2001; Fredenburg et al. 2007; Fares et al. 2014; Ghosh et al. 2014). In 
addition, A30P shows delayed fibril formation (Li et al. 2001) and, together with 
A53T, A53E and G51D, impaired membrane binding  (Fares et al. 2014; Ghosh 
et al. 2014). Presumably as a result of the differences in their structural, 
biophysical and biochemical characteristics, the different variants have been 
reported to have different cytotoxic effects, and this cytotoxicity to be 
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Nevertheless, the factors contributing to both familial and sporadic cases of PD 
are far from being understood. 
3. IMMUNE SYSTEM 
The Immune system (IS) comprises an ensemble of cells, tissues and organs 
organised to protect our body from potential harmful agents. One of the key 
features of the IS is its capacity to discriminate between self and non-self, and 
even to detect when “self” is also harmful (i.e. cancer).  Generally the IS can be 
differentiated into two sub-systems known as Innate immune system and 
Adaptive immune system. The Innate IS provides the first line of defence and it 
is independent from previous contacts with the pathogen; by contrast the 
Adaptive IS provides a long lasting immunity against pathogens due to its 
capacity to develop a named ‘immune memory’. This capacity allows the 
system to perform a more efficient response against subsequent exposures to 
the same antigen. The Innate response could define the profile of the adaptive 
response while the adaptive response could, after its activation, secrete 
mediators that will affect the innate system, activating or inhibiting its activity.  
The innate IS is mostly built up of myeloid cellular components. In addition, it is 
characterized by a fast response against pathogens and by a similar response 
against the same agent upon different exposures. Pathogen recognition is 
carried out by the identification of the so-called Pathogen Associated Molecular 
Patterns (PAMPs), which are molecular moieties or structures highly conserved 
among a wide range of microorganisms. These PAMPs are recognized by 
receptors known as Pattern Recognition Receptors (PRR), present in all the 
innate IS common cell types: neutrophils, eosinophils, basophils, macrophages, 
mastocytes and dendritic cells (Medzhitov & Janeway  Jr. 2002; Akira et al. 
2006). As a result of the recognition of the PAMPs by the PRR, a cascade of 




inflammatory cytokines, chemokines, interferons (IFNs) and co-stimulatory 
molecules (Medzhitov & Janeway  Jr. 2002; Akira et al. 2006), while the exact 
response profile will depend on the pathogen being recognised. Thus far, three 
families of PRR have been identified: C-type Lectin Receptors, Nod-like 
Receptors and Toll-like Receptors (TLRs) (Iwasaki & Medzhitov 2010; Trinchieri 
& Sher 2007). It is important to mention that the expression of these PRRs it is 
not exclusive for innate IS cells but has also been detected in several other cell 
types, including adaptive IS cell types such as B and T cells, which have been 
found to express TLRs.  
TLRs sensing function has demonstrated to be a key point in the initial stages of 
pathogen identification. TLRs are essential for the correct control and inhibition 
of the early proliferation of pathogens as well as for recruitment and further 
activation of necessary elements belonging to adaptive IS. They also play a 
critical role in the identification of so-called ‘Damage Associated Molecular 
Patterns’ (DAMPs) derived from tissue damage, produced either as a result of 
pathogen invasion, or to be caused by the action of the IS itself or by other 
processes (i.e. tumour invasion or traumatic injury). TLRs are type1 
transmembrane proteins which are evolutionary conserved from insects to 
vertebrates. To date 13 different TLR gene products in mammals and 11 in 
humans, have been identified (Akira et al. 2006; Bauer et al. 2009). 
As sensors of common pathogenic components, TLRs develop several key 
functions in the important intersection between innate and adaptive immune 
systems. For instance, TLRs can induce a signalling cascade that consequently 
determines the maturation of dendritic cells, secretion of pro-inflammatory 
cytokines and the further induction and polarization of the adaptive immune 
response. Except for TLR3, all the TLRs employ the adaptor protein MyD88 to 
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cognate ligands, MyD88 recruits different proteins that ultimately result in the 
production of pro-inflammatory cytokines through the induction of the 
transcription factor κB (NFκB) pathway (Lehnardt 2010). 
In addition, TLR family members can be divided into two subgroups depending 
on their subcellular localization: cell surface receptors (TLR-1, 2, 4, 5 and 6), 
mainly involved in the recognition of structures present in bacteria or fungi; 
and intracellular compartment receptors (TLR-3, 7, 8 and 9), primarily involved 
in the recognition of viral or bacterial nucleic acids. The correct cellular location 
of TLRs is thought to be of key importance for their function. First of all, the 
location compartment affects the proper accessibility to antigens while the 
environment could also determine the recognition; it is known that the 
interaction between nucleic acids and TLR-3, 7 and 9 depends on the acidic pH 
only reached inside endolysosomes (Blasius & Beutler 2010). And secondly the 
correct compartmentalization of the TLRs is thought to be essential for 
maintenance of self-tolerance, keeping self-antigens inaccessible for TLR 
recognition (Kawai & Akira 2010). Moreover, the function of TLRs depends on 
receptor complexes formed with other proteins and this property can 
determine the exact response provided against each antigen. Moreover, the 
formation of receptor complexes could explain, at least in part, differences 
observed between responses elicited by different antigens that bind same TLR 
and between responses produced by an antigen on different cell types. For 
instance, TLR4 needs the presence of the co-receptor MD2 to generate its 
response. However, some cell types also express homologue MD1, and as a 
result the response against bacterial lipopolysacharide (LPS) could be 
modulated, generating a non-canonical downstream signalling response 
(Gorczynski et al. 2006). In the same way, TLR2 can recognise the broadest 




specifically TLR1/TLR2 dimers are responsible of recognising triacylated 
lipopeptides from gram-negative bacteria and mycoplasma, while TLR2/TLR6 
dimers recognise diacylated lipopetides from gram-negative bacteria and 
mycoplasma. 
Although it is correct to say that TLRs have evolved to recognise pathogenic, 
foreign structures, as far as mammals and specifically humans, do not produce 
flagelin or lipoteichoic acids (Medzhitov & Janeway  Jr. 2002), accumulating 
evidence showing the recognition of endogenous molecules by different TLRs 
point to another growing theory that holds that, further to its known functions, 
the Immune System has evolved also to detect and respond to endogenous 
danger signals (Seong & Matzinger 2004). Nowadays several endogenous 
proteins and molecules have been identified to bind and be recognised by the 
TLRs and other innate IS receptors. As we have said, the correct 
compartmentalization of TLRs is essential for their function, by avoiding the 
contact between TLRs and possible self-antigens. However, under some 
situations, e.g. cell necrosis or traumatic tissue damage, the cell content could 
be released to the extracellular milieu. Under these scenarios, molecules that 
normally are not able to interact with TLRs become available and could be used 
as DAMPs by the IS in order to respond to damage. In spite of the fact that 
activation of the IS in response of these DAMPs could be of benefit, cleaning 
the damaged tissue and liberating trophic factors and consequently promoting 
tissue repair, in some cases it could degenerate and become deleterious.  
In fact, all the accumulating knowledge about the signalling pathways related to 
TLRs has provided a growing field of potential therapeutic strategies in order to 
properly modulate possible pathological responses. (Liu et al. 2010; Takeda & 
Akira 2004; Romagne 2007; Kato et al. 1994). However, it is also important to 
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signalling has been related with highly deleterious immune-depressed state 
(Akira et al. 2006). 
Table TLR ligands (Jiménez-Dalmaroni et al. 2016) 










positive bact.) di-acylated 
and tri-acylated bacterial 
lipopetides 
Hsp60, Hsp70, Hsp90, HMGB-
1, Gp96, Biglycan, SP-D 
TLR4 LPS (Gram-negative bact.) Biglycan, Hsp60, Hsp70, Hsp90, 
Fibrinogen, Fibronectin, 
Hyaluronic acid, OxLDL (assoc. 
With TLR6), β-Amyloid (assoc 
with TLR6) 
TLR5 Flagelin ?  
TLR3 dsRNA (virus) mRNA (necrotic cells) 
TLR7 ssRNA ssRNA, Imiquimod 
TLR8 ssRNA ssRNA, µRNA 
TLR9 CpG motif (Bact. And virus) Self DNA 
 
3.1 IMMUNE SYSTEM INSIDE THE CENTRAL NERVOUS SYSTEM 
For decades, the CNS was considered as an immune privileged organ, primarily 
due to the presence of the Blood Brain Barrier (BBB). The BBB is a highly 




junctions and astrocytes that surround the CNS vascular system (Chow & Gu 
2015). This structure can limit the presence inside the brain of most of the IS 
actors, i.e. preventing the pass of Lymphocytes, antibodies and/or complement 
proteins (Ransohoff & Engelhardt 2012; Daneman & Prat 2015) . As an 
example, antigen presentation is a key process in the immune response against 
invading pathogens. But this process was thought to be limited or inexistent 
inside the CNS due to the presence of the BBB. Firstly, antigen presentation 
requires the action of the Antigen Presenting Cells (APCs). These cells are 
capable of phagocytosing and processing micro-organisms and foreign 
molecules, and present them as antigenic peptides together with the class II 
major histocompatibility complex (MHC-II), on its cell surface. Different APCs 
exist most tissues in order to sense the corresponding organs to detect invading 
pathogens. Upon activation, APCs are able to engage and activate T cells inside 
local lymphatic draining glands. After its activation, T cells start proliferating 
and, upon gene rearrangement, they differentiate by increasing its affinity for a 
concrete antigen. These processes permit further re-stimulations against future 
re-exposures, the named immune memory. However, the view of the CNS as an 
Immune privileged system has been widely confronted and reviewed. Indeed a 
growing body of evidence point to the CNS as a target of several immune 
disturbances mediated by diverse mechanisms (Lehnardt 2010; Louveau et al. 
2015; Guerriero et al. 2016; Vieira et al. 2015; Surendranathan et al. 2015; 
Wang et al. 2016). To support this statement, there are several observations: 
first of all, astrocytes, microglia and endothelial cells, all of them CNS 
constituent cells, have been found to be able to express MHC-II molecules on 
their cell surface and to be recognised by CD4+ T cells, while neurons are able to 
express MHC-I, recognizable by CD8+ T cells. Secondly, we now know that 
microglia and astrocytes can act as APCs in the CNS (Gimsa et al. 2013; Michell-
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to cervical lymph nodes (Weller et al. 2010) and more recently the presence of 
lymphatic vessels on the surface of the human brain has been demonstrated 
(Louveau et al. 2015; Aspelund et al. 2015). As a consequence, the actual 
degree of sealing of the BBB is currently under much debate (Su & Federoff 
2014; Heneka et al. 2015). 
As aforementioned, the BBB surrounds all CNS vascular systems. However, 
some areas of the CNS are considered BBB-free areas, such as the choroid 
plexus blood-CSF barrier and the outer CFS-brain barrier, the Pia Arachnoid. 
Moreover, under neural inflammatory insult the tight junctions of the BBB are 
known to suffer a rearrangement that permits peripheral lymphocytes to cross 
the BBB entering the brain (Stolp et al. 2013), again in direct opposition to the 
immune-privilege status of the CNS. In addition, the BBB has been 
demonstrated to show in its surface different receptors and transporters that 
enable the capacity to sense the environment. Consequently, the BBB is 
without any doubt essential not only for the maintenance of homeostasis inside 
the brain parenchyma, but also as a key ruler in neuro-inflammatory processes, 
regulating the proper entry of IS mediators inside the CNS, such as 
lymphocytes, cytokines, chemokines and/or antibodies (Daneman & Prat 2015; 
Chow & Gu 2015). 
Under pathological conditions, increased amount of immune cells, e.g. B and T 
Lymphocytes, can be found inside the meninges and the CSF. As a result, these 
cells can access the brain parenchyma, crossing the BBB. As aforementioned, 
the BBB regulates the proper transit of molecules and cells throughout cerebral 
vascular system, and this function is essential for the maintenance of the 
cerebral homeostasis. Actually, the dysregulation of the BBB traffic has been 
associated with certain pathologies. One example is multiple sclerosis, in which 




common characteristic in a large number of patients (Antel & Owens 1999; 
Adams et al. 1989; Prineas & Wright 1978). Taken together, these observations 
point to the importance of studying the mechanisms that control the migration 
of cells, and particularly IS mediator cells, throughout the BBB (Daneman & Prat 
2015; Su & Federoff 2014; Heneka et al. 2015).  
As for the rest of our system, in the Nervous System, cytokines are part of the 
machinery responsible of the correct activation, proliferation, differentiation 
and they ultimately define the phenotype of different cell types. Moreover, 
they participate in inflammatory response, tissue remodelling and repair 
mechanisms. Importantly, two essential features of cytokines are their 
pleiotropism, which means that one cytokine can display different effects in 
different cell types or different scenarios; and their redundancy, meaning that 
different cytokines can elicit the same response. Inside the CNS, astrocytes and 
microglia cells are the principal sources of cytokines(Hanisch 2002; Dong & 
Benveniste 2001). Although other cells have been documented to produce 
cytokines under certain circumstances, for example oligodendrocytes and 
Schwann cells (Zeis et al. 2015; Scheib & Höke 2016) 
Cytokines are involved in complex signalling networks between Nervous System 
and IS. Accordingly, cytokines secreted by astrocytes or microglial cells are 
capable of spreading the inflammatory response, for example recruiting IS 
mediator cells such as lymphocytes. On the other hand, the IS has tools to self-
control the response in order to limit and control the inflammatory response 
after accomplishing its function. That is, for instance, the existence of cytokines 
with inhibitory or regulatory functions; e.g. IL-10. However, when these self-
limiting mechanisms fail, or turn out dysregulated, the whole system could fall 
into a pathological state. Certainly, the suppression or the spread of the 
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activation state of the cells, defined by their expression of different factors such 
as cytokine receptors, both pro and anti-inflammatory, which determine the 
effective susceptibility to stimulation; b) the concentration and exact 
localization of cytokines, both pro and anti-inflammatory; c) the temporal 
sequence of the exposition to these cytokines by each group of effector cells. 
Therefore, the interaction of all these complex factors will result in the ultimate 
response generated. 
As mentioned earlier, microglia cells are the resident macrophages of the CNS. 
So they represent the first line of defence against foreign agents. As 
components of the innate IS they express large numbers of PPRs, and 
specifically TLRs, to recognise possible foreign agents (Lehnardt 2010; Kawai & 
Akira 2010). Furthermore, the TLR system has been related with either 
neuroprotective processes or neurodegenerative diseases, highlighting the 
crucial importance of completely understanding this system(Jiménez-Dalmaroni 
et al. 2016; Kawai & Akira 2010; Alvarado & Lathia 2016). 
Under non-pathologic insult, microglia rest quiescent with a characteristic 
morphology with long and ramified processes. However, microglia can become 
active under several conditions leading to a neuro-inflammatory scenario: 
Nervous System infections, neural injury and neurodegenerative diseases 
among others (Jin & Yamashita 2016; Hu et al. 2015). Upon activation, 
microglial cells change their morphology to an amoeboid state characterised by 
enlarged soma with less and sorter ramifications. In addition they acquire 
phagocytic capacity and start producing and secreting numerous cytokines and 
chemokines. Moreover, after activation microglia cells increase the surface 
expression of important receptors like MHC-II involved in antigen presentation 
function (Aloisi 2001; Lehnardt 2010; Glass et al. 2010; Jin & Yamashita 




activities, inside the nervous system there are different overlapping ways 
operating to fine control this process under physiological conditions.  
As has been noted, microglia cells main function is to sense the neuronal tissue 
to detect damage or foreign agent’s invasion, but they also show an important 
restorative capacity. As a consequence of all these processes, microglia is 
capable of eliminating parenchymal residues and promoting neuronal healing 
(Lehnardt 2010; Aloisi 2001; Jin & Yamashita 2016). Conversely, under certain 
neurodegenerative pathologies, the control network fails, resulting in neuronal 
damage. In addition, the same mediators have been related with both 
processes. As explained earlier, pro-inflammatory mediators such as TNF-α, IL-
1, IL-6, IL-12, IL-18; chemokines like IL-8, MIP, MCP o RANTES; and even 
immune modulatory cytokines like IL-10 or TGF-β mediate in the inflammatory 
process under physiological conditions. By contrast, different processes, most 
of all currently unknown, can lead to a dysregulation of the normal response 
networks and can be related with neurodegenerative diseases (Jin & Yamashita 
2016; Heneka et al. 2015; Hu et al. 2015). 
Recent findings have demonstrated the importance of the IS and the 
inflammatory response, as a factor that can promote, and even expand, 
neuronal damage associated with CNS chronic diseases. For example the role of 
the IS in the progression of AD (Richards et al. 2016; Heneka et al. 2015; Brück 
et al. 2016), and importantly PD that will be discussed later. In addition this 
relation has been reported in acute diseases, like cerebral stroke (Kaur & Ling 
2008). In fact, some of best known neurological diseases, such as ALS or MS, 
share the implication of IS activation as a primary ruler on the development of 
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Although we have been speaking about active microglia, nowadays we know 
that the activation of monocyte/macrophages covers a wide range of different 
polarized states. On the one hand, we have the so-called M1 activation state. 
Firstly described in 1962 by Mackaness, the M1 or classical activation state is 
the one normally associated with inflammation and pro-killing 
activities(Mackaness 1962). The M1 state is characterized by its secretion of 
cytokines, chemokines and surface marker expression profile. Commonly, M1 
macrophages secrete pro-inflammatory cytokines such as TNF-α, IL-6, IL-12 and 
IL-1β, and chemokines, such as CCL2 and CXCL10. They also express the active-
related markers MHC-II and CD86 on the surface, while they increase the 
expression of the inducible pro-inflammatory-related form of the nitric oxide 
synthase enzyme iNOS (Nau et al. 2002; Martinez et al. 2006). As expected, to 
induce this ‘classical active’ state the paradigmatic stimuli are IFN-γ and the 
activation though the TLRs family by their known cognate agonists, e.g. LPS 
recognition by TLR-4 (Hu & Ivashkiv 2009). On the other hand, we have the 
activation state generally associated with immune modulation and healing. As 
opposed to the more specific M1 state, the M2 phenotype, also called 
‘alternative activation’ state, has been related with a much broader range of 
profiles, and therefore it has been divided into three subtypes. The first one 
described was the M2a state, primary related to host defence against parasites 
and allergy. Its paradigmatic stimulus is the Th2 emblematic cytokine IL-4. The 
M2a state is characterized by the expression of IL-10 (common to all M2 states) 
and polyamines, the surface expression of CD206 and importantly used as a 
marker, the cytosolic expression of Arginase 1 (Arg1). Secondly, related to 
upregulated phagocytosis and immune modulation, we have M2b state. 
Commonly induced by the activation of the TLR system followed by IgG 
constant domain, the M2b is characterised by large secretion of IL-10 and low 




accompanied by the surface expression of CD86 (Sánchez-Mejorada & Rosales 
1998; Takai 2005; Edwards et al. 2006). And finally we have the M2c state, most 
related with tissue repair and deactivation of M1/Th1 immune responses 
(Fiorentino et al. 1989; Glocker et al. 2009). The most paradigmatic inducer of 
this state is the immune-modulatory cytokine IL-10, interestingly secreted by all 
the other two states. The activation of the M2c state is accompanied by the 
secretion of IL-10, CXCL13, CXCL4 and matrix proteins (Park-Min et al. 2005). In 
conclusion M2 in opposition to M1 lead to a broader range of responses while 
all of them are related with immune modulatory actions. Despite the fact that 
microglia has a different embryonic origin than monocyte/macrophages, the 
M1/M2 paradigm has been proposed to be similar in microglia and 
macrophages (Durafourt et al. 2012), introducing an interesting field of 
research that is currently under focus (Extensively reviewed in (Moehle & West 
2014; Hu et al. 2015)). 
3.2 NEUROINFLAMMATION IN PARKINSON’S DISEASE 
As we have largely mentioned above, the active role of the IS in most 
neurodegenerative diseases has been extensively shown. Specifically, in the last 
few years, it has become evident that the immunological component is of 
central importance in PD pathogenesis and progression. Certainly, the presence 
of a robust inflammatory response mediated by activated microglia and 
reactive astrocytes in affected areas of the SNpc is an important pathological 
feature in PD brains (Brück et al. 2016). Indeed, inflammation in the CNS and 
sustained over-activation of microglia, i.e. reactive microgliosis, are currently 
believed to be actively involved in the pathogenesis of various 
neurodegenerative diseases including PD, AD, MS, ALS (Gao & Hong 2008; Glass 
et al. 2010; Kim & Joh 2006; Long-Smith et al. 2009; Heneka et al. 2015; 
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ultimately protects or actually exacerbates neuronal loss in the context of PD 
and other related diseases had been under strong debate (Delgado & Ganea 
2003; Gao & Hong 2008; Halliday & Stevens 2011; Sánchez-Pernaute et al. 
2004; Vila et al. 2001; Wu et al. 2002; Wyss-Coray & Mucke 2002; Wu et al. 
2014; Chen et al. 2016). Evidence of microglial attack and neuroinflammation in 
PD is supported by findings from epidemiological studies, animal models, and 
cell culture experiments (Allen Reish & Standaert 2015; Kannarkat et al. 2013). 
The first evidence of microglial implication in PD was the finding of active 
microglial cells surrounding degenerating dopaminergic neurons in SNpc of PD 
patient’s post-mortem brains (McGeer et al. 1988). Since in vivo PET imaging 
has confirmed the presence of active microglia in active degenerating sites and 
furthermore, this presence directly correlates with PD severity both clinically 
and pathologically (Ouchi et al. 2005). In the same way, several molecular 
inflammatory mediators such as cytokines and chemokines have been found to 
be upregulated in post-mortem brains and in CSF and blood serum of PD 
patients. Specifically, IL-1β, IL-6, TNF-α and IFN-γ are increased in brains and 
fluids from PD patients compared to controls (Brodacki et al. 2008; Blum-Degen 
et al. 1995; Mogi, Harada, Riederer, et al. 1994; Mogi, Harada, Kondo, et al. 
1994). Importantly Kuziorowsky and co-workers found a direct correlation 
between IL-6 levels and disease severity (Koziorowski et al. 2012)(Kuziorowsky 
et al 2012) while dopaminergic neurons have shown to be more sensitive to 
proinflammatory cytokines like IFN-γ and TNF-α (Tansey & Goldberg 2010). In 
addition, epidemiological studies have revealed that taking ibuprofen anti-
inflammatory agent regularly is associated with lower risk of developing PD (X. 
Gao et al. 2011; Samii et al. 2009). Taken together, all these findings support 
the concept that inflammatory attack is contributing to dopaminergic neuronal 
loss. Although currently it is not stablished whether the implication of the IS is 




to note that the activation of the IS has been found to occur prior to neuronal 
loss in different animal models (Chung et al. 2009).  
At the moment, two major groups of PD animal models are available: Toxin-
based models like MPTP, 6-OHDA or Rotenone, and Transgenic animal models, 
which are based on the over-expression of aSyn. In both groups, microglia has 
been found to be in activated state (McGeer et al. 2003; Akiyama & McGeer 
1989; Sherer et al. 2003; Theodore et al. 2008; Harms et al. 2013; Chung et al. 
2009; Watson et al. 2012), while the suppression of the inflammatory response, 
either by anti-inflammatory drugs or by inhibiting key proinflammatory 
mediators, is capable of ameliorating and even completely inhibiting neuronal 
loss (Du et al. 2001; Harms et al. 2011; Tanaka et al. 2013). Moreover, it has 
been recently reported that treatment with CSF from PD patients strongly 
affects cultured microglial cells, resulting in reduced cell growth, morphological 
changes, as well as increased content and aggregation of aSyn (Schiess et al. 
2010). This illustrates how microglia itself, and not only dopaminergic neurons, 
can be highly affected by the medium in a PD scenario. The current picture is 
that microglial-mediated inflammation could have a dual effect, as seems to 
happen in other neurological pathological processes such as MS or Traumatic 
Brain Injury (Moehle & West 2014; Jin & Yamashita 2016). In this scenario 
microglia activation can be thought of being neuroprotective during the initial 
stages and deleterious/neurodegenerative at the mid and advanced stages of 
disease. 
3.3 ALPHA-SYNUCLEIN AND INNATE INMUNE SYSTEM IN PARKINSON’S 
DISEASE 
The results gathered thus far using the different PD animal models have 
substantially increased our understanding of PD’s pathogenesis by usually 
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aforementioned, while the MPTP mouse model of PD indicates that 
inflammation in the SN can be self-propagating and leads to progressive 
neurodegeneration, the aSyn transgenic animal model demonstrates that 
overexpression of this endogenous protein can certainly provide a powerful 
source of inflammation (Allen Reish & Standaert 2015). Whether microglial 
activation is essentially caused by the release of aberrant aSyn species to the 
extracellular space, (Reynolds, Glanzer, et al. 2008; Wersinger & Sidhu 2006; 
Zhang et al. 2005; Halliday & Stevens 2011; Harms et al. 2013; Roodveldt et al. 
2010; Brück et al. 2016) or otherwise, that neuronal dysfunction and/or death 
itself drives microglial immune responses in an aSyn-independent manner 
(Mandel et al. 2005; McNaught et al. 2010; Walker et al. 2016; Leak 2014), is 
still under debate. However, there is ample accumulated evidence pointing at 
aSyn as the main trigger of microglial activation in PD (Roodveldt et al. 2008; 
Ren et al. 2016). For example, several studies have demonstrated that 
extracellular and nigral aSyn-containing aggregates are often surrounded by 
activated microglia or inflammatory mediators in PD brains (McGeer et al. 
1988; Yamada et al. 1992; Chao et al. 2014), similarly to what has been 
described for amyloid plaques in AD (Griffin et al. 2006). Moreover, the extent 
of microglial activation in the SN from PD patients has been found to be 
correlated with the degree of aSyn accumulation (Croisier et al. 2005) and with 
increased aSyn levels as evidenced by in vitro (Kim et al. 2009; Klegeris et al. 
2008) and in vivo (J.-K. Lee et al. 2009; Sanchez-Guajardo et al. 2010) studies, 
strongly supporting the view that the protein has a major role in phenotypic 
changes of microglia (Reviewed in (Brück et al. 2016; Ren et al. 2016)). Up to 
this point, a considerable number of in vivo studies with animal models of PD 
that directly link aSyn with microglial activation have been reported. It has been 
demonstrated in mice that overexpression of aSyn alone (by using adeno-




only classical microglial activation but also stimulation of adaptive immunity, 
preceding the appearance of overt neurodegeneration signs (Theodore et al. 
2008; Su et al. 2008; Su et al. 2009; Halliday & Stevens 2011). In line with this 
finding, different rat and mouse models overexpressing Wt or mutant variants 
of aSyn variant in the SNpc revealed dramatic changes in cytoskeletal protein 
levels and activated microglia-mediated neuroinflammation in the striatum 
(with increased release levels of IL-1β, IFN-γ, and TNF-α proinflammatory 
cytokines), well before neuronal loss was evident (Su et al. 2008; Su et al. 2009; 
Chung et al. 2009; Chesselet et al. 2012). Importantly, another study using a 
AAV rat PD model showed that overexpression of Wt aSyn in the SN not only 
leads to persistent microglia activation, but that depending on the degree of 
aSyn-induced neurophatology that models either the onset or the late stages of 
the disease, different microglial responses will occur: upon lower aSyn 
expression levels where only neurodegeneration occurs, microglia with 
antigen-presenting capabilities predominate, whereas levels that can induce 
neuronal cell death correlate with long-term induction of macrophagic 
microglia (Sanchez-Guajardo et al. 2010), suggesting that microglia may play 
different roles during disease progression (Sanchez-Guajardo et al. 2010).  
The link between neuroinflammation and aSyn dysfunction has been stablished 
using different approaches. The use of LPS injection in rat (Choi et al. 2010; 
Sharma & Nehru 2015) or mice (H. M. Gao et al. 2011), to trigger systemic and 
brain inflammation was used firstly. In the first study, the authors observed 
increased microglia activation and secretion of proinflammatory cytokines as 
well as greater nitration of proteins including aSyn, in elderly rats, suggesting 
that an exaggerated neuroinflammatory response that occurs naturally with 
aging might contribute to aSyn aggregation and dopaminergic 
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evaluated dopaminergic neurodegeneration, aSyn pathology and 
neuroinflammation in Wt and transgenic A53T aSyn-overexpressing mice (H. M. 
Gao et al. 2011). They observed that, while both models initially displayed 
acute neuroinflammation, only the latter developed persistent 
neuroinflammation together with chronic progressive degeneration of 
nigrostriatal dopamine pathway, accumulation of aggregated, nitrated aSyn, 
and formation of LB (H. M. Gao et al. 2011), suggesting that genetic factors and 
environmental exposures act synergistically to precipitate the development of 
PD. In addition recent studies have found a link between stress and 
neuroinflammation with further aSyn dysfunction leading to dopaminergic cell 
death and providing another prove of the central role of the microglia and its 
neuroinflammatory capabilities in PD (de Pablos et al. 2014; Sugama et al. 
2016). 
On the other hand, microglial cells from aSyn-knockout mice have been shown 
to exhibit a remarkably different morphology compared to Wt cells (Austin et 
al. 2006), displaying elevated levels of secreted pro-inflammatory cytokines 
such as TNF-α and IL-6 after activation, indicating that aSyn plays a critical role 
in modulating the microglial activation state.  
 In the last few years, several in vitro studies have focused on the effects of 
extracellular aSyn on microglial activation. Zhang et al. (Zhang et al. 2005) first 
reported that exogeneous, aggregated aSyn cause activation of microglial cells, 
which then become toxic towards cultured dopaminergic neurons. Their results 
indicate that microglial phagocytosis of aSyn and activation of NADPH oxidase, 
are critical in aSyn-induced microglial activation and neurotoxicity. This finding 
is highly relevant considering that, as has been mentioned, aSyn has been 
shown to be present in body fluids and brain parenchyma of health and disease 




vitro and in vivo (Tyson et al. 2016; Emmanouilidou & Vekrellis 2016; Lim et al. 
2016).  
Up to this point, research on aSyn-mediated cell response has focused primarily 
on the effects of aSyn on neuroinflammation (Benner et al. 2008) or microglial 
activation (Cookson 2009; Reynolds, Kadiu, et al. 2008; Thomas et al. 2007; 
Zhang et al. 2007; Zhang et al. 2005; Harms et al. 2013; Kim et al. 2016) with 
aSyn in its aggregated form. Interestingly, Reynolds and coworkers (Reynolds, 
Glanzer, et al. 2008) have found that nitrated, aggregated aSyn (N-aSyn) has a 
stronger stimulating effect on microglia than that of nitrated but non-
aggregated aSyn. In addition, several investigations have found that N-aSyn, 
which has been detected in LB of human brains with PD (Giasson et al. 2000) 
and has been linked to neurodegeneration in PD mouse models (Benner et al. 
2008; Gao et al. 2008), induces a neurotoxic inflammatory microglial phenotype 
that accelerates dopaminergic neuronal loss (Biasini et al. 2004; Thomas et al. 
2007; Zhang et al. 2005; Zhou et al. 2005). By integrating genomic and 
proteomic techniques, Gendelman and colleagues created a fingerprint of 
microglial cell activation following its interactions with aggregated N-aSyn in 
cell culture (Reynolds, Glanzer, et al. 2008), indicating that the activation, which 
was found to be capable of mediating dopaminergic neurotoxicity, is mainly 
mediated by the NFκB pathway (Reynolds, Glanzer, et al. 2008). However, 
whether extracellular aSyn contains the same modifications than the protein 
found in LB (Anderson et al. 2006; Giasson et al. 2000; Hodara et al. 2004), 
which is a typically pro-oxidative environment, is still uncertain (Lee 2008). 
Over the last few years, certain differential consequences of the presence of 
non-aggregated aSyn in the extracellular medium in glia have been reported. It 
has been observed that, in contrast to the aggregated form, monomeric aSyn 
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explore the effects of non-aggregated aSyn on the cytokine release profile of 
potentially relevant cells have been done using monocytic (Klegeris et al. 2008) 
or macrophage (S. Lee et al. 2009) cell lines, and primary astrocyte (Klegeris et 
al. 2006) or microglial (Roodveldt et al. 2010; Su et al. 2009; Su et al. 2008) 
cultures. Indeed, we have observed a strong innate immune response in 
primary glial and microglial cell cultures elicited by exogenous, non-aggregated 
aSyn (Roodveldt et al. 2010). Interestingly, a comparative study using 
unmodified aSyn has recently shown that exogenous non-aggregated aSyn 
induces higher TNF-α, IL-1β and ROS release levels than aggregated aSyn in 
microglia (Lee et al. 2010). These and other recent findings point at the 
importance of exploring the effects on the immune response of aggregated as 
well as non-aggregated aSyn.  
Even though a study using monocytic THP-1 cell line (Klegeris et al. 2008) had 
shown modest increases in IL-1β and TNF-α secretion levels after stimulation 
with A30P, E46K, A53T or aSyn variants compared to the Wt protein, there is a 
lack of a comprehensive study of the effect exerted by non-aggregated aSyn, 
performed with primary cell cultures.  
With this in mind, we analysed the cytokine release profile of primary microglial 
cultures ―which represents a more comparable physiological environment― 
after stimulation with Wt or the PD-linked aSyn mutants (Roodveldt et al. 
2010). Indeed, we found remarkable differences between the aSyn variants in 
the interleukin and chemokine release profiles and significant effects on the 
microglial phagocytic capacity (Roodveldt et al. 2010). In particular, we 
observed marked differences in IL-6 and IL-1β pro-inflammatory cytokines, IL-
10 immunoregulatory cytokine, as well as IP-10/CXCL10, RANTES/CCL5, MCP-
1/CCL2 and MIP-1α/CCL3 chemokines release levels. Our results indicate that 




inflammatory response in glia, together with a reduction of the 
immunoregulatory response, and a moderate stimulation of Th1 chemokine 
secretion. The A30P and E46K pathological variants, on the other hand, can 
induce strong pro-inflammatory and immunoregulatory responses, together 
with marked increases in chemokine release levels. This exacerbated innate 
immune response might explain the earlier onset and more rapid evolution of 
these two genetic cases of PD as compared to the sporadic kind. Intriguingly, 
our results from the pathologically-linked A53T variant showed not to provoke 
a significant innate immune response, which might suggest that other 
neurodegeneration mechanisms contributing to the pathogenesis of PD, 
probably involving the adaptive immune response might exist in this case. 
Combined with the effect on microglial phagocytosis, our results indicate that 
these aSyn-induced phenotypes might reflect either a classical (A30P and E36K) 
or an alternative (A53T) microglial activation state, or a hybrid phenotype (Wt), 
which could probably explain the different disease progression modes that can 
occur in PD. Although nowadays all the evidence points to a classical activation 
state (M1) as the main microglia phenotype contributing to PD progression, it is 
important to say that microglia, and macrophages, use to display a continuum 
of phenotypes from M1 to M2 (Martinez & Gordon 2014; Moehle & West 
2014). Examples of the presence of these mixture of M1, M2 phenotypes has 
been largerly described in the prototypical neuro-inflammatory disorder MS 
(Zhang et al. 2011; Moreno et al. 2014). A similar scenario could be operating in 
the context of PD, but further investigations will be needed  
As aforementioned, upon activation microglia and astrocytes start secreting 
inflammatory cytokines in order to communicate wither other cells and mount 
the immune response to counteract disease or injury. The cytokines TNF-α, IL-
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increased in the nigrostriatal region and CSF of patients with PD or DLB (Croisier 
& Graeber 2006; Allen Reish & Standaert 2015). More recently, Williams-Gray 
and co-workers pointed to TNF-α, IL-1β, IL-2 and IL10 as possible PD biomarkers 
as far as they found increased levels of all these cytokines in PD patient serum 
compared to age matched controls (Williams-Gray et al. 2016). In the same 
way, Kuziorowsky and colleagues found a direct correlation between serum IL-6 
and severity of PD (Koziorowski et al. 2012). As a result of aSyn-induced 
activation of microglia in vitro, a few cytokines and metabolites have been 
shown to be significantly up-regulated (reviewed in (Roodveldt et al. 2008; 
Brück et al. 2016): IL-6, IL-1β, ICAM-1, TNF-α, IFN-γ, MCP-1, O2-, iROS, and 
PEG2, glutamate, and iCys. In general, disease-linked aSyn variants show a 
stronger effect on cytokines release than does the Wt protein. Interestingly, 
analysis of the microglia transcriptome by Gendelman and coworkers 
(Reynolds, Glanzer, et al. 2008) after stimulation with aggregated N-aSyn, 
revealed a significant up-regulation of the TLR-2 gene. As previously 
mentioned, TLRs sense the molecular signatures of microbial pathogens, and 
play a fundamental role in innate immune responses, inducing the expression 
of diverse inflammatory genes (Kawai & Akira 2010). In the same way, recent 
findings are pointing to a possible role of the TLR system in the aetiology of PD; 
TLR2 has been shown to be the link between neuron secreted oligomeric aSyn, 
microglial activation and the subsequent dopaminergic neuronal damage (Kim 
et al. 2016). At the same time TLR4 has been related with the recognition of 
monomeric aSyn and to play a role on its correct clearance (Fellner et al. 
2013).Therefore, it seems plausible that cells challenged with aSyn, or with 
certain forms of aSyn, could become hyper-responsive to inflammatory signals 




Activated microglia can also produce substantial amounts of superoxide 
radicals, which may be the major source of the oxidative stress thought to be 
largely responsible for dopaminergic cell death in PD (Blesa et al. 2015). The 
generation of ROS by microglia activated by aSyn (Alvarez-Erviti et al. 2011; 
Wang et al. 2016) can result in oxidation and nitration of proteins, DNA 
modifications, and lipid peroxidation, leading to neurotoxicity (Zhang et al. 
2005; Kim et al. 2015). Oxidation (Ko et al. 2000; Chavarría & Souza 2013) and 
nitration (Giasson et al. 2000; Chavarría & Souza 2013) of aSyn which in turn 
can lead to the formation of more aggregates and result in increased cytotoxic 
effects (Goodwin et al. 2013). 
3.4 ADAPTIVE IMMUNE SYSTEM IN PARKINSON’S DISEASE 
The Adaptive IS, unlike the Innate IS is characterised by the capability of 
developing specific responses to specific antigens (proteins, pathogens, self-
antigens, etc.) and to provide a long lasting immunity against these antigens 
due to its capacity to develop a so-called ‘immune memory’. The General 
mechanism of action of the Adaptive immunity requires the antigens to be 
recognised by T cells, usually with the intervention of APCs, and the subsequent 
activation of B cells to differentiate and produce specific antibodies against 
such antigens (Fakhoury 2016). In recent years accumulating evidences has 
pointed at the importance of the Adaptive IS in the initiation and progression of 
several neuro-degenerative diseases such as AD, ALS and specifically in PD 
(Sanchez-Guajardo, Barnum, et al. 2013; Allen Reish & Standaert 2015; 
Fakhoury 2016).  
The initial observation in PD patients that a small amount of CD8+ 
Tlymphocytes occur in proximity to degenerating nigral neurons (McGeer et al. 
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triggered complement cascade (Yamada et al. 1992) suggested a possible 
involvement of the adaptive immunity in the PD process. Since then, the 
relation of the AIS with the pathogenesis of PD has been established from a 
growing body of convergent evidences. First of all, different works have shown 
increased numbers of T cells, both CD4+ and CD8+, in SNpc in post-mortem 
brains of PD patients (Brochard et al. 2009; Farkas et al. 2000). Indeed Brochard 
and colleages found 10-fold greater infiltration of T cells in PD brains compared 
with age-matched controls. Additionally, the peripheral IS cell pool has been 
found to be altered during PD progression. In particular, a reduction of total 
circulating CD4+ T cells has been observed, while the total numbers of CD8+ T 
cells seem to remain unaffected (Calopa et al. 2010; Baba et al. 2005; Niwa et 
al. 2012; Stevens et al. 2012). Importantly, has been found that the existing 
CD4+ T cells exhibit an increased Th1/Th2 ratio that positively correlates with 
PD severity (Chen et al. 2015; Baba et al. 2005). While Saunders and co-workers 
have found increased numbers of effector T cells together with impaired 
function of regulatory T cells in peripheral blood of PD patients and a positive 
correlation with their UPDRSIII (Unified Parkinson’s Disease Rating Scale Part III) 
performance (Saunders et al. 2012). Taking together these results point to a 
pro-inflammatory Th1 scenario during PD progression. In agreement with these 
findings, different animal models have been found to exhibit similar 
lymphocytes recruitment to brain parenchyma. Indeed, a remarkable T- and B-
cell infiltration into the SN linked to aSyn overexpression was observed at the 
early stages of disease development, i.e. before the appearance of significant 
dopaminergic neuronal loss, in a rAAV-aSyn mouse model overexpressing aSyn, 
reaching levels in the SN of up to 10-fold and 5-fold compared to controls 
(Theodore et al. 2008). While in an MPTP mouse model the composition of the 
infiltrating populations was reported to change during disease progression, 




and changing to increased CD8+ cytotoxic T cells after the microgliosis peak had 
occurred and significant neuronal loss had been detected(Sanchez-Guajardo et 
al. 2010; Brochard et al. 2009). 
Thus far, accumulated data demonstrate that in the MPTP model of PD, 
misfolded and aggregated aSyn are secreted from neurons, which promotes 
pro-inflammatory M1-type microglia and cytotoxic T-cells, therefore amplifying 
neuronal damage. In sporadic human PD, it is currently unkown which factor 
triggers disease onset, but it has been proposed that under certain 
circumstances, a similar set of temporal and mechanistic events could 
transform neuroprotective microglia and T cells into cytotoxic cells, thereby 
accelerating disease progression (Appel et al. 2010). This way, activated 
microglia and the cytokine milieu that they generate might promote T-cell 
differentiation into different cell subsets in the context of PD (Appel et al. 
2010). Indeed, it has been shown that M1 (pro-inflammatory) cells promote, 
whereas M2 (non-inflammatory) cells reduce, CD4+ Th1 cell proliferation and 
function (Verreck et al. 2004), but also that, conversely, T-cells can dictate 
microglial pro- or anti-inflammatory phenotypes (Giuliani et al. 2003; Kebir et 
al. 2007; Mount et al. 2007) 
Whether microglia dictate the specific T-cell phenotype or otherwise, that T-
cells dictate the specific microglial phenotype (i.e. M1 vs. M2), is still unknown 
(Appel et al. 2010). But overall, the communication established between 
microglia, T cells and neurons seem to indicate that the immune response is not 
only a consequence of injury, but that it actively contributes to the balance 
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On the other hand, although infiltration of B cells has not been observed yet 
into PD patients’ brains, the humoral immunity has been implicated in the 
pathophysiology by several findings. To analyse this possibility, Orr et al. (Orr et 
al. 2005) analysed the association between nigral degeneration and humoral 
immune markers in brain tissue of patients with idiopathic or genetic PD and 
controls. All the patients with PD revealed IgG, but not IgM, binding on 
dopamine neurons. Moreover, the proportion of IgG-immunopositive neurons 
showed a negative correlation with the degree of cell loss in the SNpc, and 
positive correlation with the number of activated microglia. IgG was found to 
be concentrated at the cell surface of neurons, but also on their LB, and was 
shown to co-localize with aSyn. These results, in combination with their finding 
that activated microglia express high-affinity IgG receptors (FcγRI) in both 
idiopathic and genetic forms of PD, might suggest that the activation of 
microglia may be induced by neuronal IgG (Orr et al. 2005). The question 
regarding the functional importance of antibodies against antigen-specific, 
disease-associated neuronal proteins still needs to be addressed. It has been 
demonstrated that an IgG fraction purified from serum of PD patients causes 
death of dopaminergic neurons in vivo following stereotaxic injection in the SN 
of experimental animals (Chen et al. 1998; He et al. 2002), and the presence of 
immunoglobulins in PD brain tissue have been proposed to lead to the 
targeting of dopaminergic nigral neurons for destruction (Orr et al. 2005). 
Currently, it remains unknown whether these anti-aSyn AAb are neurotoxic, or 
on the contrary, they actually have a neuroprotective role, as has been shown 
in a human aSyn transgenic mouse model of PD (Masliah et al. 2005). A recent 
study has assessed the presence of auto-antibodies (AAb) against all three 
synucleins in the peripheral blood serum of PD patients and healthy controls 
(Papachroni et al. 2007; Han et al. 2012). While the presence of AAb against β- 




detected in 65% of all patients, with a strong correlation with the inherited 
mode of the disease. In addition, a recent study based on measuring AAb levels 
against monomeric, oligomeric, and fibrillar aSyn in serum from PD patients 
(Gruden et al. 2011), showed that all three AAb specificities reached the highest 
values after 5-year of disease duration, and subsided in 10-year sufferers. 
Intriguingly, there was a ca. 15-fold increase in AAb titre values relative to 
monomeric aSyn (72% of patients), and a ca. 4-fold increase for aSyn oligomers 
(56% of patients). Moreover, the authors also found a decline in CD3+, CD4+ 
and CD8+ T-lymphocyte and B-lymphocyte subsets. Based on these results, 
they suggest that aSyn toxicity elimination by AAb in early PD pathology might 
be linked with the decline of lymphocyte subsets reflecting the influence of 
inflammatory and oxidative stress processes (Gruden et al. 2011) 
4. IMMUNOTHERAPY IN PARKINSON’S DISEASE 
As we have largely explained in previous sections, the relation between 
disturbances in the IS have been related with disease onset and progression of 
PD and other neurodegenerative diseases. In this way, different anti-
inflammatory compounds have been tested for their capacity to act as 
therapeutic options, in PD mouse models (Olson & Gendelman 2016). Indeed 
several  epidemiological studies and mouse model experiments, have shown a 
possible protective effect of taking ibuprofen in PD (Rees et al. 2011). Along the 
same line, the use of minocycline has been tested due to its higher anti-
inflammatory activity, but no effect was demonstrated (NINDS NET-PD 
Investigators 2006; NINDS NET-PD Investigators 2008). Moreover, different 
natural compounds, such as Resveratrol or Silymarin, have shown promising 
results in rodent PD models as treatment agents, because of their anti-
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al. 2014). However, anti-inflammatory agents have failed to show clinical utility 
and further investigations will be required(Olson & Gendelman 2016). 
Table 2. aSyn Vaccination strategies (adapted from (Schneeberger et al. 2016)) 






Induction of aSyn–specific IgG Abs 
Reduction of misfolded aSyn in neuronal 
cell bodies and synapses 
Neuropathological improvement 











Immune responses exacerbate 
neuroinflammation and nigrostriatal 
degeneration 
Activation of peripheral leukocytes 
Exacerbations are mostly mediated by 
aSyn–induced/specific Tcells 
Treg cells attenuated microglial 
inflammatory responses and led to robust 
nigrostriatal protection 










High- anti–aSyn antibody response  
Reduction in PD-typical aggregates; 
Accumulation of CD4-+, MHC II+ ramified 
microglia in SN 













Induction of an aSyn selective IgG Ab 
response (aSyn recognized, β-Synuclein 
spared) 
Generated Abs pass the BBB and bind to 
aSyn deposits 
Reduction of pathological aSyn (oligomers, 
aggregates) 
Reduction of model-specific 
neuropathological alterations 






conjugate   
Mouse,Wt-
C57Bl/6 
All 3 conjugates induce human aSyn–
specific Abs (aSyn 85-99, aSyn109-126, 
aSyn126-140) 
T cell responses to P30, but not to 
human aSyn (aSyn 109-126-TT P30 
conjugate)                                          
Generated Abs h aSyn in brain 
extracts(aSyn 126-140-TT P30 conjugate) 
(Ghochikyan 




Given the already stablished relationship between aSyn and the activation of 
the IS, several groups have developed immune therapies that primaryly target 
aSyn species (Schneeberger et al. 2016)(Table2). Indeed various studies 
performed following pioneering work by Masliah et al. (Masliah et al. 2005) 
have explored different types of approaches for immunization with aSyn in 
animal models. Overall, these different approaches can be subdivided into 
three ‘schools’. The first one uses the immunization strategy to obtain a potent 
humoral response against aSyn species, coupled with negligible or even absent 
cellular response(Masliah et al. 2005; Mandler et al. 2014; Ghochikyan et al. 
2014). Although these approximations have shown promising results in mouse 
models, such as reduction of aSyn aggregates, and improvement in motor 
function, direct translation to clinics still needs to be assessed due to possible 
break of self-tolerance (Schneeberger et al. 2016). Importantly, two 
formulations based on this principle are now under clinical trials, after showing 
promising results in 3 animal models. AFFITOPE technology uses small peptides 
that mimic the target epitope as vaccine antigens, avoiding the Tcell respose 
and the problem of braking self-tolerance but capable of generate a long-
lasting, sustained antibody response (Mandler et al. 2014). Currently two 
AFFITOPE fomulations, PD01 and PD03, are now being tested for their 
tolerability and safety properties (Identifiers: NCT01885494, NCT02267434). In 
an opposite direction Gendelman and co-workers have developed different 
approximations in order to promote a cellular response, in particular an 
antigen-specific regulatory T cell (Treg) response, to try restore the immune 
imbalance in PD (Benner et al. 2008; Reynolds, Kadiu, et al. 2008; Olson & 
Gendelman 2016). Between these two opposite approximations we find the 
work of Sanchez-Guajardo and co-workers. Actually they found that 
immunization of AAV rat model with full-length aSyn displayed increased aSyn 
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immune response was accompanied by a reduction in aSyn aggregates 
(Sanchez-Guajardo, Annibali, et al. 2013). In conclusion, despite the promising 
results showed shown by these different approximations, neither approach on 
its own has shown to be sufficient to counteract the multiple pathogenic 
avenues in PD, most notably the uncontrolled neuro-inflammatory state linked 
to neurodegeneration, and further, their therapeutic efficacy in human subjects 
still needs to be tested. Moreover, an important limitation when designing 
immunotherapeutic strategies against PD is the insufficient state of knowledge 
about the activation and evolution of the immune response linked to PD along 
the course of disease and which immune profiles are beneficial, and which ones 
are detrimental, for PD progression. 
4.2 CHAPEROME IN IMMUNOTHERAPY 
The eukaryotic ‘chaperome’ has been defined as an interconnected network 
composed of a large number of molecular chaperones and co-chaperones that 
are essential for protein homeostasis (Brehme et al., 2014). Indeed, the main or 
best known functions of this kind of proteins is to chaperone nascent 
polypetides to assist de novo protein folding and to prevent protein misfolding 
and aggregation under heat-shock or several other environmental stresses 
(Albanèse et al., 2006). Accordingly, the members of the chaperome are the 
most abundant proteins inside the cell while their presence in the extracellular 
space is a well-known DAMPs (Miyake and Yamasaki, 2012; Y Tamura et al., 
2012; Yasuaki Tamura et al., 2012). In fact, several heat-shock proteins (HSPs) 
have lately been reported to play diverse roles as modulators of innate and 
adaptive immunity (Binder, 2014; Tosti et al., 2014; Radons, 2016). Firstly, it 
was established that different members of the HSP70 and HSP90 families of 
chaperones, such as hsp70 (HSPA1A), and gp96/grp94  are necessary for the 




and MHC-II histocompatibility complexes (Binder, 2014). Lately, different 
studies have shown that extracellular HSPs can act as danger signals (DAMPs) 
and actually different APCs express, on their surface, receptors capable of 
recognizing specific HSPs (Binder, Han and Srivastava, 2000; Basu et al., 2001; 
Binder, 2014). Since then, several immune-modulating functions have been 
described for different members of the chaperome, from promoting antigen 
cross-presentation and maturation of dendritic cells  to exerting 
immunosuppressive signals, or facilitating the activation of lymphocytes and 
macrophages (Murshid, Gong and Calderwood, 2012; Y Tamura et al., 2012; De 
Maio and Vazquez, 2013; Muralidharan and Mandrekar, 2013).  
As a result of these novel immunomodulatory activities of HSPs, different HSPs 
have been studied for their treatment feasibility in certain diseases. First of all 
Srivastava and coworkers demonstrated that immunization in mice with 
gp96/grp94 (an endoplasmic reticulum-resident chaperone member of the 
Hsp90 family) isolated from tumours was capable of providing resistance 
against further challenges with the same tumours (Srivastava, DeLeo and Old, 
1986). Surprisingly, the specificity of the elicited immune response was shown 
to be due to a differential peptide repertoire chaperoned by gp96. After that, a 
few other HSPs have been tested for their chaperone and anti-tumour 
capabilities. For instance hsp70, hsp90, hsp110 or grp170 have shown their 
anti-tumour activity in different animal models (Udono and Srivastava, 1993, 
1994; Wang et al., 2001). The use of chaperones in immune-therapeutic 
approaches has also been explored for treatment of autoimmune diseases, 
such as Rheumatoid Arthritis (RA), as well as in a variety of infections 
(Srivastava, 2012; Binder, 2014). Interestingly, in the case of RA, 
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capacity to induce antigen-specific T cell suppression activity in different RA 
murine animal models (Van Herwijnen et al., 2013; Panayi and Corrigall, 2014).  
Therefore, HSPs and probably other chaperone proteins possess highly valuable 
features that could be potentially exploited to neutralize or redirect the 
abnormal, neurodegeneration-linked immunity elicited by misfolding proteins 
in misfolding/amyloid disorders, namely, their classical ‘chaperone’ functions in 
combination with their proved immunomodulatory activities. 
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43 CHAPTER 1: OBJETIVES 
OBJECTIVES 
Along the past decade the relationship between the accumulation of abnormal 
α-synuclein species, microglial activation and the pathophysiology of several 
neurodegenerative diseases, including Parkinson’s disease, has been 
demonstrated. However, the exact mechanisms underlying its pathological 
actions are poorly understood. On the other hand, the finding through 
epidemiological studies and animal models, of a link between specific microbial 
infections and the occurrence of these neurological disorders point to a 
possible role of the TLR system in the onset and progression of these diseases. 
In order to further investigate this question we aimed to: 
Study the impact of extracellular aSyn priming on the microglial innate immune 
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Preconditioning of Microglia by α-Synuclein Strongly Affects 
the Response Induced by Toll-like Receptor (TLR) Stimulation 
Cintia Roodveldt1☯, Adahir Labrador-Garrido1,2☯, Elena Gonzalez-Rey3, 
Christian C. Lachaud1, Tim Guilliams4, Rafael Fernandez-Montesinos1,2, Alicia 
Benitez-Rondan1, Gema Robledo3, Abdelkrim Hmadcha1, Mario Delgado3, 
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1CABIMER, Andalusian Center for Molecular Biology and Regenerative 
Medicine, Seville, Spain 
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School of Medicine, University of Seville, Spain 
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4Department of Chemistry, University of Cambridge, Cambridge, United 
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1. Abstract 
In recent years, it has become accepted that α-synuclein (aSyn) has a key role in 
the microglia-mediated neuroinflammation, which accompanies the 
development of Parkinson’s disease and other related disorders, such as 
Dementia with Lewy Bodies and Alzheimer’s disease. Nevertheless, the cellular 
and molecular mechanisms underlying its pathological actions, especially in the 
sporadic forms of the diseases, are not completely understood. Intriguingly, 
several epidemiological and animal model studies have revealed a link between 
certain microbial infections and the onset or progression of sporadic forms of 
these neurodegenerative disorders. In this work, we have characterized the 
effect of toll-like receptor (TLR) stimulation on primary murine microglial 
cultures and analysed the impact of priming cells with extracellular wild-type 
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By assaying key interleukins and chemokines we report that specific stimuli, in 
particular Pam3Csk4 (Pam3) and single-stranded RNA40 (ssRNA), can 
differentially affect the TLR2/1- and TLR7-mediated responses of microglia 
when pre-conditioned with aSyn by augmenting IL-6, MCP-1/CCL2 or IP-
10/CXCL10 secretion levels. Furthermore, we report a skewing of aSyn-primed 
microglia stimulated with ssRNA (TLR7) or Pam3 (TLR2/1) towards intermediate 
but at the same time differential, M1/M2 phenotypes. Finally, we show that 
the levels and intracellular location of activated caspase-3 protein change 
significantly in aSyn-primed microglia after stimulation with these particular 
TLR agonists. Overall, we report a remarkable impact of non-aggregated aSyn 
pre-sensitization of microglia on TLR-mediated immunity, a phenomenon that 
could contribute to triggering the onset of sporadic α-synuclein-related 
neuropathologies. 
2. Introduction 
The synucleinopathies are a group of pathologies increasingly affecting the 
population over 65 years old, comprising various progressive, 
neurodegenerative disorders including Parkinson’s disease (PD), dementia with 
Lewy bodies (DLB) and multiple system atrophy (MSA) (Fellner & Stefanova 
2012). Despite the particular characteristics regarding the type of cells and 
brain areas affected, these disorders have in common the accumulation of α-
synuclein (aSyn) insoluble aggregates as the main pathological feature 
(Marques & Outeiro 2012). Moreover, aSyn has also been identified as a 
component of amyloid brain tissues in AD patients (Hamilton 2000). PD, the 
most prevalent of these pathologies, is characterized pathologically by the 
presence of intraneuronal inclusions highly enriched in aSyn (known as Lewy 
bodies) in the substantia nigra (SN) of the brain (Spillantini et al. 1998; Croisier 
et al. 2005; Chiti & Dobson 2006), and the loss of dopaminergic neurons 
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(Moore et al. 2005). Three missense mutations of aSyn, A30P, E46K, and A53T, 
as well as multiple copies of the wildtype (Wt) gene, are linked to rare, early 
onset PD cases (Moore et al. 2005). Even though aSyn is now recognized as a 
key player in the pathogenesis of PD and other aSyn-related disorders, the 
cellular and molecular events underlying its pathological actions are not 
understood in detail. Moreover, the underlying mechanisms driving the 
development of sporadic PD and other synucleinopathies and which constitute 
the vast majority clinical cases, remain largely unknown (Marques & Outeiro 
2012; Cookson 2009).  
Accumulated evidence shows that inflammation is involved in the pathogenesis 
of a number of neurodegenerative diseases including PD, AD, and multiple 
sclerosis (MS), among others (Kim & Joh 2006). Indeed, it is now well 
established that the onset and progression of PD is accompanied by a robust 
inflammatory response essentially mediated by activated microglia in affected 
areas of the brain, which is thought to precede neuronal degeneration (Gao et 
al. 2008; Long-Smith et al. 2009; Marinova-Mutafchieva et al. 2009). Moreover, 
several in vitro studies have revealed the ability of exogenous aSyn, especially 
the PD-linked mutational variants and the oligomeric forms of aSyn, to induce 
such a response by stimulated microglia (Fellner et al. 2011; Roodveldt et al. 
2010; Roodveldt et al. 2011). This finding is particularly important as the 
presence of aSyn has been detected in extracellular biological fluids including 
human cerebrospinal fluid (CSF) (Borghi et al. 2000; El-Agnaf et al. 2003; El-
Agnaf et al. 2006; Emmanouilidou et al. 2011) and also shown to be secreted 
from neuronal cells (Emmanouilidou et al. 2011; Lee et al. 2005; Lee 2008). 
Importantly, imbalances in Wt extracellular aSyn levels –both aggregated and 
monomeric- have been detected in CSF from patients with PD, AD, DLB and 
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2011; Mollenhauer et al. 2013; Tokuda et al. 2006; Tokuda et al. 2010). Even 
though it is unclear to what extent such variations in CSF mirrors the 
concentrations within key brain regions and whether they arise at the very 
initial stages of disease, they indicate that non-aggregated extracellular aSyn 
within the local environment could be highly relevant for pathogenesis. 
Intriguingly, several epidemiological and animal studies have revealed a link 
between certain bacterial, viral and parasitic infections and the development or 
progression of sporadic PD (Takahashi & Yamada 1999; Charlett et al. 1999; 
Tsui et al. 1999; Weller et al. 2005; Jang et al. 2009; Dobbs et al. 2010; Miman 
et al. 2010) and AD (Krstic et al. 2012; Hammond et al. 2010; Balin et al. 2008). 
Nevertheless, the mechanism by which infectious agents or inflammatory 
stimuli could exacerbate or modulate these microglial phenotypes is not well 
understood. 
Activation of microglia and inflammation in the context of PD, amyotrophic 
lateral sclerosis (ALS), and AD is currently thought to involve the toll-like 
receptors (TLRs) (Lehnardt 2010; Watson et al. 2012; Béraud & Maguire-Zeiss 
2012), a group of transmembrane proteins known to detect invading pathogens 
(Kumar et al. 2011). TLRs have been reported to be up-regulated in α- 
synucleinopathy-derived brain tissue from mouse and human subjects 
(Stefanova et al. 2007; Letiembre et al. 2009), and have been proposed to 
mediate different pathways leading to either neuroprotective or neurotoxic 
phenotypes (Letiembre et al. 2009; Block et al. 2007; McKimmie et al. 2006; 
Carty & Bowie 2011). Although it has recently been shown that treatment of 
cells with aggregated aSyn is able to alter the TLRs gene expression in microglial 
cells (Beraud et al. 2011), there are as yet no reported studies on the cellular 
mechanisms modelling a pre-oligomeric stage of the disease that could 
recapitulate the setting of neuroinflammation and neurodegeneration. This fact 
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highlights the importance of studying the impact of extracellular aSyn on the 
innate immune response following TLR stimulation. In this work, by 
characterizing the effect of a set of TLR agonists on primary microglia cultures, 
we report a remarkable impact of Wt aSyn priming of cells on TLR mediated 
immunity that might reflect a causal link between certain infections and the 
initiation of sporadic neurodegenerative disease. 
3. Material and Methods 
TLR ligands 
TLR ligands were purchased from InvivoGen (San Diego, USA) and prepared 
according to the manufacturer’s recommendations. The TLR ligands were: 
bacterial lipopolysacharyde (LPS), type B CpG oligonucleotide ODN 1688 (CpG), 
low molecular weight polyinosine-polycytidylic acid (poly(I:C-LMW)) (PolyI:C), 
lipoteichoic acid from B. subtilis (LTA), synthetic bacterial lipoprotein Pam3CSK4 
(Pam3), peptidoglycan from B. subtilis (PGN), imiquimod (Imiq), and 
ssRNA40/LyoVec (ssRNA). 
α-synuclein protein overexpression, purification and characterization 
Human Wt aSyn was overexpressed in E. coli BL21(DE3) cells using plasmid pT7-
7 and purified as described previously (Roodveldt et al. 2010). The purity and 
monomeric state of the aSyn preparation (>95%) was assessed by 15% SDS-
PAGE, mass spectrometry analysis, and 4-10% native PAGE (Lonza, Basel, 
Switzerland), as previously described (Roodveldt et al. 2010). The preparation 
and characterization of soluble aSyn oligomers was carried as reported 
previously (Roodveldt et al. 2012) and purified oligomeric fractions were stored 
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measured by the ToxiSensor Chromogenic LAL Assay Kit (GenScript, Piscataway, 
USA), and values obtained were <1 EU/mg protein in all cases. The protein 
concentration of non-aggregated and oligomeric aSyn was determined by 
means of Micro BCA Reagent Kit (Pierce, Rockford, IL, USA). 
Preparation and characterization of primary microglial cell cultures 
Mixed glial cultures were prepared from cerebral cortices of 1-3 day-old 
C57BL/6 male mice (University of Seville Animal Core Facility, Seville, Spain), 
and the microglial fraction was isolated, according to previously described 
methods (Roodveldt et al. 2010). Purified microglial cells were characterized by 
immunocytochemistry as cells of the haematopoietic lineage on the basis of 
their expression of the pan haematopoietic marker CD45 and of the 
monocyte/macrophage markers CD11b, F4/80 and CD68, as described 
elsewhere (Roodveldt et al. 2010). Additionally, the absence of glial fibrillary 
acidic protein (GFAP)-positive astrocytes in purified microglial cell cultures was 
also assessed according to a previously reported method (Roodveldt et al. 
2010). 
Treatment of microglial cell cultures 
Stimulation of microglial cultures in 12-well plates was performed by replacing 
the medium by adding 1 mL Wt aSyn (or medium alone in the case of the 
following controls: ‘untreated microglia’ and ‘TLR ligand alone’ controls), at a 
final concentration of 1 μg/mL (equivalent to 70 nM) diluted in complete 
DMEM-F12 medium. After a 6-hour incubation at 37°C, 110 μL aliquot of TLR 
ligand solutions (at 10x higher concentration) in complete DMEM-F12 medium 
was added to each well containing either aSyn-primed, or non-primed cells. In 
the case of some controls, 110 μL of medium alone was instead added to the 
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wells. The final concentrations of the ligands being tested correspond to 
conditions reported previously (Castillo et al. 2008), and were: LPS, 1 μg/mL; 
CpG, 1 μg/mL; Poly(I:C), 50 μg/mL; LTA, 10 μg/mLl; Pam3, 1 μg/mL; PGN, 10 
μg/mL; Imiq; 1 μg/mL; and ssRNA, 0.25 μg/mL. Cell culture samples with aSyn-
primed cells but with no subsequent TLR ligand stimulation, as well as cells with 
no addition of aSyn or TLR ligands, were used as controls. Cells were then 
incubated for a further period of 18 hrs. In addition, some controls were 
prepared in parallel by incubating cells for 24 hrs with 1 μg/mL A30P aSyn or 
oligomeric Wt aSyn. In all cases, after incubation for a total of 24 hrs, the 
supernatants were harvested and the cells were frozen and stored at -80 °C. 
Cytokine release measurements 
After treatment and incubation of cells for a total of 24 hrs as explained in the 
previous subsection, culture supernatants were harvested and centrifuged at 
700 g for 5 min. The supernatants from treated cultures were recovered and 
stored at -80 °C before measurement of cytokine levels. IL-6, TNFα, IL-1ß, IL-10, 
IL-13 and IL17 levels were assayed using the mouse IL-6/IL-10 BD OptEIA ELISA 
set (BD Biosciences, Franklin Lakes, NJ, USA), the murine IL-13 ELISA 
Development Kit (Peprotech, London, UK), and the mouse IL-17 DuoSet® ELISA 
Development System (R&D Systems, Minneapolis, USA), according to the 
manufacturer's protocols. Chemokine levels in the culture supernatants were 
determined by a specific sandwich ELISA by using capture/biotinylated 
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Determination of TLR gene expression 
Expression levels of the genes for TLRs 1, 2, 3, 4 and 7, and for hypoxanthine-
phophoribosyltransferase (HPRT), were determined by using a two-step 
quantitative real-time PCR (qRT-PCR) method. Total RNA from treated 
microglial cells was extracted using the Tripure Isolation Reagent (Roche, Basel, 
Switzerland) according to the manufacturer's protocol. RNA (1 μg) was reverse-
transcribed by using the Quantitect Reverse Transcription kit (Qiagen GmbH, 
Hilden, Germany) according to the manufacturer's protocol. qRT-PCR was 
performed with SensiFAST™ SYBR Lo-ROX Kit (Bioline, London, UK) on an ABI 
Prism 7500 Real Time PCR System. Primer pairs were designed to anneal in 
different exons, and were: HPRT_For: 5’-GTAATGATCAGTCAACGGGGGAC-3’, 
HPRT_Rev: 5’-CCAGCAAGCTTGCAACCTTAACCA-3’; primers for TLR genes were 
purchased from Sigma (Sigma- Aldrich, St. Louis, USA). TLR4_For: 5’- 
ACCAGGAAGCTTGAATCCCT-3’; TLR4_Rev: 5’-TCCAGCCACTGAAGTTCTGA-3’; 
TLR7_For: 5’-TCAAAGGCTCTGCGAGT-3’; TLR7_Rev: 5’-
AGTCAGAGATAGGCCAGGA-3’. TLR1, TLR2 and TLR3 primers were purchased 
from Qiagen (Hilden, Germany). Multiple transcripts were analysed 
simultaneously for 40 cycles using an optimized qRT-PCR thermal profile. 
Changes in gene expression were determined using the ΔCt value taking hprt as 
endogenous control. The ΔΔCt values were calculated by subtracting ΔCt values 
of non-primed samples followed by TLR stimulation (‘TLR ligand’) from samples 
treated with aSyn priming followed by TLR stimulation (‘Wt+TLR ligand’). 
Phagocytosis assays 
FluoresbriteTM carboxylate microspheres of 0.75 μm diameter (2.64 % Solid-
Latex; Polysciences Inc, Warrington, USA) were used as fluorescein-conjugated 
tracker microparticles for measuring the phagocytosis capacity of differentially 
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activated microglial cells. 1 hr before starting the phagocytosis assay, FITC-
labelled microspheres (1.08 x 1011 particles/mL) were mixed at a ratio of 1 μL 
microspheres: 20 μL FBS for 1 hr at 37°C into inactivated FBS (BioWhittaker, 
Verviers, Belgium) and incubated for a further 1 hr at 37 °C in order to opsonise 
fully the carboxylate groups. The mixtures of microspheres and FBS were then 
resuspended in fresh DMEM-F12 medium (BioWhittaker, Verviers, Belgium), 
with L-glutamine and P/S antibiotics supplements to obtain normal 10% FBS 
supplemented media containing 5.4 x 108 microspheres/mL. After removal of 
500 μL of supernantant from the aSyn-stimulated microglial cell cultures for 
cytokine release analyses, a volume of 150 μL of resuspended microspheres 
was added to the remaining 600 μL in each well to obtain a final concentration 
of 1x108 particles/mL. Particles were then homogenously distributed 
throughout the well by gentle movement of the plate and incubated for 1 hr at 
37 °C. Medium containing non-phagocytosed microspheres was then removed 
and the cells were washed with PBS prior to fixation with 4% p-formaldehyde in 
PBS for 30 min at 4 °C. A volume of 1 mL of PBS containing the nuclear 
fluorescent dye bisBenzimide H33342 tri-hydrochloride (Hoechst 33342; 1 
μg/mL) was then added to the cells, and the plates were stored at 4 °C for a 
minimum of 24 hrs until being analysed. For this purpose, an Olympus IX71 
fluorescence microscope equipped with the digital image processing software 
DPController and DPManager (Olympus Europa, Hamburg, Germany), was 
used. For each sample, the phagocytic capacity of microglial cells was 
determined by analysing fluorescent images of phagocytosed FITC-labelled 
microspheres and Hoechst stained nuclei from four randomly chosen fields 
(each containing ~85 cells). For each random field, the total numbers of spheres 
and nuclei were determined using the Granularity application of the digital 
imaging analysis software Metamorph (MDS Analytical Technologies, Toronto, 




ALPHA-SYNUCLEIN AND IMMUNE SYSTEM CROSSTALK IN PARKINSON'S DISEASE; 
THERAPEUTICAL APPROACHES OF ITS MODULATION BY MOLECULAR CHAPERONES 
phagocytic capacity, was calculated for every field analysed. The values shown 
correspond to the mean from two or three independent experiments (N=2 or 
3), each one containing duplicate samples. 
Determination of Arg1/iNOS gene expression 
Total RNA from treated microglial cells was extracted and reverse-transcribed 
as described before in this section. The primers used were as follows: for 
mouse arginase-1/Arg1 (band size: 264 bp): Forward: 5´-
CAGAAGAATGGAAGAGTCAG-3´; Reverse: 5´-CAGATATGCAGGGAGTCACC-3´, for 
mouse iNOS (band size: 373 bp): Forward: 5´- 
GCCTCATGCCATTGAGTTCATCAACC-3´; Reverse: 5´- 
GAGCTGTGAATTCCAGAGCCTGAAG-3´, and for mouse actin (band size: 165 bp): 
Forward: 5´- TGTTACCAACTGGGACGACA-3´; Reverse: 5´- 
GGGGTGTTGAAGGTCTCAAA-3´. DNA Marker: Fermentas*phiX174 DNA/BsuR I 
(Hae III) Marker, 9.  
The positive controls for the Arg and iNOS PCR assays (PCR+) were bone 
marrow derived macrophages either non stimulated or stimulated 24 hrs with 
IL-4 (10 ng/mL), respectively. Macrophages were isolated from bone marrow 
from Balb/c mice and cultured as follows: bone marrow cells (0.4 x 106/mL) 
were cultured in DMEM (2 mM L-glutamine, 100 units/mL 
penicillin/streptomycin and 20% heat-inactivated FCS, all from 
Gibco/Invitrogen) containing 20 ng/mL M-CSF (Peprotech) for 7-8 days. 
Differentiated macrophages were detached by incubating the plates with 2 mM 
EDTA/PBS at 37 °C for 10 min. Cell preparations typically consisted of >95% 
CD11b+CD11c- macrophages. Bone marrow derived macrophages were plated 
at 8 x 105 cells/well in 6-well plates. After 4 hrs of adherence, macrophages 
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were washed with PBS and stimulated with IL-4 (BD Bioscience; 10 ng/mL) for 
24 hrs. 
Final concentrations in the PCR reaction mixture were: cDNA template: 60 ng; 
dNTPs: 0.2 mM; primers: 0.4 μM; MgCl2: 2mM; Taq polimerase (Biotools): 
0.625 units/reaction, in a total volume of 25 μL. PCR conditions were as follows: 
for Arg1: 94°C-5 min; 94°C-30 sec, 56°C-30 sec, 72°C-30 sec (30 cycles); 72°C-7 
min; 4°C-o/n. For iNOS: 94°C- 35 sec; 62°C-2min; 72°C-2 min (35 cycles); 72°C-7 
min; 4°C-o/n. For actin: 94°C-5 min; 94°C-30 sec, 60°C-30 sec, 72°C-30 sec (30 
cycles); 72°C-7 min; 4°C-o/n. 
Determination of cleaved caspase-3 levels by ELISA 
For detecting activated caspase-3 protein levels by ELISA, the Human/Mouse 
Cleaved Caspase-3 (Asp175)-DuoSet ELISA kit (R&D Systems, Abingdom, UK) 
was used. For this, total protein was extracted from treated microglial cells in 
culture with ‘lysis buffer’ according to the manufacturer’s instructions, and 
quantified with the BCA Protein Assay Reagent Kit (Thermo Fisher Scientific 
Inc., Rockford, USA). 
Determination of cleaved caspase-3 levels by immunofluorescence 
For immunofluorescence (IF) analysis, highly pure microglial cell cultures were 
obtained as described above (in the ‘Preparation and characterization of 
primary microglial cell cultures’ section), but in this case cultures were 
prepared on a hydrophilic μ-Dish (Ibidi GmbH, Germany). 3-4 days after 
isolation, microglial cells were treated as described before (in the 
‘Preconditioning of microglial cell cultures with aSyn and stimulation with TLR 
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thereafter fixed in cold PBS containing 4% p-formaldehyde for 15 min at 4 °C 
and then washed in PBS prior to being permeabilized and blocked in PBS 
containing 3% BSA (Sigma-Aldrich, St. Louis, USA) and 0.5 % Triton X-100 
(Sigma-Aldrich, St. Louis, USA) for 1 hr at 4°C. Cells were incubated o/n at 4 °C 
with cleaved caspase-3 (Asp175) antibody (Cell Signalling Technology Inc., 
Danvers, USA) at a 1/200 dilution in PBS containing 3% BSA and 0.5% Triton X-
100. After 3 washes with PBS, cells were incubated for 1 hr at room 
temperature in the dark with a donkey anti-rabbit IgG-AlexaFluor 594 
secondary antibody (Invitrogen, Paisley, UK) at a 1/800 dilution in the same 
buffer. After three washes with PBS, the nuclei were counterstained by 
incubating cells with PBS containing 1 μg/mL Hoechst 33342 (Sigma-Aldrich, St. 
Louis, USA) for 1 hour at 4 °C and examined under the fluorescence 
microscope. Fluorescence images were captured with an Olympus IX71inverted 
fluorescence microscope equipped with digital image processing softwares 
DPController and DPManager (Olympus. www.olympus.co.uk). Fluorescence 
images were taken at x20 magnification from randomly chosen fields. A 
rigorous comparative evaluation of cleaved caspase-3 immunoexpression was 
achieved by taking fluorescence images with the same exposure time. 
Fluorescence images (cleaved caspase-3 marker and nuclear Hoechst 33342 
stainings) taken for different microglial cell cultures were finally merged at the 
same ratio with the use of DPManager software. Phase-contrast images were 
also obtained from the same cultures, at x10 magnification. For quantitative 
analysis of cleaved caspase-3 levels by IF, the imaging software MetaMorph 
Offline (version 7.5.1.0, MDS Analytical technologies, USA), was used. Analysis 
was performed by using the ratio of the intensity values of Alexa 594 nm (RF) 
and Hoechst 33342 (BF) above background (areas lacking cells), and the data 
were expressed as arbitrary units (AU) and exported automatically from to 
Microsoft Excel program through a summary log. For measuring the relative 
 
 
57 CHAPTER 1: C. ROODVELDT, A. LABRADOR-GARRIDO ET AL PLOS ONE 2013 
cleaved caspase-3 levels per cell, the total specific RF/BF (red fluorescence/ 
blue fluorescence) ratio was calculated. 
Data analysis 
All values are expressed as the mean ± S.E.M. Statistical significance was 
evaluated by the Student’s t-test using SPSS Statistics 19.0 (IBM Company, 
Chicago, USA). Statistically significant differences in relative cytokine release 
levels, phagocytosis and TLR expression [(Wt+TLR ligand): (TLR ligand) fold-
changes] were calculated with the t-Student test between two sets of results by 
comparing the values under conditions of aSyn-preconditioning followed by TLR 
stimulation (Wt+TLR ligand) relative to conditions in the absence of aSyn 
preconditioning and TLR stimulation (TLR ligand). Each set of results originated 
from several independent experiments (N=3-7). In addition, in the cases of 
statistically significant changes, the absolute values were also compared by 
applying a two-way Student’s t-test for each (Wt+TLR ligand) sample condition 
to those resulting from stimulation of cells with aSyn alone (‘Wt aSyn’) or 
untreated cells (‘Control’). For quantitative analysis of cleaved caspase-3 levels 
by IF, three images from random fields (N=3), each containing 80-90 cells, were 
used to calculate the mean RF/BF value and SEM for each sample condition. For 
quantitative ELISA assays, results originated from three independent 
experiments (N=3). Statistically significant differences of results from IF and 
ELISA assays were calculated by applying the Student’s t test in relation to the 
values obtained with the corresponding TLR ligand in the absence of aSyn-
preconditioning and with Wt aSyn alone. In all cases, statistically significant 
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Ethics Statement 
All animals were handled in strict accordance with good animal practice as 
defined by the relevant national/EU guidelines and The CEA-CABIMER 
Experimental Animal Committee, and all animal work was approved by the 
appropriate committee (file CEA-2010-14). 
4. Results 
Priming of microglia with Wt aSyn primarily affects the TLR2 and TLR7-
mediated immune response 
Given that the underlying mechanisms initiating and accompanying the 
development of sporadic synucleinopathies remain essentially unknown, we 
decided to carry out our studies with Wt aSyn protein. Although various types 
of cells have been identified as a source of cytokines in the central nervous 
system (CNS), microglia appear to be a principal source of pro-inflammatory 
and immune regulatory cytokines (Kim & Joh 2006). In order to explore the 
possible impact of aSyn as a priming factor in the microglial immune response 
following pathogen invasion, we challenged Wt aSyn-primed microglial cultures 
with a set of TLR agonists, namely Pam3Csk4 lipopeptide (Pam3; TLR2/1), 
peptidoglycan from B. subtilis (PGN; TLR2), lipoteichoic acid from B. subtilis 
(LTA; TLR2), Poly(I:C)-LMW―a synthetic analog of dsRNA- (PolyI:C; TLR3), 
bacterial lipopolysaccharide (LPS; TLR4), imiquimod ―a small synthetic antiviral 
molecule- (Imiq; TLR7), ssRNA40 oligonucleotide complexed with LyoVec 
(ssRNA; TLR7), and type B CpG oligonucleotide (CpG; TLR9). We omitted the 
study of TLR5 stimulation based on previous reports of its absence in mouse 
microglia (McKimmie et al. 2006; Applequist et al. 2002), and on our own 
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observations of a lack of effect with the TLR5 ligand flagellin as measured by 
secreted levels of proinflammatory cytokines (data not shown).  
After incubation with 1 μg/mL (equivalent to ca. 70 nM) of non-aggregated Wt 
aSyn for 6 hrs (or mock solution in the case of non-preconditioned samples and 
untreated controls), the cell cultures were incubated for a further 18 hrs with 
standard concentrations of different TLR agonists, or otherwise treated with 
medium alone to serve as controls. The aSyn working concentration was 
chosen considering the typical range from previous reports and especially 
based on our earlier work in which a similar experimental setup has been used 
(Roodveldt et al. 2010). After incubation of cells for a total of 24 hrs, the 
supernatants were recovered for later analysis of their interleukin/chemokine 
contents. Given that the aggregated aSyn as well as the A30P aSyn variant have 
been previously shown to exert a stronger pro-inflammatory effect on microglia 
(Roodveldt et al. 2010; Zhang et al. 2005), control samples were prepared by 
incubating cells for 24 hrs with 1 μg/mL A30P aSyn variant or 1 μg/mL 
oligomeric aSyn species. 
A set of key interleukins, namely pro-inflammatory IL-6, immunoregulatory IL-
10, anti-inflammatory IL-13, and autoimmunity-related IL-17, were assayed by 
ELISA (Table 1). Our results show that, at the concentrations used, all eight TLR 
ligands, as well as A30P and oligomeric aSyn, produced higher IL-6 secretion 
when added alone to microglial cells, relative to untreated controls (Table 1). In 
addition, stimulation with LPS and Poly I:C caused an increase in IL-10 and IL-13 
levels, respectively, while oligomeric aSyn appeared to cause a reduction in IL-
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Control 64.4 ± 10.3 120 ± 34,4 44.1 ± 
12.6 
8.6 ± 1.1 
Wt aSyn 198 ± 89.8 20.8 ± 12.9 72.3 ± 
21.6 
9.2 ± 0.8 




11.6 ± 4.4 
Olig. Wt aSyna 481 ± 130 N/A 33.1 ± 
10.8 
N/A 
LPS 7719 ± 
2231 
253 ± 37.5 61.6 ± 8.1 9.8 ± 1.4 
CpG 1542 ± 296 182 ± 45.4 65.6 ± 
12.5 
9.0 ± 1.2 
Pam3 1604 ± 283 111.4 ± 
57.3 
47.8 ± 7.4 11.0 ± 2.0 
Imiq 1041 ± 235 66.5 ± 18.6 48.1 ± 
6.67 
8.9 ± 1.2 
ssRNA 256 ± 40 68.5 ± 26.1 66.8 ± 
20.6 
9.9 ± 1.4 
PGN 1037 ± 379 63 ± 25.6 61.0 ± 
10.8 
7.9 ± 0.9 




7.9 ± 1.2 
Poly I:C 1641 ± 541 64 ± 23.9 178.0 ± 
34.2 
7.9 ± 1.0 
Table 1. Values of secreted interleukins in primary microglia 24 hrs after treatment. 
Following treatment of cells with aSyn or with TLR agonists at the concentrations 
described in the Materials and Methods section, cell culture supernatants were 
harvested after incubation for 24 hrs, and cytokine levels were assayed by ELISA. Values 
correspond to the mean of six independent experiments (N=6) each containing 
duplicate samples and error corresponds to SEM, except for (a , in which the values 
shown are the mean of two independent experiments (N=2) each containing four 
replicas and the error corresponds to SD. doi: 10.1371/journal.pone.0079160.t001 
We then sought to assess the impact of aSyn-preconditioning of microglia on 
the interleukin secretion profile (Figure 1A). A general increase trend in TNFα 
secreted levels could be observed for the primed cells after TLR stimulation, in 
particular with (TLR7) ssRNA, (TLR2/1 Pam3) and (TLR2) PGN (Figure S1). This 
effect was not seen for IL-1ß, as only (TLR3) Poly I:C produced an increase trend 
in its secretion levels under aSyn priming conditions (Figure S1). On the other 
hand, a significant 4-fold increase in IL-6 release levels was observed for the Wt 
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aSyn-primed cells after stimulation with Pam3 (TLR2/1) (p=0.024), relative to 
the corresponding controls with the TLR agonists in the absence of priming with 
αSyn. Of particular note is that neither IL-10 nor IL-17 levels displayed changes 
in Wt aSyn-primed cells for any of the tested TLR ligands. Interestingly, even 
though they did not reach statistical significance, moderate fold-change 
reductions of IL-13 anti-inflammatory cytokine levels were observed in the 
cases of stimulation of primed microglia with the TLR7 agonists Imiq and 
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Figure 1. Impact of Wt aSyn-priming on microglial cytokine release after TLR 
stimulation. After treating the microglial cells either with Wt aSyn at 1 μg/mL (‘priming’ 
or pre-conditioning) or with ‘mock’ solution (no pre-conditioning) for 6 hrs, the TLR 
agonists were added to their specified final concentrations (see Materials and 
Methods), and incubated for further 18 hrs at 37 °C. The culture supernatants were 
harvested and used to measure (A) the levels of the interleukins IL-6, IL-10, IL-13, and 
IL-17, or (B) of the chemokines IP-10/CXCL10, RANTES/CCL5, MCP-1/CCL2, by ELISA. 
Values are the fold-change calculated as the signal ratio of aSyn-primed, TLR-stimulated 
cells (‘aSyn+TLR ligand’) relative to non-primed, TLR-stimulated cells (‘TLR ligand’). The 
results shown (mean ± SEM) are the average of several independent experiments (IL-6: 
N=5-7; IL-10: N=4-6; IL-13: N=3; IL-17: N=2-3; IP-10, RANTES, MCP-1, and MIP-1α: N=3-
5), each containing duplicate samples. Statistically significant differences (* p<0.05) 
were calculated by applying the Student t test between the two sets of results, for all 
the TLR ligands tested. (#) denotes a result that is significantly different from that 
obtained after treatment of cells with Wt aSyn alone (p<0.05). 
 
Figure S1. Impact of Wt aSyn-priming on microglial TNFα and IL-1ß release after TLR 
stimulation. After treating the microglial cells either with Wt aSyn at 1 μg/mL (‘priming’ 
or preconditioning) or with ‘mock’ solution (no pre-conditioning) for 6 hrs, the TLR 
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Methods), and incubated for further 18 hrs at 37 °C. The culture supernatants were 
harvested and used to measure the levels of TNFα and IL-1ß cytokines by ELISA. Values 
are the fold-change calculated as the signal ratio of aSyn-primed, TLR-stimulated cells 
(‘aSyn +TLR ligand’) relative to non-primed, TLR-stimulated cells (‘TLR ligand’). The 
results shown (mean ± SD) are the average from duplicate samples and is 
representative of three independent experiments for each cytokine measurement. 
Untreated cells and treatment of cells with Wt aSyn alone were used as controls in both 
cases. (TIF) 








Control 16.9 ± 12.9 315 ± 88 1.8   0.4 11.8 ± 7.2 
Wt aSyn 47.2 ± 27.5 505 ± 255 3.8 ± 1.1 4.9 ± 3.3 
A30P aSyn 2290 ± 656 1887 ± 395 11.8 ± 5.9 696 ± 276 
Olig. Wt aSyna 870 ± 341 N/A 6.8 ± 1.7 N/A 
LPS 3693 ± 303 3967 ± 767 27.0 ± 4.6 1832 ± 289 
CpG 1503 ± 557 2183 ± 323 14.8 ± 2.8 1276 ± 285 
Pam3 610 ± 273 1289 ± 225 15.5 ± 3.9 973 ± 75 
Imiq 436 ± 192 1891± 224 18.0 ± 5.0 1277 ± 171 
ssRNA 209 ± 114 609 ± 147 4.5 ± 1.1 176 ± 105 
PGN 549 ± 229 722 ± 275 9.9 ± 4.8 291 ± 92 
LTA 2454 ± 490 2970 ± 620 18.4 ± 3.3 1479 ± 287 
Poly I:C 3116 ± 460 3679 ± 725 20.8 ± 2.4 943 ± 178 
Table 2. Values of secreted chemokines in primary microglia 24 hrs after treatment. 
Following treatment of cells with aSyn or with TLR agonists at the concentrations 
described in the Materials and Methods section, cell culture supernatants were 
harvested after incubation for 24 hrs, and chemokine levels were assayed by ELISA. 
Values correspond to the mean of six independent experiments (N=6) each containing 
duplicate samples and error corresponds to SEM, except for (a, in which the values 
shown are the mean of two independent experiments (N=2) each containing four 
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We then analysed the secretion profile of treated cells for a set of key 
chemokines, namely IP-10/CXCL10, RANTES/CCL5, MCP-1/CCL2, and MIP-
1α/CCL3 (Table 2). Virtually all eight TLR ligands tested, as well as A30P and 
aggregated aSyn, produced an increase in chemokine secretion for all four 
chemokines tested when added to cells, relative to untreated controls (Table 
2). Remarkably, preconditioning of cells with aSyn resulted in a 4.5-fold 
increase in IP-10 levels upon stimulation with ssRNA (TLR7) (p=0.015) (Figure 
1B). Furthermore, a 2-fold increase in the MCP-1 level was measured for the 
case of stimulation with Pam3 (TLR2/1) (p=0.024), and a similar, although not 
statistically significant, trend was seen with Imiq and ssRNA (TLR7) (Figure 1B). 
On the other hand, small and non-significant increases were observed in 
relative levels of RANTES with LTA (TLR2) or MIP-1α with Pam3, relative levels. 
Importantly, all of the increases described above that were statistically 
significant proved to be independent of the sole addition of aSyn (in all cases p 
values were <0.05), implying that these alterations arise from a complex 
combination of aSyn-priming and subsequent TLR-stimulation effects on 
microglia. 
aSyn-preconditioning of microglia alters TLR expression when stimulated with 
Imiq, PGN and Poly I:C 
Given the substantial changes observed in the cytokine secretion profiles as a 
consequence of the preconditioning process, we sought to investigate whether 
or not such alterations could result from changes in TLR expression levels. 
Therefore, we measured the mRNA levels of TLRs 2, 3, 4 and 7 in the samples 
after treatment as described above, and compared the change in TLR 
expression in aSyn-preconditioned vs. non-preconditioned, cells. Because 
stimulation with CpG (TLR9) ligand showed essentially no change trends in 
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either cytokine release levels as a consequence of priming with aSyn, we 
omitted further studies with this ligand and continued our characterization with 
the seven remaining TLR agonists tested (Figure 2). On the one hand, significant 
suppression of TLR7 and TLR3 expression levels were detected in aSyn-
preconditioned cells upon stimulation with Imiq (p=0.002) and Poly I:C 
(p=0.030) ligands, respectively. On the other hand, a modest increase in TLR2 
expression was measured aSyn-preconditioned cells stimulated with PGN 
(p=0.031) (Figure 2). However, even though moderate increases in TLR 
expression were observed for samples stimulated with Pam3 (TLR 2/1), and LTA 
(TLR2), only a 50% increment in the case of PGN (TLR2) reached statistical 
significance (p=0.031), while no changes were measured for the cases of LPS 
and ssRNA (Figure 2). These results suggest that targeting receptor-ligand 
interactions rather, than TLR expression could provide a better rationale and 
strategy for the management of aSyn-related pathologies. 
Figure 2. Comparison of TLR gene expression levels of Wt aSyn-primed vs. non-primed 
microgia, after TLR stimulation. After treating cells as before (see legend to Figure 1), 
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were then examined by qRT-PCR and the hprt gene was used as the internal control to 
calculate ΔCt values. The ΔΔCt values were calculated by subtracting ΔCt values of non-
primed samples upon TLR stimulation (‘TLR ligand’) from ΔCt values of samples treated 
with aSyn-priming upon TLR stimulation (‘Wt+TLR ligand’), to give the fold-change in 
TLR expression in cells with ‘aSyn+TLR ligand’ relative to ‘TLR ligand’ treatments. In all 
cases the TLR gene analysed (indicated inside bars) corresponded to the TLR agonist 
used in that particular sample. Fold-changes represent the average of three 
independent experiments (N=3), each one performed with duplicate samples. Bars 
correspond to SEM. Statistically significant differences (* p<0.05) were calculated by 
applying the Student t test between the two sets of results, for all the TLR ligands 
tested. doi: 10.1371/journal.pone.0079160.g002 
Impact of aSyn priming on microglial phagocytic capacity upon TLR 
stimulation 
Recently, it was reported that, in contrast to the aggregated form, monomeric 
aSyn enhances the microglial phagocytic capacity (Park et al. 2008). Indeed, our 
previous observation that non-aggregated Wt aSyn promotes a moderate but 
significant increase in microglial phagocytosis (Roodveldt et al. 2010) is 
consistent with this finding.  
Therefore, we sought to test whether or not the changes previously observed 
in the secretion of specific cytokines for aSyn-primed microglia, following 
stimulation by certain TLR ligands, could be accompanied by alterations in the 
relative phagocytic capacity of microglia that could be possibly linked to the 
pathogenesis of the synucleinopathies. For this purpose, we used fluorescein-
conjugated tracker microparticles to test the phagocytic capacity of aSyn-
primed vs. non-primed microglia, following stimulation with certain TLR ligands 
(Figure 3). Despite the fact that a certain trend towards moderate increases in 
microglial phagocytosis was noticed in the cases of stimulation with (TLR2/1) 
Pam3 of Wt-primed microglia (~30%), the differences did not reach statistical 
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significance (Figure 3) and therefore we can conclude that the contribution of 
aSyn preconditioning in the neurodegenerative process or immune imbalance 
after TLR triggering, within the microglial environment, is independent of 
phagocytosis. 
Figure 3. Relative phagocytic capacity of Wt aSyn-primed vs. non-primed microglia 
after TLR stimulation. After treatment of the primary microglial cell cultures and 
incubation for a total of 24 hrs as described in the legend to Figure 1, cells were 
incubated with fluorescent microspheres for 1 hr. After fixing the cells, phagocytosis 
was assessed by fluorescence microscopy and calculation of the number of spheres/cell 
as described in the Methods section. Four images were analysed for each sample in 
each independent experiment. The ‘relative phagocytic capacity’ corresponds to the 
ratio (fold-change) of the number of spheres/cell of aSyn-primed cells followed by TLR 
stimulation (‘aSyn+TLR ligand’) relative to the number of spheres/cell of non-primed, 
TLR-stimulated cells (‘TLR ligand’). The values shown are an average of three (for ssRNA 
and PGN) or four (for all the others) independent experiments (N=3 or 4), and error 
bars represent the SEM. Statistically significant differences (* p<0.05) were calculated 
by applying the Student t test between the two sets of results, for all the TLR ligands 
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treatment of cells with Wt αSyn alone (p<0.05). doi: 
10.1371/journal.pone.0079160.g003 
aSyn preconditioning of microglia followed by stimulation with TLR ligands 
leads to differential profiles of cell polarization 
In recent years, it has become clear that, as a result of exposure to 
microenvironmental signals, microglial cells can undergo alternative polarized 
activation modes. The two extreme phenotypes of macrophages are defined as 
M1 (the classical, proinflammatory macrophages) and M2 (the ‘alternatively 
activated’/resolving anti-inflammatory cells); however, a full spectrum of 
activation states which share some overlapping properties with those of the 
poles, are currently thought to exist (Shechter & Schwartz 2013). To gain 
further insight into the effect on cell phenotype of aSyn-primed microglia after 
stimulation withPam3 and ssRNA TLR ligands, we assayed the gene expression 
of standard M1 and M2 phenotypic markers iNOS and Arg1, respectively 
(Ponomarev et al. 2013). As can be observed (Figure 4), treatments with either 
Pam3 or ssRNA alone produced an iNOS+/Arg1- phenotype which, in 
combination with their cytokine release profiles (higher secreted levels of IL-6 
or IP-10 and lower levels IL-10) (Table 1, Figure 1), indicate varying degrees of 
polarization towards an M1-like state.  
Interestingly, treatment of aSyn-primed cells with ssRNA (as well as with Wt 
aSyn alone) produced an iNOS-/Arg1- (double negative) phenotype, while 
stimulation of cells with A30P aSyn induced the expression of the Arg1 marker. 
Remarkably, treatment of aSyn-preconditioned microglia with Pam3 agonist, 
just like exposing cells to oligomeric aSyn, produced an iNOS+/Arg1+ (double 
positive) intermediate phenotype (Figure 4). This result was also the case for 
treatment with LPS, which is consistent with reports of ‘M2 skewing’ and the 
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Arg1+ phenotype of microglia produced by administration of LPS in vitro (Zhang 
et al. 2009) and in vivo (Chen et al. 2012; Lee et al. 2010). The iNOS+/Arg1+ 
phenotype observed in these particular samples, together with the increase in 
secreted IL-6, TNFα, IP-10 and MCP-1 levels (Tables 1 and 2) and with an 
essentially unaltered phagocytic capacity (Figure 2), suggests a skewing 
towards an M1/M2 intermediate or mixed microglial phenotype. 
 
Figure 4. Arg1 and iNOS PCR gene expression assays of aSyn-preconditioned microglia 
stimulated with Pam3 or ssRNA. Primary microglial cells were either treated with Wt 
aSyn (Wt), A30P aSyn (A30P), or oligomeric Wt aSyn (oligomers) at 1 μg/mL, or with 
culture medium alone, for 6 hrs at 37 °C. Subsequently, the TLR agonists or medium 
alone were added accordingly, and cells were incubated for a further 18 hrs as 
described before. After treatment, RNA was extracted and reverse transcribed for PCR 
analysis of arginase-1 (Arg1) and iNOS gene expression. Actin expression was used as a 
reference and the positive controls for the PCR assays (PCR+) were from bone marrow-
derived macrophages stimulated (for Arg1) or not (for iNOS) for 24 hrs with IL-4 (10 
ng/mL). doi: 10.1371/journal.pone.0079160.g004 
aSyn-preconditioning alters activated caspase-3 levels in microglia following 
stimulation with Pam3 and ssRNA 
Even though there is a strong link established between the activation of 
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mediated neuroinflammation and neurodegeneration have been elusive. 
Activated caspase-3 has been observed in the SN of patients with PD 
(Hartmann et al. 2000; Tatton 2000; Jellinger 2009), specifically in microglia 
within the SN of human subjects suffering from PD and AD (Burguillos et al. 
2011). Furthermore, caspase-3 was recently shown to have a key role in the 
regulation of microglia activation and neurotoxicity (Burguillos et al. 2011). 
Therefore, we sought to compare the expression of activated caspase-3 in 
primary microglia produced by the different treatments (Figure 5A). Except for 
an increase produced by stimulation of cells with (TLR7) ssRNA and (TLR3) Poly 
I:C, the basal cleaved caspase-3 levels were not significantly altered by 
treatment with the TLR ligands or the Wt aSyn alone. However, higher cleaved 
caspase-3 levels were indeed observed for Wt aSyn-preconditioned microglia 
upon stimulation with (TLR2/1) Pam3. Remarkably, the observed increase 
induced by (TLR7) ssRNA alone was strongly suppressed by preconditioning of 
cells with Wt aSyn (Figure 5A). Furthermore, these alterations were also 
observed by immunofluorescence (IF) analyses of primary microglial cultures 
that were similarly treated, by using specific antibodies against cleaved 
caspase-3 (Figure 5B and Figure 6). As observed for the untreated cells 
(‘control’), treatment of microglia with Wt aSyn or (TLR2/1) Pam3 alone barely 
produced detectable levels of activated caspase-3. However, preconditioning of 
cells with Wt aSyn and subsequent stimulation with Pam3 produced a general 
increase in fluorescence (ca. 2-fold, p=0.031), located primarily in the cytosol 
(Figure 6). Finally, stimulation of cells with (TLR7) ssRNA ligand alone produced 
an increase in cleaved caspase-3 protein, which localized essentially in the 
cytosol. In agreement with the results obtained by ELISA (Figure 5A), 
preconditioning of cells with Wt aSyn was found to suppress such an ssRNA-
induced increase, by IF analysis. Moreover, this lower level of activated 
caspase-3 was observed mainly to localize in the cell nuclei (Figure 6). 
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Figure 5. Quantitation of activated caspase-3 levels in treated microglial cells, by 
ELISA and immunofluorescence. (A) After treatment of the primary microglial cell 
cultures and incubation for a total of 24 hrs as described in the legend to Figure 1, cells 
were lysed and tested by a specific ELISA assay for cleaved caspase-3 levels 
quantitation. The results shown (ng/mL cleaved casp-3 per μg of total protein) 
correspond to the mean of four independent experiments (N=4), each one performed 
with duplicate samples. Bars correspond to SEM. A discontinuous line represents the 
mean value obtained for untreated cells. Statistically significant differences were 
calculated by applying the Student’s t test in relation to the values obtained with the 
corresponding TLR ligand in the absence of aSyn-preconditioning (* p<0.05) and with 
Wt aSyn alone (# p<0.05). Treatment with staurosporine from Streptomyces sp. (5 μM) 
for 6 hrs was used as a positive control. (B) Cells were cultured in appropriate culture 
plates and treated as explained above (see legend to Figure 1) for subsequent labelling 
of cleaved caspase-3 and nuclear Hoechst 33342 staining for IF analysis, as described in 
the Methods Section. Samples were analyzed under the fluorescence microscope and 
three images from random fields containing ca. 80-90 cells each, were recorded, and 
analyzed for fluorescence quantification. The total specific red fluorescence (RF) and 
blue fluoresce (BF) were measured and the RF/BF ratio was used as a quantitation 
method and is represented in this figure. The results shown (RF/BF ratio) correspond to 
the mean of three images analysed (N=3) within one representative experiment, and 
bars correspond to SEM. A discontinuous line represents the mean value obtained for 
images from untreated cells. Statistically significant differences were calculated by 
applying the Student’s t test in relation to the values obtained with the corresponding 
TLR ligand in the absence of aSyn-preconditioning (* p<0.05) and with Wt aSyn alone (# 
p<0.05). Treatment with staurosporine from Streptomyces sp. (5 μM) for 6 hrs was 
used as a positive control. doi: 10.1371/journal.pone.0079160.g005 
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Figure 6. Immunofluorescence analysis of cleaved caspase-3 levels in treated 
microglial cells. Representative images taken from immunolabeled primary microglial 











ALPHA-SYNUCLEIN AND IMMUNE SYSTEM CROSSTALK IN PARKINSON'S DISEASE; 
THERAPEUTICAL APPROACHES OF ITS MODULATION BY MOLECULAR CHAPERONES 
Wt αSyn. The TLR ligands tested were Pam3 and ssRNA40 at the concentrations 
described before (see Materials and Methods). Cells treated with 5 μM staurosporine 
(Strsp) from Streptomyces sp. for 6 hrs served as a positive control. Specific anti-
(Asp175) cleaved caspase-3 primary antibodies and Alexa Fluor 594 secondary 
antibodies were used to visualize activated caspase-3 (first column), and nuclei were 
counterstained with Hoescht (second column). Merged images are shown in the third 
column and phase-contrast images of the same cultures are shown in the right column. 
White scale bars: 50 μm; grey scale bar (inset): 5 μm. 
5. Discussion 
Despite much progress done in recent years, the underlying mechanisms that 
trigger the onset of the sporadic form of several neurodegenerative diseases 
including AD, PD, DLB, and ALS, remain to be elucidated. Given that they all 
have in common a strong inflammatory response mediated by activated 
microglia, the existence of additional factors that could potentially exacerbate 
such neuroinflammatory process is currently thought to be pivotal. Indeed, it 
has been proposed that microglia in the neurodegenerated brain are somehow 
‘primed’, and signals from systemic infection or inflammation trigger an 
enhanced response that contributes to disease progression (Perry et al. 2007).  
In previous studies, by comparing the effects on primary microglia of Wt aSyn 
with those produced by the PD-linked aSyn mutants, we and others have 
observed a strong proinflammatory microglial response for the A30P and E46K 
variants, as compared to Wt aSyn (Fellner et al. 2011; Roodveldt et al. 2010). 
Intriguingly, and for reasons still unknown, the levels of brain extracellular 
aSyn, including its non-aggregated form, have been found to be largely altered 
in diagnosed patients for several neurodegenerative disorders including AD, PD, 
DLB, and the prion disease (Mollenhauer et al. 2008; Mollenhauer et al. 2011; 
Mollenhauer et al. 2013; Tokuda et al. 2006; Tokuda et al. 2010). 
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In the present work, we have addressed the question of whether or not 
preconditioning with non-aggregated Wt aSyn could possibly affect the innate 
immune response of microglia under conditions of TLR challenge. This issue is 
of great relevance as it may provide information on the microglia-mediated 
functional innate response upon infection at the very initial stages of disease 
onset. 
Our results show that the impact of aSyn-preconditioning of microglia on the 
innate immune response following stimulation with TLR ligands largely depends 
on the nature of the subsequent TLR agonist challenge. Indeed, we observed no 
significant changes in the cytokine secretion profile for certain TLR ligands 
tested, including LPS (TLR4). The latter is consistent with previous reports of the 
response following a challenge with LPS performed both on a transgenic mouse 
model overexpressing Wt aSyn (Gao et al. 2008) and after injection of non-
aggregated Wt aSyn into the mouse SN (Couch et al. 2011), suggesting that 
similar inflammatory reactions were induced by LPS independently of the 
presence of αSyn. Interestingly however, we found that Wt aSyn-primed 
microglia can indeed affect the immune response mediated by TLR2/1 and 
TLR7, either by increasing the secretion of the pro-inflammatory cytokines IL-6 
and TNFα, or by lowering the expression of the anti-inflammatory IL-13. 
Interestingly, IL-1 has been shown to reduce dopaminergic neuronal cell 
mortality within a normal environment, but to contribute to their loss under 
oxidative stress conditions (Morrison et al. 2012). 
Very few studies have so far addressed the involvement of chemokines in PD 
and other related pathologies. In particular, analysis of functional 
polymorphisms in the genes encoding interleukins and chemokines, and their 
links with the age of onset or the overall risk of developing PD, has not resulted 
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the search for chemokine biomarkers of PD in serum has not so far provided 
useful candidates for diagnosis (Scalzo et al. 2011). In this sense, our results 
highlight the possible implications of locally affected chemokine environments 
in primed microglia as a result of specific infections, that have been involved in 
the recruitment of reactive lymphocytes and in promoting neuronal cell death 
(Rostène et al. 2016). According to our results, Wt aSyn-priming additionally 
affects the Pam3 (TLR2/1)- and ssRNA (TLR7) -stimulated microglia by 
increasing the secretion levels of the chemokines MCP-1/CCL2 and IP-
10/CXCL10, respectively, which have been found to be elevated in the CSF of 
AD brains from the very early stages of disease and to be linked to 
neurodegeneration (Galimberti et al. 2006). Overall, the change observed in the 
cytokine release profiles of aSyn-preconditioned microglia stimulated with 
Pam3 and ssRNA resemble that generated by treatment with aSyn oligomers 
and with the A30P aSyn variant, both linked to PD and known to elicit a strong 
inflammatory response mediated by microglia activation (Roodveldt et al. 2010; 
Zhang et al. 2005). In addition, the differential cytokine secretion profiles upon 
stimulation with Pam3 and ssRNA are not mediated by significant changes in 
TLR expression in the case of aSyn-primed cells. 
It is now accepted that multiple forms of activated microglia exist, and whether 
the roles that such differential patterns of activation play in the pathobiology of 
neurodegenerative diseases are beneficial or detrimental, is currently the 
subject of much debate (Shechter & Schwartz 2013). Microglial phagocytosis 
has traditionally been related to steady-state tissue homeostasis by preventing 
the release of proinflammatory intracellular components from dead or dying 
cells, and by contributing to the resolution of inflammation (Colton & Wilcock 
2010; Schwartz 2010). More recently, microglial phagocytosis has also been 
shown to have a role on neuronal death during inflammation triggered by TLR 
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stimulation (Neher et al. 2011). Our present results show that there is no clear 
effect of aSyn-preconditioning on the phagocytic capacity of TLR-stimulated 
microglia. In addition, assessment of Arg1 and iNOS gene expression, together 
with analysis of cytokine release, has revealed a skewing towards an M1/M2 
mixed or intermediate activation phenotype for aSyn-preconditioned microglia 
upon stimulation with ssRNA or Pam3 (Figure 7). It is noteworthy that an 
intermediate M1/M2 microglial phenotype has been found in vivo in AD murine 
models (Colton & Wilcock 2010). However, the double negative or double 
positive character of these resulting activation phenotypes suggest that they 
are of a different nature depending on the particular TLR ligand involved. Our 
results also indicate that the mixed M1/M2-like response elicited by treatment 
of aSyn-primed microglia with Pam3 is reminiscent of that displayed after 
treatment with aSyn oligomers, which are thought to be the most inflammatory 
and toxic forms of aSyn (Marques & Outeiro 2012; Kalia et al. 2013; Cremades 
et al. 2012). This finding is highly relevant as it has been demonstrated recently 
that the inoculation of aggregated forms of Wt aSyn into mouse brains is 
sufficient to trigger PD-like neurodegeneration and the development of PD 
characteristic symptoms (Kelvin C Luk et al. 2012; K. C. Luk et al. 2012). 
In recent years, a link between activated caspase-3 and PD and AD has been put 
forward; higher activated caspase-3 levels have been detected in the SN of PD 
patients (Hartmann et al. 2000; Tatton 2000; Jellinger 2009) and specifically in 
microglial cells within the SN of PD and AD human subjects (Burguillos et al. 
2011). Furthermore, activated caspase-3 was recently shown to play a key role 
in the regulation of microglia activation and to correlate positively with 
neurotoxicity, initially as a result of TLR stimulation (Burguillos et al. 2011). In 
this context, our findings indicate that aSyn-primed microglia result in 
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bacteria-related Pam3. On the other hand, virus-like ssRNA produces the 
opposite effect in addition to relocation from the cytosol to the nucleus, which 
might suggest an activation of the apoptosis pathway (Zheng et al. 1998), and 
therefore our findings could also be of potential interest for selective 
manipulation of apoptotic or neurotoxic signalling pathways in a 
synucleinopathy-prone scenario. 
In summary, our results show that extracellular wild-type aSyn could potentially 
act as a priming factor for microglia to produce an altered TLR response as 
compared to the same challenge in the absence of such priming. Moreover, we 
show that the features of this altered response are highly dependent on the 
identity of the agonist engaging such TLR-mediated responses (Figure 7). We 
propose that this priming effect could be especially relevant in the case of 
sporadic synucleinopathies and other related disorders with aSyn imbalances 
since it postulates that specific infections or inflammatory stimuli, even at the 
pre-oligomeric stage of the aSyn aggregational process, could potentially act as 
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Figure 7. Proposed model of the impact of αSyn-priming and TLR stimulation on 
microglial phenotype and neuroinflammation. Surveyling microglia undergo 
polarization towards an M1-like phenotype after exposure to (TLR7) ssRNA and Imiq, 
and (TLR2/1) Pam3, TLR agonists, characterized by a lack of expression of Arg1, 
expression of iNOS, and high IL-6 production (see Results). On the one hand, αSyn-
preconditioning of microglia and subsequent stimulation with (TLR7) ssRNA (and 
probably Imiq) produces an Arg1-/iNOS- (double negative) mixed or intermediate 
phenotype, and causes an increase in IP-10 and TNFα secretion, and a reduction of IL-
13 levels. In addition, this treatment leads to a reduction in activated caspase-3 levels 
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accompanied with a change in its intracellular location from the cytosol towards the 
nucleus of the microglial cell. On the other hand, exposure of αSyn-primed microglia to 
(TLR2/1) Pam3 agonist induces a skewing towards a different M1/M2 mixed or 
intermediate phenotype, exhibiting an Arg1+/iNOS+ (double positive) expression 
pattern, together with higher IL-6 and MCP-1 secretion levels. Remarkably, this 
phenotype agrees with the one observed for microglia that have been exposed to 
oligomeric αSyn. In addition, the ‘αSyn + Pam3’ treatment causes increase in activated 
caspase-3 levels in microglial cells. doi: 10.1371/journal.pone.0079160.g007 
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CONCLUSIONS 
1. Extracellular non-aggregated α-synuclein could potentially act as a priming 
factor for microglia to produce exacerbated TLR7 and TLR1/2 responses upon 
further challenge as compared to the same challenge in the absence of such 
priming. 
2. α-synuclein-priming of microglia causes a skewing of the immune response 
upon stimulation with ssRNA (TLR7) or Pam3 (TLR2/1) TLR ligands, towards 
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OBJECTIVES 
During the last decade, it has become accepted that there is a link between α-
synuclein and the sustained neuroinflammation and immune imbalance 
associated to Parkinson’s disease. As a result, different approximations have 
been tested to try to restore it. Molecular chaperones have a key role in 
preventing abnormal protein aggregation by interacting with misfolding 
proteins, including α-synuclein. On the other hand, several members of the 
chaperome network have shown immune modulatory capabilities and to be 
potentially useful for treating cancer and certain infections. In order to put in 
common these two features, which are particularly relevant for PD and other 
neurodegenerative misfolding diseases, we performed a set of experiments to: 
1st Characterize the peripheral immune response generated by immunization 
with the complex-forming Hsp70 and aSyn combination in the absence of 
added adjuvant. (A.Labrador-Garrido et al. IID 2014) 
2nd Screen a large set of chaperones on their immune-modulatory capabilities 
to find other promising candidates. (A.Labrador-Garrido et al. FASEBJ 2015) 
3rd Characterize the peripheral immune response elicited by immunization of 
healthy mice with two selected chaperone candidates, by two different 
protocols: 
      3.1 Immunization with Grp94 or FKBP4 in combination with monomeric 
aSyn (A.Labrador-Garrido et al. FASEBJ 2015) 
      3.2 Immunization with Grp94 or FKBP4 in combination with oligomeric aSyn 
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4th Investigate the peripheral immune response and the associated immunity at 
the CNS level, elicited in a PD mouse model by prophylactic immunization with 
Grp94 in combination with monomeric aSyn, by two different approximations: 
     4.1 Adoptive transfer of splenocytes derived from immunized healthy mice 
to recipient PD model animals (J.Villadiego*, A.Labrador-Garrido* el al. 
JNeurosci 2017 –in preparation-) 
    4.2 Direct immunization of PD model mice with Grp94 in combination with 
monomeric aSyn. (J.Villadiego*, A.Labrador-Garrido* el al. JNeurosci 2017 –in 
preparation-) 
5th Determine the effect of these two interventions on dopaminergic neuron 
cell death and on PD symptoms. (J.Villadiego*, A.Labrador-Garrido* el al. 
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Chaperoned amyloid proteins for immune manipulation:      
a-Synuclein/Hsp70 shifts immunity toward a modulatory 
phenotype 
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School of Medicine, University of Seville, Spain 
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6Department of Medical Physiology and Biophysics, School of Medicine, 
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1. Abstract 
a-Synuclein (aSyn) is a 140-residue amyloid-forming protein whose aggregation 
is linked to Parkinson’s disease (PD). It has also been found to play a critical role 
in the immune imbalance that accompanies disease progression, a 
characteristic that has prompted the search for an effective aSyn-based 
immunotherapy. In this study, we have simultaneously exploited two important 
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activities and their recently discovered and diverse ‘‘immunoactive’’ properties. 
In particular, we have explored the immune response elicited by immunization 
of C57BL/6 mice with an aSyn/Hsp70 protein combination in the absence of 
added adjuvant. Our results show differential effects for mice immunized with 
the aSyn/Hsp70 complex, including a restrained aSyn-specific (IgM and IgG) 
humoral response as well as minimized alterations in the Treg 
(CD4+CD25+Foxp3+) and Teff (CD4+Foxp3-) cell populations, as opposed to 
significant changes in mice immunized with aSyn and Hsp70 alone. 
Furthermore, in vitro-stimulated splenocytes from immunized mice showed the 
lowest relative response against aSyn challenge for the ‘‘aSyn/Hsp70’’ 
experimental group as measured by IFN-g and IL-17 secretion, and higher IL-10 
levels when stimulated with LPS. Finally, serum levels of Th1-cytokine IFN-g and 
immunomodulatory IL-10 indicated a unique shift toward an 
immunomodulatory/immunoprotective phenotype in mice immunized with the 
aSyn/Hsp70 complex. Overall, we propose the use of functional ‘‘HSP-
chaperoned amyloid/aggregating proteins’’ generated with appropriate HSP-
substrate protein combinations, such as the aSyn/Hsp70 complex, as a novel 
strategy for immune-based intervention against synucleinopathies and other 
amyloid or ‘‘misfolding’’ neurodegenerative disorders. 
2. Introduction 
a-Synuclein (aSyn) is a highly conserved, soluble protein which is abundant in 
various regions of the brain, and which is currently believed to play a role in 
modulating synaptic plasticity, neurotransmitter release, and presynaptic 
vesicle pool size (Abeliovich et al. 2000; Murphy et al. 2000; Cabin et al. 2002). 
However, the aberrant misfolding and aggregation of this protein and, 
ultimately, its conversion into insoluble amyloid-like fibrils, are linked to 
Parkinson’s disease and other synucleinopathies (Marques & Outeiro 2012). 
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These and other ‘‘misfolding/conformational’’ disorders are characterized by 
conversion of an initially soluble and functional polypeptide into aggregation 
intermediates to ultimately produce insoluble aggregates that can be 
structurally amorphous or fibrillar (Chiti & Dobson 2006). In each particular 
disorder, unfolding and/or misfolding of specific proteins (for simplicity, herein 
referred to as ‘‘aggregating proteins’’) are key initial steps in the aberrant 
aggregation and amyloid formation process (Knowles et al. 2014). 
Like many of the peptides and proteins that are involved in the most common 
misfolding and amyloid diseases – including Alzheimer’s, Huntington’s, type II 
diabetes, and spongiform encephalopathies – aSyn is an intrinsically disordered 
protein (IDP) in its free soluble form (Knowles et al. 2014). IDPs are a group of 
polypeptides that lack significant secondary and tertiary structure, as well as 
many specific intra-chain interactions (Uversky 2013). The high degree of 
conformational flexibility in IDPs has been suggested to underlie the 
observations that these proteins upon immunization tend to produce weak 
immune responses (Uversky et al. 2005) and that they help certain pathogens 
escape immune detection by the host (Dunker 2013).  
In the last decade, a link has been established between aSyn and the abnormal 
immunological process that accompanies the onset and progression of 
synucleinopathies (Roodveldt et al. 2011; Sanchez-Guajardo, Barnum, et al. 
2013). In addition to a robust microglia activation and sustained 
neuroinflammation in the brain, changes in the T cell mediated immunity in the 
brain and the periphery – including an increased presence of T effector (Teff) 
memory cells and dysfunctional regulatory T (Treg) cells – are seen during PD 
progression (Saunders et al. 2012). In the case of the synucleinopathies, several 
studies performed in animal models have found that CD4+ T cells are critically 
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associated to disease (Sanchez-Guajardo, Annibali, et al. 2013; Brochard et al. 
2009; Reynolds et al. 2007; Reynolds et al. 2010). Based on this evidence, it has 
been proposed that identifying modulators that are able to restore the 
imbalance in the Treg-/Teff-mediated immunity and to induce a regulated, 
‘‘neuroprotective’’ immunological environment, might be the key for 
developing effective immunotherapeutic strategies against neurodegenerative 
disorders (Reynolds et al. 2007; Ha et al. 2012; Romero-Ramos et al. 2014). 
Several studies carried out following the pioneering work by Masliah et al. 
(Masliah et al. 2005) have explored different types of approaches to 
immunization with a-synuclein in animal models, which have produced 
promising albeit mixed results, or with as yet uncharacterized therapeutic 
efficacy in human subjects (Sanchez-Guajardo, Annibali, et al. 2013; Benner et 
al. 2008; Masliah et al. 2005; Masliah et al. 2011; Valera & Masliah 2013; 
Ghochikyan et al. 2014; Mandler et al. 2014). Therefore, the development of 
novel aSyn-based vaccination strategies for synucleinopathies and related 
disorders stands as a highly attractive but challenging avenue for research and 
development.  
In addition to the long-established chaperoning functions of heat-shock 
proteins (HSPs) including binding to, remodelling, and conformational 
stabilization of, unfolded/ misfolded client polypeptides (Hartl et al. 2011), 
certain HSPs have been increasingly reported to play diverse roles as 
modulators of the innate and adaptive immunity (Henderson et al. 2010; 
Pockley et al. 2008; Quintana & Cohen 2011; Srivastava 2002). Such functions 
range from promoting antigen cross-presentation and the maturation of 
dendritic cells, to exerting immunosuppressive signals, or facilitating the 
activation of lymphocytes and macrophages (De Maio & Vazquez 2013; Tamura 
et al. 2012; Murshid et al. 2012; Muralidharan & Mandrekar 2013). 
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Therefore, HSPs possess two highly valuable features that could be 
simultaneously exploited for aggregating protein-based manipulation of the 
immune response against misfolding or amyloid disorders, namely, their 
classical ‘‘chaperone’’ functions combined with their recently discovered 
‘‘immunoactive’’ properties. Indeed, this second property has been used to 
boost the antibody production by immunizing mice with DnaK (bacterial) HSP 
chemically cross-linked with Ab peptide (Koller et al. 2004) and PrP protein 
(Koller et al. 2002), and with a 17-aminoacid sequence from Hsp60 conjugated 
to an Ab epitope (Nemirovsky et al. 2011), that is by utilizing either inactivated 
HSP proteins or HSP short fragments, as carriers. Still, to the best of our 
knowledge, no comprehensive characterization of the immune response 
elicited by an ‘‘HSP-chaperoned aggregating protein’’ complex – that is a 
complex generated with a ‘‘functional chaperone’’ able to interact productively 
with the aggregating protein substrate and display its full biological activities – 
has thus far been reported. In this study we decided to investigate, as a proof-
of-concept, the immune response elicited by immunization with a complex-
forming HSP-aSyn combination. We took advantage of the acquired knowledge 
on Hsp70, a highly conserved HSP (Saibil 2013), which has been shown to bind 
to aSyn aggregation intermediates (Dedmon et al. 2005; Huang et al. 2006; 
Roodveldt et al. 2009; Luk et al. 2008) and to interact with aSyn monomers 
(Roodveldt et al. 2009). We report a differential immunological profile as a 
result of immunizing naive mice with a combination of highly purified human 
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3. Material and Methods 
a-Synuclein and Hsp70 protein overexpression, purification, and 
characterization 
Human Wt aSyn was over-expressed in Escherichia coli BL21 (DE3) cells using 
pT7-7 plasmid and purified as described previously (Roodveldt et al. 2010). The 
purity and monomeric state of the aSyn protein preparation (>95%) were 
assessed by15% SDS-PAGE, 4–12% native PAGE (Lonza, Basel, Switzerland), and 
mass spectrometry (not shown), aspreviously described (Roodveldt et al. 2010). 
Recombinant N-hexa-His-tagged human Hsp70 (HSPA1A), which was previously 
cloned into the pET28b vector (Novagen, Merk Millipore, Darmstadt, Germany) 
was overexpressed in E. coli BL21(DE3) (Lucigen, Middleton, WI, USA) and then 
purified and treated as described previously (Roodveldt et al. 2009). The purity 
of the Hsp70 preparation (>95%) was assessed by 12% SDS-PAGE. After passing 
the protein solution through a Amicon Ultra-100 kDa (Merck Millipore Ltd., 
Carrigtwohill, IRL), the protein was assayed for its endotoxin content by the 
ToxiSensor Chromogenic LAL Assay Kit (GenScript, Piscataway,USA). The 
endotoxin levels of the protein preparations were <1 EU/mg protein in all 
cases. Protein concentrations were determined by means of Micro BCA 
Reagent Kit (Pierce, Rockford, IL, USA). 
Preparation of the aSyn/Hsp70 complex 
In order to favour the formation of the aSyn/Hsp70 complex, the purified aSyn 
and Hsp70 proteins were pre-incubated at a1:1 molar ratio in ‘‘Hsp70 buffer’’ 
(50mM Tris/HCl pH 7.4;150mM KCl, 2mM MgCl2) in the presence of 
4mMadenosine 50-triphosphate magnesium salt (ATP) (Sigma–Aldrich, St. 
Louis, USA) for two hours at room temperature(RT), after which time adenosine 
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50-diphosphate monopotassium salt dehydrate (ADP) (Sigma–Aldrich St. 
Louis,USA) was added to a 2.5mM final concentration and incubated for a 
further two hours at RT. Sample preparations consisted of aSyn alone, Hsp70 
alone, a mixture of both, orHsp70 buffer, and they all contained the same 
buffer and received the same incubation treatment. For immunization 
purposes, samples were diluted accordingly in PBS after incubation. 
Western blot assay for aSyn/Hsp70 complex characterization 
In order to assay the formation of the aSyn/Hsp70 complex, protein 
preparations were loaded onto a 4–12% native PAGE (Lonza, Basel, 
Switzerland) and subjected to electrophoresis at 120 V, and transferred for 45 
min onto 0.2mm nitrocellulose membrane (GE Healthcare, Buckinghamshire, 
UK).After blocking overnight with 5% skimmed milk in PBST (0.05% Tween 20 in 
PBS), the membranes were probed with the mouse anti-a/b-synuclein (N19) 
polyclonal antibody(Santa Cruz Biotechnology Inc. Heidelberg, Germany) or the 
anti-Hsp70 monoclonal antibody (C96F3-3) (Enzo LifeSciences inc. Farmingdale, 
NY, USA). HRP-conjugated anti-goat (Santa Cruz Biotechnology inc. Heidelberg, 
Germany)and anti-mouse (Promega, Madison, WI, USA), secondary antibodies 
were used to visualize blots by using ImmobilionTM Western Chemiluminescent 
HRP Substrate (Millipore,Billerica, MA, USA) and Amersham HyperfilmTM 
ECL(GE Healthcare, Buckinghamshire, UK). 
Surface plasmon resonance detection of a-synuclein-Hsp70 interaction 
Surface plasmon resonance experiments were performed in a Biacore X100 
instrument with a CM5 sensor chip (GE Healthcare). 50nM Hsp70 (ligand) was 
immobilized through the amine coupling chemistry, as follows. Both flow cells 
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(NHS) and 0.4M 3-N,N-dimethylamino(EDC) at a flow rate of 5mL/min. 
Immobilization was performed in sodium acetate buffer (pH 5.0). The ligand 
(originally in a solution in ‘‘Hsp70 buffer’’) was injected at 5mL/min in 10mM 
sodium acetate buffer (pH 5.0) at a concentration of 480nM on the activated 
sensor surface2 (Fc2) and then 1Methanolamine-HCl (pH 8.5) was added to 
block the unreacted N-hydroxysuccinimide groups. The level of immobilized 
ligand was 3173 response units (RU).The sensor surface 1 (Fc1) was 
activated/deactivated without ligand for its use as reference surface for 
subtraction of nonspecific signal effects. The running buffer for all the 
experiments was 1x PBS supplemented with 0.05%Surfactant P20, 2mM MgCl2, 
and 2.5mM adenosine 50-triphosphatedisodium salt (ATP). All samples were 
diluted in running buffer at 0, 20, 40, 80, 160, and 320mM, in increasing 
concentrations order with at least one duplicate of lower concentration after 
the highest analyte concentration. Contact time for binding and dissociation 
time were 300 sec. All the binding cycles were performed at 158C. No 
regeneration was applied to the sensor surfaces as sensorgrams readily 
returned to the baseline in the dissociation phase. An extra wash with running 
buffer was applied at the end of each cycle. 
Interaction data were analysed using the Biacore X100Evaluation Software (GE 
Healthcare). The equilibrium dissociation constant (KD) was calculated from 
steady-state sections of the curves 5 sec before analyte injection stop, by using 
the Affinity Wizard tool. 
Animals 
Six to seven week old, C57BL/6 male mice were purchased from the University 
of Seville Center for Animal Production and Experimentation (Espartinas, 
Spain). Animals were kept for one week in the local animal house before the 
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start of the immunization protocol, to allow the mice to acclimatize to their 
new environment. At all stages of the study, animals from each experimental 
group were allocated into different cages such that each cage contained up to 
five mice, in every case corresponding to a mix from different experimental 
groups. All animal procedures were in accordance with good animal practice as 
defined by the relevant national/EU and ARRIVE guidelines and the CEEA-
CABIMER Experimental Animal Committee, and all animal procedures were 
approved by the corresponding committee (CEEA-2010-14). 
Immunization protocol 
Mice were immunized on day 0 with 5 or 50 µg of Hsp70 (‘‘low’’ or ‘‘high’’ dose, 
respectively) and/or 1.06 or 10.6 µg of aSyn (‘‘low’’ or ‘‘high’’ dose, 
respectively). All preparations were diluted in PBS (ca. 50-fold dilution of the 
preincubation mixtures) in the absence of added adjuvants. Mice were injected 
with a single 100 mL s.c. shot in the lumbar region. The same procedure was 
repeated on day 7. On day 14, mice were sacrificed, and the spleen and 500–
700 mL of blood, were extracted for analyses. 
Determination of CD4+, Treg and Teff cell populations 
Splenocytes were isolated from the spleen of immunized mice by perfusing 
with 10 mL with PBS after which erythrocytes were lysed by osmotic shock. The 
number of cells was determined by counting them in a hemocytometer and 106 
cells were labelled with anti-CD4-FITC, anti-CD25- APC, and anti-Foxp3-PE, 
antibodies (BD Biosciences, San Diego, CA, USA), by following the 
manufacturer’s instructions. Flow cytometry analysis was performed with FACS 
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The Treg cell population was calculated as the percentage of cells positive for 
CD4, CD25, and Foxp3 staining among the CD4+ lymphocyte population. The 
Teff (non-regulatory) cell population was calculated as the percentage of cells 
that stained positively for CD4 and negatively for Foxp3 from the CD4+ 
lymphocyte population (Supporting Information Fig. S1). 
In vitro stimulation of splenocytes and determination of secreted cytokines 
Splenocytes were isolated from the spleen of immunized mice after sacrifice, as 
previously described. 3#106 cells from each mouse were divided and cultured 
in three wells (of a 12-well plate) in RPMI medium (BioWhittaker, Verviers, 
Belgium) with 10% inactivated foetal bovine serum (FBS, BioWhittaker, 
Verviers, Belgium). Each well was treated as follows: well 1, medium alone 
(control); well 2, aSyn (20µg/ml); well 3, lipopolysaccharide from Escherichia 
coli serotype 0127:B8 (LPS) (Sigma–Aldrich, St. Louis, USA) (0.5mg/mL). After 
incubation for 24 h, supernatants were collected and centrifuged at 500 g for 5 
min to eliminate any remaining cells and debris, and stored at -80°C for 
subsequent cytokine assaying.  
For quantifying IFN-g, IL-10, and IL-17 levels from culture supernatants, specific 
ELISA kits, namely Mouse IFN-gamma and Mouse IL-10 BD OptEIATM kits (BD 
Biosciences, San Diego, CA, USA), and ELISA Development Kit Murine IL17 
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Antibody content and cytokine measurement in mouse sera 
Blood samples extracted after sacrifice were left for 1 h at 48C and 1h at RT to 
let them clot. After clot formation samples were centrifuged at 21,000 g for 15 
min to obtain cell-free serum, and stored at "808C for further analyses. 
To assay the content of total IgM and IgG antibodies, samples were diluted 
1:240,000 in PBS and 100 mL aliquots were transferred to a 96-well plate well 
(MaxiSorp plate, NUNC, Roskilde, Denmark) and incubated for 1 h at 378C. 
Next, wells were washed three times with 350 mL of PBST (PBS, 0.05% 
Tween20) and blocked for 1 h with Assay Diluent (BD Biosciences, San Diego, 
CA, USA). After washing as in the previous step, wells were incubated for 1 h at 
378C with anti-IgM-(Miltenyi, Bergisch Gladbach, Germany) or anti-IgG- 
(Promega, Madison, WI, USA) -HRP conjugated secondary antibodies diluted 
1:4000 in Assay Diluent (BD Biosciences, San Diego, CA, USA). Afterwards, wells 
were washed five times with PBST, and 3,30,5,50-tetramethylbenzidine (TMB) 
substrate reagent was added to determine the antibody content by following 
the manufacturer’s instructions. To measure the anti-aSyn specific antibodies in 
the serum samples, a similar protocol was followed but with some 
modifications. MaxiSorp (NUNC, Roskilde, Denmark) plates were coated with 
1mg of aSyn diluted in 100mL of PBS in each well and incubated for 1 h at 378C. 
After coating, washing, and blocking steps were performed as described above, 
and 1:40 diluted serum samples in Assay Diluent (BD Biosciences, San Diego, 
CA, USA) were added and incubated for 2 h at 378C. Detection of IgM and IgG 
antibodies was performed as in the protocol described above. All samples were 
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To determine the IFN-g and IL-10 levels, specific ELISA kits, namely Mouse IFN-
gamma and Mouse IL-10 BD OptEIATM kits (BD Biosciences, San Diego, CA, USA), 
were used according to the manufacturer’s instructions. 
Statistical analyses 
Statistical analyses were performed by using the IBM SPSS Statistics 20 pack. 
For all parameters (T cell populations, antibody determinations, and cytokine 
measurements), the Kruskal–Wallis one-way analysis of variance was firstly 
performed to evaluate the existence of significant differences among the 
experimental groups. In order to determine the differences between groups 
and to obtain the P values, the non-parametric Mann–Whitney U test for two 
independent samples was performed. Each group consisted of 5–7 mice (n=5–
7). Statistically significant differences were those with P<0.05. 
4. Results 
Preparation and characterization of a monomeric aSyn/Hsp70 complex 
Based on our previous finding that recombinant human Hsp70 chaperone 
interacts with monomeric aSyn in vitro (Roodveldt et al. 2009), we chose 
human Hsp70 to evaluate our immunization strategy with aSyn. In the 
preparation of the aSyn/Hsp70 complex to be used in biochemical studies as 
well as for immunization protocols, conditions favouring Hsp70/substrate-
binding and therefore, the formation of the aSyn/Hsp70 complex, were chosen 
and applied for all sample preparations (i.e., aSyn/Hsp70 mixture, aSyn and 
Hsp70 proteins alone, and buffer/vehicle). For this, highly purified aSyn and 
Hsp70 in buffer (50mM Tris pH 7.4, 150mM KCl, 2mM MgCl2) at a 1:1 molar 
ratio (or the corresponding protein amount for samples with aSyn or Hsp70 
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alone) were incubated at RT in the presence of 4mM ATP for 2 h to induce the 
opening of the Hsp70 substrate binding pocket, and for a further 2 h with ADP 
added to a final concentration of 2.5mM to favor the formation of the ‘‘high 
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Figure 1. Characterization of the Hsp70-monomeric aSyn association and complex 
formation. Native PAGE and Western blot analysis of samples, by using anti-aSyn or 
anti-Hsp70 antibodies. In addition to the bands corresponding to Hsp70 and aSyn 
proteins, a highly overlapping, lower-mobility band can be seen in both Western blots, 
indicating the formation of an Hsp70/aSyn complex. Bovine serum albumin was used as 
a protein marker (indicated) (A). Binding of monomeric a-Syn to Hsp70 immobilized on 
a Biacore sensor chip. Sensorgrams illustrating dosage-dependent binding of a-Syn to 
1173 RU of immobilized Hsp70 are represented (B). Steady-state concentration plot of 
a-Syn bound to Hsp70 5 seconds before the end of the analyte (a-syn) injection (C). 
In order to evaluate the formation of an aSyn/Hsp70 complex, we subjected the 
incubated mixtures to native PAGE electrophoresis followed by Western blot 
with anti- Hsp70 and anti-aSyn specific antibodies (Fig. 1A). Indeed, we were 
able to detect a band shift in the lane corresponding to the aSyn/Hsp70 sample, 
as compared to the lanes loaded either with aSyn or with Hsp70 alone in both 
membranes labelled with either specific antibodies (Fig. 1A). This additional 
band, with apparently similar electrophoretic migration distance in both 
labelling assays, should correspond to a monomeric aSyn/Hsp70 complex. 
To prove the interaction between monomeric aSyn and Hsp70 and further 
demonstrate the formation of an Hsp70/aSyn complex, we used surface 
plasmon resonance (Biacore, GE Healthcare). This allowed to monitor the 
interaction, in real time, between ATP-loaded Hsp70 and monomeric a-Syn 
through the covalent immobilization of the chaperone onto flow cell 2 (active 
cell) of the sensor chip and the injection of different a-Syn concentrations 
through both active and reference, flow cells. Signals from the active cell were 
corrected by subtracting signal from the reference one. Our data showed that 
the immobilized ligand (Hsp70) was able to specifically bind to the flowing 
analyte (monomeric aSyn) in an ATP-containing buffer (Fig. 1B). None of the 
sensorgrams could be fitted to a simple 1:1 Langmuir binding model in order to 
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calculate kinetic parameters (Ka and Kd), probably because the interaction 
between both molecules is more complex. Binding levels corresponding to a 
section of the curves 5 sec before the end of the injections were used to 
calculate the dissociation equilibrium constant (KD). The steady state binding 
levels against analyte concentration were plotted and fitted to a simple 1:1 
fitting model available in the Biacore Evaluation Software. A good fit was 
obtained (ꭓ2 value of 0.0599 RU2), with a calculated KD value of 192±41 µM (Fig. 
1C), which should correspond to the (ATP) Hsp70/aSyn complex, that is in the 
‘‘low affinity’’ state (Mayer 2013). Therefore, it can be inferred that the KD 
value of the (ADP) Hsp70/aSyn complex induced in our sample preparation for 
immunization, is lower than 190 µM. 
Restrained levels of anti-aSyn antibodies by aSyn/Hsp70-immunization 
To determine the ability of Hsp70 to act as a paradigm ‘‘chaperone adjuvant’’ 
with aSyn, we designed and tested two immunization protocols in mouse with a 
combination of human aSyn and Hsp70 leading to the formation of a moderate-
affinity complex. For this purpose, highly purified, endotoxin-free recombinant 
Hsp70 and aSyn proteins were used. Six to seven weeks old C57BL/6 male mice 
were injected subcutaneously at days 0 and 7, with either ‘‘low’’ (5 µg Hsp70 
and/or 1.06 µg aSyn) or ‘‘high’’ (50 µg Hsp70 and/or 10.6 µg aSyn) protein 
doses, or buffer (vehicle), and maintaining a ca. 1:1 molar ratio for the mixture 
between aSyn and Hsp70. One week after the booster injection, mice were 
sacrificed and their spleen and whole blood were extracted for further 
analyses. 
In order to evaluate the aSyn-specific humoral response resulting from the 
immunization protocol, we measured the levels of anti-aSyn as well as total IgM 
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anti-aSyn and relative anti-aSyn (calculated as anti-aSyn IgM/total IgM) 
antibodies was detected in the mouse groups immunized with both doses of 
aSyn  (ca. 35–50%),  and  with ‘‘low’’ Hsp70  (ca. 40%,  for absolute  IgM  levels),  
Figure 2. Humoral immune response characterization. Absolute anti-aSyn IgM (A) and 
relative anti-aSyn IgM (B) antibodies in serum from immunized mice. Absolute anti-
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specific anti aSyn IgM and IgG antibodies were calculated by dividing anti aSyn IgM or 
IgG levels by the total corresponding antibody levels. AU: arbitrary units. Represented 
values are mean±S.E.M. (n=5–7). Asterisks correspond to statistically significant 
differences between one particular group and the “vehicle” group. Hash signs indicate 
statistically significant differences between different groups. */# P<0.05, **/## P<0.01. 
while this increase was virtually suppressed in the mouse group immunized 
with the aSyn/Hsp70 combination (Fig. 2A, B). A similar profile was observed 
for the measured IgG antibodies, with similar trends that did not reach 
statistical significance in absolute anti-aSyn and relative anti-aSyn (calculated as 
anti-aSyn IgG/total IgG) antibodies, for the ‘‘aSyn’’ experimental group (Fig. 2C, 
D). Also in this case, the anti-aSyn IgG antibody levels for both ‘‘aSyn/Hsp70’’ 
mouse groups were close to those in control mice, indicating a differential 
‘‘restrain’’ effect arising from immunization with the aSyn/Hsp70 combination 
(Fig. 2B, D). 
The regulatory (Treg) and effector (Teff) T cell contents are affected by 
immunization 
Because of the pivotal participation of CD4+ T cells in the development of 
synucleinopathies and other misfolding neurodegenerative diseases associated 
to chronic inflammation, we firstly compared the impact of immunizing mice 
with vehicle, aSyn, Hsp70, or the aSyn/Hsp70 combination, on the CD4+ cell 
populations within total splenocytes (Supporting Information Fig. S1). 
Splenocytes were isolated from immunized and sacrificed mice. The content of 
CD4+ cells in total splenocytes as analysed by flow cytometry showed no 
significant differences between mouse groups (data not shown). 
Next, in order to compare the regulatory T (Treg) cell population contents 
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labeled cells in the isolated splenocytes (Fig. 3A and Supporting Information 
Fig. S1). Our results showed that at ‘‘low’’ concentrations of immunogen, both 
the groups immunized with aSyn and, to a lower degree, Hsp70, produced a 
significant increase in the Treg percentage (15.7±0.5% and 14.3±0.5%, 
respectively), as compared to the mouse group immunized with vehicle 
(control) (11.1±1.0%). However, this effect was not observed using the 
aSyn/Hsp70 mixture (13.1±1.2%), further indicating a differential effect of this 
combination (Fig. 3A). The mice immunized with high protein doses, on the 
other hand, did not show any differences in the percentages of Treg cells 
compared to the control mice. 
Figure 3. Treg and Teff cell populations determination. Percentage of Treg lymphocytes 
calculated as the percentage of cells positive for CD4, CD25, and Foxp3 staining among 
the CD4+ lymphocyte population (CD4+CD25+Foxp3+) (A). Percentage of Teff 
lymphocytes calculated as the percentage of cells with positive staining for CD4 and 
negative for Foxp3 among the CD4+ lymphocyte population (CD4+Foxp3-) (B). 
Represented values are mean±S.E.M. (n=5–7). Asterisks correspond to statistically 
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Figure supplementary 1. Representative flow cytometry plots for Treg and Teff 
populations. The Treg cell population (left column) was calculated as the CD4, CD25 and 
Foxp3 positive staining among the total lymphocyte population (CD4+CD25+Foxp3+). 
The Teff cell population (right column) was calculated as the percentage of CD4 
positively stained cells with negative staining for Foxp3 among the total lymphocyte 
population (CD4+Foxp3-). Plots are from one representative mouse of the ‘vehicle’ (A), 
‘low’ aSyn (B), ‘low’ Hsp70 (C) and ‘low’ aSyn/Hsp70 complex (D) groups. 
Finally, in order to compare the content of the non-regulatory/effector T (Teff) 
cell population in the isolated splenocytes from the different mouse groups, we 
assayed the percentage of Foxp3- (Fig. 3B and Supporting Information Fig. S1). 
In this case, a significant reduction was measured in the CD4+ Foxp3- cell 
population content for the mouse group immunized with a ‘‘low’’ dose of aSyn 
(22.8±0.7%) relative to the group injected with ‘‘vehicle’’ (38.1±7.8%) (Fig. 3B). 
Differential immunoreactivity of aSyn- versus LPS-pulsed splenocytes from 
immunized mice 
Next, as a way to monitor possible aSyn-specific, hyper-/hypo-immune 
responses, we measured cytokine release profiles of cultured splenocytes 
isolated from immunized mice after sacrifice. To this end the cultured cells 
from the different experimental groups were pulsed either with 20 mg/mL aSyn 
(to model the antigen specific immunoreactivity in vitro) or 1 mg/mL LPS (to 
model non-specific/ polyclonal immunoreactivity in vitro) or, alternatively, 
medium alone to determine the basal secretion levels, which corresponds to a 
non-stimulated control (Fig. 4). In particular, IFN-γ and IL-17 as well as IL-10, 
were measured in the supernatant collected after 24 h of incubation. Our 
results show that splenocytes from mice immunized with a ‘‘high’’ dose of 
Hsp70 produced higher basal levels of IFN-γ (260±97 pg/mL), as compared to 
splenocytes from mice immunized with vehicle (Fig. 4A, left panel). On the 
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other hand, stimulation of cultured splenocytes with LPS induced higher IFN-γ 
secreted levels in cells from mice immunized with ‘‘low aSyn’’ (15±10 ng/mL) 
and the ‘‘low aSyn/Hsp70’’ complex (20±12 ng/mL), as well as with ‘‘high 
Hsp70’’ (21±9 ng/mL), as compared to the group immunized with vehicle (Fig. 
4A, central panel). However, the largest induction of IFN-γ was observed for 
cells isolated from mice immunized with the ‘‘high aSyn/Hsp70’’ combination 
(36±14 ng/mL) (Fig. 4A, central panel). Notably, this higher general reactivity in 
the case of the high dose of ‘‘aSyn/Hsp70’’ did not correlate with that elicited 
by aSyn pulsing, as lower than basal levels of IFN-γ were measured as a result of 
aSyn-pulsing of splenocytes for this group (Fig. 4A, left panel). Interestingly, 
lower values of secreted IL-17 levels for the ‘‘low aSyn/Hsp70’’ (4.5±0.17 
pg/mL) and ‘‘high aSyn’’ (4.6±0.11 pg/mL) groups were measured as compared 
to the group immunized with vehicle (5.4±0.11 pg/mL), while an increase for 
the ‘‘high Hsp70’’ group (6.1±0.34 pg/mL) relative to the control (5.0±0.35 
pg/mL was detected upon aSyn-pulsing of splenocytes (Fig. 4B, left panel). On 
the other hand, no significant differences in secreted IL-17 levels as a result of 
LPS-stimulation of splenocytes were detected (Fig. 4B, central, panel). 
Regarding the immunomodulatory-linked cytokine IL-10, splenocytes from all 
groups, except for the ‘‘low Hsp70’’ group, showed higher basal levels of IL-10 
as compared to splenocytes from mice immunized with vehicle (three- to 
fivefold higher) (Fig. 4C, left panel). Pulsing splenocytes with aSyn did not 
significantly alter this profile, except for the ‘‘low Hsp70’’ experimental group. 
Stimulation with LPS produced more variability in IL-10 levels between the 
various groups, although none of them reached statistical significance as 
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Figure 4. Cytokine release profile of splenocytes isolated from immunized mice. IFN-γ 
(A), IL-17 (B), andIL-10 (C) levels were measured in supernantants from cultured 
splenocytes isolated from immunized mice 24 hours after treatment with αSyn (20 
μg/ml) or complete medium alone (left column), or with LPS (0,5 μg/ml) (center 
column). All cytokines were measured by ELISA. Pairwise αSyn/LPS ratios (right column) 
were calculated by dividing the cytokine levels elicited by αSyn (pg/ml) over the 
corresponding cytokine response to LPS (pg/ml) for each mouse. The detection limit for 
the IL-10/IFN-γ and IL-17 assay kits were <30 pg/ml, and 4 pg/ml, respectively. 
Represented values are mean ± S.E.M. (n = 5-7). Asterisks correspond to statistically 
significant differences between one particular group and the ‘vehicle’ group. Hash signs 
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In order to normalize the aSyn-specific response to the general splenocyte 
reactivity, we also analyzed the aSyn/LPS ratio for the three cyokines measured 
(Fig. 4A, right panel). A clear downregulation in the relative IFN-γ secretion 
levels upon challenge with aSyn could be observed for mice immunized with 
the aSyn/Hsp70 combination at both doses (three- to fivefold lower) and 
essentially unaltered relative IL-17 levels (Fig. 4A, B, right panel). Conversely, 
significant increases in the relative IL-10 levels upon aSyn challenge were seen 
for the ‘‘high aSyn’’ and ‘‘high Hsp70’’ experimental groups (five-fold higher), in 
addition to ‘‘high aSyn/Hsp70’’ combination (threefold higher) (Fig. 4C, right 
panel). Taken together, our results suggest that highly reactive splenocytes that 
are hypo-responsive toward aSyn and which display high IL-10 basal secreting 
levels, have been uniquely generated by immunization of mice with the 
aSyn/Hsp70 combination. 
IFNγ and IL-10 cytokine levels in serum indicate a shift toward an 
immunomodulatory response in aSyn/Hsp70-immunized mice 
To evaluate the biological relevance in vivo of immunization with the 
aSyn/Hsp70 complex, we assayed the levels of IFN-γ and IL-10 in serum 
obtained from immunized mice, one week after the booster (Fig. 5). While 
virtually all mouse groups showed no significant alterations in serum IFN-γ 
levels as compared to the vehicle group (12±5 pg/mL), the only significant 
change in this cytokine levels corresponded to a threefold reduction for the 
‘‘high aSyn/Hsp70’’ combination (3.6±1.4 pg/mL) (Fig. 5A). Furthermore, the 
only significant change in serum IL-10 levels observed corresponded to a 
fourfold increase for the mouse group immunized with ‘‘high aSyn/Hsp70’’ 
(28±8 pg/mL) as compared to mice immunized with ‘‘vehicle’’ (7.0±1.8 pg/mL) 
(Fig. 5A). Finally, we analysed the pairwise serum IL-10/IFN-γ ratio (i.e., the IL-
 
 
111 CHAPTER 2: A. LABRADOR-GARRIDO ET AL  IID 2014 
10/IFN-γ measured levels for each mouse) and compared the different 
experimental groups. Remarkably, while the IL-10/IFN-γ ratio for the ‘‘aSyn’’ 
and ‘‘Hsp70’’ groups remains close to that observed for the ‘‘vehicle’’ group, 
immunization of mice with the ‘‘aSyn/Hsp70’’ combination at both doses 
produces a ca. eightfold increase in this ratio (Fig. 5B). This unique effect of the 
‘‘aSyn/Hsp70’’ combination is evidenced by the shift in the serum IL-10/IFN-γ 
relative levels, from a pro-inflammatory, toward an immunomodulatory, profile 
(Fig. 5B). 
Figure 5. IFN-γ and IL-10 serum levels in immunized mice. IFN-γ (gray) and IL-10 (black) 
levels were measured in mouse sera one week after the end of the immunization 
protocol, by ELISA (A). Pairwise IL-10/IFN-γ ratios were calculated by dividing the 
measured IL-10 cytokine level by the measured IFN-γ cytokine level for each mouse (B). 
The detection limit for the IL-10 and IFN-γ assay kits were <30 pg/mL, Values are 
mean±S.E.M. (n=5–7). Asterisks correspond to statistically significant differences 
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5. Discussion 
Over the last few years, immunotherapy has become an expanding subject of 
study as a novel approach for the treatment of neurodegenerative amyloid or 
misfolding diseases, which remain essentially incurable. Accumulated evidence 
highlights the central role in neurodegenerative disorders of an uncontrolled 
cellular-mediated response that could promote microglial activation and 
neuroinflammation, and ultimately lead to neurodegeneration (Mosley et al. 
2012; Appel et al. 2010). In the present work we have combined the 
aggregating, IDP protein aSyn and the full-length and functional Hsp70 
chaperone to promote the formation of an aSyn/Hsp70 complex in vitro, and 
used it to vaccinate naive mice in the absence of added adjuvants, to evaluate 
the resulting immune response. 
Our findings reveal that, while increased levels of anti-aSyn IgM and IgG 
antibodies were produced by immunization with aSyn and Hsp70 proteins 
alone, no such effect was observed for the group vaccinated with the 
aSyn/Hsp70 combination, as compared to the control group. This unique effect 
of aSyn/Hsp70 immunization to produce a restrained anti-aSyn Ab response 
might be beneficial in the context of PD as it has been suggested that anti-aSyn 
antibodies are involved in the pathogenesis of the inherited form of the disease 
(Papachroni et al. 2007; Benkler et al. 2012; Chen et al. 1998). Moreover, this 
feature could be especially positive in the case of well-established 
autoimmune-related neurodegenerative diseases such as Multiple Sclerosis 
(MS) or Acute Motor Axonal Neuropathy, where elevated levels of specific IgM 
and IgG antibodies directed against certain self-antigens have been shown to 
contribute to disease onset and progression (Zhang et al. 2005; Huizinga et al. 
2007; Beltrán et al. 2012; Sádaba et al. 2012; Shahrizaila et al. 2014). 
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A similar trend was seen for the Treg and Teff cell populations, in which the 
increments and reductions, respectively, elicited by immunization with aSyn 
and Hsp70 alone were restrained as a result of vaccination with the aSyn/Hsp70 
complex, again indicating a differential effect of the combined proteins and the 
formation of an immune-functional complex. This ‘‘buffering’’ of the regulatory 
and non-regulatory/effector T cell content toward basal levels as a result of 
immunization with the aSyn/Hsp70 complex – as opposed to immunization with 
both proteins separately – could be potentially beneficial as it indicates a 
capacity of the aSyn/Hsp70 immunization to restore or maintain the Treg/Teff 
equilibrium in a disease, or preonset, scenario. 
Our results with cultured splenocytes from immunized mice and subsequent 
challenge with aSyn or LPS, show clearly that the aSyn-specific response is 
suppressed in the case of vaccination with the aSyn/Hsp70 complex when 
compared to vehicle-injected mice, as indicated by lower aSyn-specific IFN-γ 
and IL-17 relative secretion levels. Even though other cells types present within 
splenocytes could also respond to LPS stimulation, in addition to T cells – such 
as B cells or dendritic cells – this result may reflect a lower Th1/Th17 response 
(a T cell-mediated response involving the liberation of IFN-γ and IL-17) toward 
aSyn as a result of immunization with the aSyn/Hsp70 complex. In addition, we 
found that this change is accompanied by higher basal levels of secreted IL-10 
that are not significantly altered when challenged with aSyn. 
Finally, we found that immunization with the aSyn/Hsp70 complex uniquely 
produced changes in the cytokine levels in serum, consisting of a threefold 
reduction of IFN-γ and a fourfold increase of IL-10 absolute levels, as well as a 
six-fold increase in the pairwise IL-10/IFN-γ ratio, as compared to vehicle-
injected mice. These results clearly demonstrate that the aSyn/Hsp70 
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– and presumably protective – phenotype. This effect could potentially be 
highly beneficial for treatment against misfolding diseases and other 
neurodegenerative disorders, as the Th1/Th17 response has been linked to 
microglia polarization and/or maintenance toward an M1 (classical) pro-
inflammatory phenotype (Mount et al. 2007; Kebir et al. 2007), which in turn 
has been shown to enhance neurodegeneration in PD (Reynolds et al. 2010; Wu 
et al. 2002; Batchelor et al. 1999). 
Overall, our results show that human Hsp70 chaperone acts as a cell immunity 
adjuvant in combination with full-length aSyn, producing a shift in the immune 
response characterized by a restrained aSyn-specific humoral immunity 
coupled to a modulatory/protective phenotype, in immunized naive mice 
(Scheme 1). This shift toward an immunomodulatory phenotype cannot, in 
principle, be attributed to an increase in the Treg cell content, as similar levels 
of Treg cells from spleen were measured in the aSyn/Hsp70-immunized mice as 
compared to the control group. Therefore, either a different quality of Treg 
cells, or the engagement of other cell types such as NKT cells, B lymphocytes or 
even dendritic cells, could potentially be involved in this particular phenotype. 
With the aim of minimizing the potential adverse effects of immunization, such 
as exacerbated inflammation or autoimmunity, two aSyn-based vaccination 
approaches designed to bypass the antigen-specific cellular immunity 
completely, while promoting a strong antigen-specific humoral response, have 
been recently reported (Ghochikyan et al. 2014; Mandler et al. 2014). In this 
work we describe an alternative strategy that is based on the use of a 
combination of Hsp70 and aSyn to produce a restrained anti-aSyn humoral 
response coupled to an immunomodulatory phenotype. We propose that such 
a combined response might simultaneously tackle two aspects of PD 
pathobiology at the onset and progression stages: firstly, an immune-regulatory 
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phenotype in the periphery is expected to exert a neuroprotective effect by 
communicating and interacting with chronically activated microglia and other 
immunocompetent cells in the CNS, and therefore counteracting neuro-
inflammation. Secondly, it might prevent the development of potentially 
detrimental polyclonal antibody responses against aSyn in an aSyn 
overexpression or aggregation scenario, as opposed to a specific antibody 
response directed toward toxic oligomeric species or epitopes, of aSyn. 
Scheme 1. Immunization with aSyn/Hsp70 produces a shift from a proinflammatory 
profile toward an immunomodulatory profile. Immunization of mice with the 
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consisting of highly reactive splenocytes toward a nonspecific/ polyclonal insult which 
display higher IL-10 basal secreting levels, and which are hypo-responsive toward aSyn. 
In vivo, immunization with aSyn/Hsp70 produces a restrained anti-aSyn Ab humoral 
response, as compared to immunization with aSyn alone. This effect is accompanied by 
unique changes in IL-10 and IFN-γ cytokines serum levels, consisting of higher 
immunomodulatory IL-10 and lower Th1-linked IFN-γ, and producing clear-cut shifts in 
the serum IL-10/IFN-γ relative levels. Overall, immunization with the “aSyn/Hsp70” 
combination generates a shift in cellular immunity from a proinflammatory profile, 
toward an immunomodulatory phenotype. 
Furthermore, we suggest that the exploitation of the differential immune 
response elicited by specific combinations of aggregating proteins with 
immune-active and functional chaperones, or by certain HSP/aggregating 
protein complexes, could be an effective means of suppression of the 
uncontrolled pro-inflammatory environment associated to neurodegeneration 
in amyloid and other misfolding disorders. 
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1. Abstract 
We have investigated the potential role of molecular chaperones as modulators 
of the immune response by using α-synuclein (aSyn) as an aggregation prone 
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preselected candidate chaperones and selected 2 from this set as displaying 
immunological activity with differential profiles, Grp94/Gp96 and FKBP4/52. 
We then immunized mice with both chaperone/α-synuclein combinations using 
monomeric or oligomeric α-synuclein (MaSyn or OaSyn, respectively), and we 
characterized the immune response generated in each case. We found that 
Grp94 promoted aSyn-specific T-helper (Th)1/Th17 and IgG1 antibody 
responses (up to a 3-fold increase) with MaSyn and OaSyn, respectively, 
coupled to a Th2-type general phenotype (generating 2.5- fold higher 
IgG1/IgG2 levels). In addition, we observed that FKBP4 favoured a Th1-skewed 
phenotype with MaSyn but strongly supported a Th2-type phenotype with 
OaSyn (with a 3-fold higher IL-10/IFN-g serum levels). Importantly, results from 
adoptive transfer of splenocytes from immunized animals in a Parkinson’s 
disease mouse model indicates that these effects are robust, stable in time, and 
physiologically relevant. Taken together, Grp94 and FKBP4 are able to generate 
differential immune responses to α-synuclein–based immunizations, depending 
both on the nature of the chaperone and on the aggregation state of α-
synuclein. Our work reveals that several chaperones are potential modulators 
of the immune response and suggests that different chaperones could be 
exploited to redirect the amyloid-elicited immunity both for basic studies of the 
immunological processes associated with neurodegeneration and for 
immunotherapy of pathologies associated with protein misfolding and 
aggregation. 
Key Words: misfolding/amyloid disease • Parkinson • heatshock protein • 
immunotherapy 
Abbreviations: aSyn, α-synuclein; AT, adoptive transfer; AU, arbitrary units; 
BSA, bovine serum albumin; EU, endotoxin unit; HSP, heat-shock protein; 
MaSyn, monomeric α-synuclein; MPTP, 1-methyl-4-phenyl-1,2,3,6-
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tetrahydropyridine; OaSyn, oligomeric α-synuclein; PD, Parkinson’s disease; 
Teff, effector T; Th, T-helper; Treg, regulatory T 
2. Introduction 
The eukaryotic chaperome has been defined as an interconnected network 
composed of a large number of molecular chaperones and co-chaperones, 
which are essential for de novo protein folding and to prevent protein 
misfolding and aggregation under heat-shock or environmental stress 
(Albanèse et al. 2006). In addition to the long-established chaperoning 
functions of heat-shock proteins (HSPs) with their client polypeptides (Hartl et 
al. 2011), certain HSPs have lately been reported to play diverse roles as 
modulators of innate and adaptive immunity (Binder 2014). Such emerging 
activities, which include promoting dendritic cell maturation, exerting 
immunosuppressive signals, facilitating the activation of lymphocytes and 
macrophages, and promoting antigen cross-presentation and T-cell priming 
(Binder 2014; Pockley et al. 2008; Murshid et al. 2012; Srivastava 2002), have 
mainly been studied with tumor antigens and peptides, and exogenously 
administered HSPs are currently being tested for the treatment of cancer, 
autoimmune disease, and a variety of infections (Srivastava 2012). Recently, as 
a result of exploiting both features, its immunogenic and chaperoning activities, 
we have reported that Hsp70 is able to redirect the immune response elicited 
by α-synuclein (aSyn), a protein whose misfolding and aggregation are linked to 
neurodegenerative diseases, toward a T-helper (Th)2-type immunity (Labrador-
Garrido et al. 2014). 
Misfolding or amyloid disorders, such as Parkinson’s disease (PD), Alzheimer’s, 
and Huntington’s diseases, and also other conditions including type II diabetes 
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initially soluble and functional polypeptide into oligomeric intermediates and 
then into insoluble fibrillar aggregates (Chiti & Dobson 2006). In each particular 
disorder, unfolding and/or misfolding of specific aggregation-prone proteins are 
thought to be key initial steps in the development of disease (Knowles et al. 
2014). In the case of PD and other synucleinopathies, the aberrant aggregation 
of aSyn in certain regions of the brain ultimately produces insoluble amyloid-
like fibrils linked to pathogenesis and disease progression (Marques & Outeiro 
2012). 
A common pathologic feature of neurodegenerative misfolding disorders is 
sustained microglial activation and neuroinflammation in the central nervous 
system, both of which are currently thought to involve mechanisms mediated 
by peripheral immunity (Appel et al. 2010; Glass et al. 2010). Nevertheless, the 
question regarding which immunological profiles are protective and which lead 
to neurodegeneration along the course of disease has not been completely 
resolved (Appel et al. 2010; Glass et al. 2010). Importantly, a link has been 
established between aSyn and the abnormal immunologic process that 
accompanies the onset and progression of synucleinopathies, which includes 
alterations in the T-cell–mediated immunity in the brain and in the peripheral 
system (Allen Reish & Standaert 2015; Sanchez-Guajardo, Barnum, et al. 2013; 
Roodveldt et al. 2011). Not surprisingly, several attempts have been made to 
induce a protective immune response against PD and other misfolding/amyloid 
disorders, including immunization with aSyn in mouse models of disease 
(Masliah et al. 2005; Masliah et al. 2011; Valera & Masliah 2013; Sanchez-
Guajardo, Annibali, et al. 2013; Ghochikyan et al. 2014; Benner et al. 2008; 
Mandler et al. 2014). 
Thus far, the potential of the chaperome as a modulator of the immune 
response has not been reported. The aims of the present study were, first, to 
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interrogate the chaperome on its immunomodulatory capabilities—and their 
degree of diversity—in relation to aSyn, a typical misfolding/amyloidogenic 
protein, and second, to characterize in detail the immunological profiles 
promoted by chaperoned aSyn as a result of immunization in mouse. Such an 
insight could be highly relevant for future studies on the physiopathology and 
immunotherapeutic strategies on PD and other related disorders. To those 
aims, we first identified those members of the chaperome, which, according to 
previous reports, had either been linked to aSyn or PD, or alternatively had 
been found to display immunological activity. 
We then applied an in vitro screening strategy using a set of 21 preselected 
candidates to identify immune-functional aSyn/chaperone combinations. Two 
chaperones showing different profiles in vitro, Grp94/Gp96 and FKBP4/52, 
were selected and used in aSyn-based immunization protocols using either 
monomeric (MaSyn) or oligomeric (OaSyn) forms of aSyn in C57BL/6mice, and 
the resulting immune responses were characterized by assaying the different T-
cell populations, humoral antibody responses, and serum cytokine profiles. 
Remarkably, the results revealed very significant differences in the 
immunological phenotype in each case, depending both on the chaperone 
employed and on the aggregation state of aSyn. This study, therefore, indicates 
that a variety of molecular chaperones, including Grp94/Gp96 and FKBP4/52, 
can modulate the immunity generated by a misfolding or amyloidogenic 
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3. Material and Methods 
Source of molecular chaperones and preincubation buffers used for in vitro 
screening 
All proteins were human, recombinant, and highly purified: Hsp70 (HSPA1A, 
#10-054-165238), 14-3-3γ (#10-002-38082), 14- 3-3ε (#10-002-38083), and 14-
3-3τ (#10-002-38084) were obtained from GenWay Biotech (San Diego, CA, 
USA); Hsc70 (HSPA8, #ab78431), Grp75/mortalin (HSPA9, #ab79145), Hsp90β 
(Hsp90B, #ab80353), STUB1/CHIP (HSPABP2, #ab82791), FKBP12 (#ab85840), 
cyclophilin A (CypA, #ab96022), DJ-1 (PARK7, #ab51198), apolipoprotein-
J/clusterin (APO-J, #ab69754), Pin1 (#ab51230), Hsp105 (HSPH1, #ab78790), 
and cyclophilin 40 (Cyp40, #ab78815) were obtained from Abcam (Cambridge, 
United Kingdom); FKBP4/52 (#NBC1-22936), Hsp27 (HSPB1, #NBP1-30308), 
Rab11A (#NBP1-44381), Hsp40 (DNAJB1, #NBC1-18369), and Grp94/Gp96 
(HSP90B1, #NBC1-21058) were obtained from Novus (Cambridge, United 
Kingdom). Highly purified Hip (ST13) protein was a kind gift of Prof. Jose M. 
Valpuesta’s laboratory (Centro Nacional de Biotecnologia, Madrid, Spain). All 
purchased recombinant proteins contained an endotoxin level of <1 endotoxin 
unit (EU)/µg protein. 
Buffer conditions used for preincubating the chaperone/aSyn combinations, or 
the corresponding proteins alone as references, were as follows: buffer 1, 
25mMTris, 150mM KCl, 5mM MgCl2, pH 7.4 (Hsp70 and Hsc70); buffer 2, 20 
mM Tris, 100 mM NaCl, pH 8.0 (Grp75, Hsp90β, CHIP/STUB1, FKBP12, CypA, DJ-
1, Pin1, and Hsp105); buffer 3, 20mM HEPES, 150mM KCl, 1mM DTT, 1 mM 
PMSF, 5% glycerol, pH 7.5 (Hip); buffer 4, 20 mM Tris, pH 7.4 (14-3-3γ, 14-3-3ε, 
14-3-3τ, and Cyp40); buffer 5, 20 mM Tris, pH 8.0 (FKBP4/52, clusterin, Hsp27, 
Rab11A, Hsp40, and Grp94). In the cases of Hsp70, Hsc70, and Hsp90β, 4 mM 
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ATP and, 2 h later, 2.5 mM ADP, were added to the preincubation mixtures and 
the corresponding controls. 
Overexpression and purification of aSyn and preparation of aSyn oligomers 
Human wild-type aSyn was overexpressed in Escherichia coli BL21(DE3) cells 
using plasmid pT7-7 and purified as described previously (Roodveldt et al. 
2010). Before lyophilization, the aSyn solution was passed through a 100 kDa 
cutoff Amicon Ultra membrane, 0.5 ml (Millipore, Billerica, MA, USA) to remove 
any aSyn aggregates or bound endotoxins. The purity and monomeric state of 
the aSyn preparation (>95%) was assessed by 15%SDS-PAGE, mass 
spectrometric analysis, and 4–10% native PAGE (Lonza, Basel, Switzerland), as 
previously described (Roodveldt et al. 2010). To remove endotoxin, the aSyn 
solution was passed through a 100 kDa cutoff filter, before being lyophilized 
and stored at -80°C. The preparation and characterization of soluble aSyn 
oligomers were carried out as reported previously (Roodveldt et al. 2012; 
Roodveldt et al. 2013) with human A53T aSyn and the purified oligomeric 
fractions in PBS were stored at 4°C and used within 4 h. Endotoxin levels in the 
protein preparations were measured by the ToxiSensor Chromogenic LAL Assay 
kit (GenScript, Piscataway, NJ, USA), and the values obtained were <1 EU/mg 
protein. The concentrations of non-aggregated and OaSyn were determined by 
means of Micro BCA Reagent kit (Pierce, Rockford, IL, USA). 
Isolation of murine splenocytes 
Splenocytes were isolated from excised mice spleen by perfusing with 10 ml of 
PBS, after which the erythrocytes were lysed by osmotic shock. In the case of 
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pooled together. In all cases, the number of cells was determined by counting 
in a hemocytometer. 
In vitro immunoscreening of chaperones and aSyn/chaperone combinations 
Splenocytes were isolated from the spleen of 4 nonimmunized 5- to 7-wk-old 
C57BL/6 male mice and pooled together, as previously described (Labrador-
Garrido et al. 2014). Cells (3x 106 per well) were cultured in a 12-well plate in 
RPMI medium (BioWhittaker, Verviers, Belgium) with 10% inactivated fetal 
bovine serum (BioWhittaker). Before cell culture treatment, all proteins alone 
or in combination, were preincubated for 4 h at room temperature at 10 times 
their final concentrations in their corresponding buffer as detailed above. After 
diluting each mixture 10 times in culture medium containing 10 µg/ml 
polymixin B (Sigma-Aldrich, St. Louis,MO,USA), each well with cultured 
splenocytes was treated either with medium alone (control), with chaperone at 
a concentration of 140nM(except for FKBP12, cyclophilinA,DJ-1, and Pin1, 
which were used at 715 nM because of their lower immunogenicity, and 
Hsp105 and Grp94/Gp96, which were used at 14 nM because of their higher 
immunogenicity), with a combination of each chaperone and aSyn at equimolar 
concentrations, or with aSyn alone (at 140, 715, or 14 nM, accordingly). After 
incubation for 24 h, the cell culture supernatants were collected and 
centrifuged at 500 g for 5 min to separate the cells, and 106 cells were labeled 
with anti–CD86-FITC and anti–I-A/I-E-PE antibodies (BD Biosciences, San Diego, 
CA, USA) by following the manufacturer’s instructions. They were then analysed 
by flow cytometry using a FACS Calibur cytometer with CellQuest Pro (BD 
Biosciences) software. Two independent experiments were performed, both 
containing sample duplicates. The cell-free supernatant solutions were stored 
at -80°C for subsequent cytokine assaying. 
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Overexpression and purification of FKBP52 and Grp94 proteins used for 
immunization procedures 
Highly purified, recombinant Grp94/Gp96 protein (canine, #ab92290) 
overexpressed with baculovirus was purchased from Abcam. Highly purified, 
recombinantFKBP4/52 (FKBP59,human) was produced and purified as 
previously described (27). Briefly, the latter protein was overexpressed in E. coli 
as a gluthathione- S-transferase fusion and purified on Glutathione Sepharose 
(GE Healthcare Life Sciences, LittleChalfont,United Kingdom) equilibrated in 
PBS. Unbound material was washed from the column with 10mM ATP-
magnesium salt (Sigma-Aldrich) in PBS and then with PBS containing 1 mM DTT. 
FKBP52/4 was eluted from the column following cleavage from gluthathione-S-
transferase with bovine thrombin. The protein was subsequently purified by gel 
filtration on a G200 Sepharose HR26/60 column equilibrated in 50 mM Tris-HCl 
(pH 7.4), 150 mM NaCl and then on a Mono Q HR10/10 column (GE Healthcare 
Life Sciences) binding in 20 mM bis-Tris (pH 6.2) containing 1 mM DTT and 
eluting with a linear gradient from 0 to 1 M NaCl over 180 ml. Fractions 
containing the protein were analysed by SDS-PAGE and dialyzed overnight in 50 
mM TrisHCl (pH 7.4) containing 1mM DTT. Purified FKBP52 was incubated with 
polymixin B-agarose (Sigma-Aldrich) preequilibrated with buffer containing 1 
mM DTT, according to the manufacturer’s instructions, to remove endotoxins. 
Endotoxin levels in the purified protein preparations were measured by the 
ToxiSensor Chromogenic LAL Assay kit, and the values obtained were <1 EU/mg 
protein. 
Animals 
Male C57BL/6 mice 6–7 wk old were purchased from the University of Seville 
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Animals were kept for 1 wk in the local animal house before the start of the 
immunization protocol, to allow the mice to acclimatize to their new 
environment. At all stages of the study, animals from each experimental group 
were allocated into different cages such that each cage contained up to 5 mice, 
in every case corresponding to a mix from different experimental groups. All 
animal procedures were in accordance with good animal practice as defined by 
the relevant national/EU and Animal Research: Reporting of In Vivo 
Experiments guidelines and the ´Ético de Experimentación Animal–Centro 
Andaluz de Biología Molecular y Medicina Regenerativa -Andalusian Molecular 
Biology and Regenerative Medicine Centre (CEEA–CABIMER) Experimental 
Animal Committee, and were approved by the corresponding committee 
(CEEA-2010-14). 
Protein uptake and splenocytes cytokine secretion assays 
Purified A90C aSyn variant and bovine serum albumin (BSA; Sigma) labelled 
with Alexa Fluor 647 (AF647) in PBS were used. For protein labelling, purified 
aSyn was first passed over a PD10 desalting column equilibrated in PBS (GE 
Healthcare Life Sciences, Buckinghamshire, United Kingdom) to remove 10 mM 
DTT present in the stock protein solution to keep the cysteine residue reduced. 
The BSA was dissolved in PBS at 2 mg/ml and both proteins were labelled with 
AF647 via amine coupling. Reactions were carried out at a 1.5 molar excess of 
label to protein. The excess label was separated from the protein via gel 
filtration using a PD10 column. 
In the protein uptake assay, murine splenocytes in culture were treated either 
with medium alone (control) or with preincubation mixtures containing the 
selected chaperones (Hsp70, Grp94/Gp96, or FKBP4/52) at a final 
concentration of 420 nM, or a combination of each chaperone and labelled 
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client protein (aSyn or BSA) at equimolar concentrations, or labelled client 
protein (aSyn or BSA) alone, at the same concentration as described above. 
Before being added to the cell culture, preincubation mixtures were prepared 
as described in the screening procedures. After incubation for 1 h, cells were 
harvested and processed for flow cytometry analysis for MHC-II and labeled 
client protein detection. 
Immunization protocols 
Immunizations with MaSyn (protocols 1 and 2) and with BSA 
Preincubation mixtures were prepared forGrp94 and/or MaSyn in 20 mM 
HEPES (pH 7.5) for 2 h at 42°C (28), and for FKBP52 and/or MaSyn in 20 mM Tris 
(pH 8.0) for 2 h at 30°C, keeping a 1:1 molar ratio for chaperone:MaSyn. 
Afterward, the preincubated mixtures were diluted in PBS (approximately 50-
fold dilution of the preincubation mixtures) in the absence of added adjuvant. 
Mice were immunized with the different preparations, as follows: Grp94 (5 µg) 
and/or MaSyn (0.8 µg) (protocol 1), FKBP52 (30 µg) and/orMaSyn (8.6 µg) 
(protocol 2). Mice were injected on d 0 with a single 100 µl s.c. injection in the 
lumbar region. The same procedure was repeated on d 7. On d 14,mice were 
killed, and the spleen and 500–700 µl of blood were extracted for analyses. In 
addition, removal of endotoxin from the Hsp70 preparation and immunizations 
with Hsp70/aSyn, Hsp70, aSyn, vehicle/buffer (n = 5), BSA and Hsp70/BSA(n=3) 
were done as previously described (8). BSA (Fraction V; Sigma- Aldrich) solution 
was previously depleted of endotoxin by passing the solution through a 100 
kDa cutoff filter by centrifugation. Endotoxin levels in the protein preparations 
were measured by the ToxiSensor Chromogenic LAL Assay kit (GenScript), and 
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Immunizations with OaSyn (protocol 3) 
Preincubation mixtures were prepared as described above for protocols 1 and 
2. Mice were immunized with Grp94 (8 µg) and/or OaSyn (13 µg) or FKBP52 
(9.4 µg) and/or OaSyn (13 µg) to generate molar ratios of 1:10 and 1:5 
chaperone:aSyn, respectively. All preparations were diluted in PBS (~50-fold 
dilution of the preincubation mixtures) in the absence of added adjuvant. On d 
0, mice were injected with a single 100 µl s.c. injection in the lumbar region. 
The same procedure was repeated on d 7 and 21. On d 28, the mice were killed, 
and the spleen and 500–700 µl of blood was extracted for analyses. 
Determination of CD4+, regulatory T-cell, and effector Tcell populations in 
isolated splenocytes 
After isolation of splenocytes as described above, 106 cells were labeled with 
anti–CD4-FITC, anti–CD25-APC, and anti–Foxp3-PE antibodies (BD Biosciences), 
by following the manufacturer’s instructions. Flow cytometry analysis was 
performed with a FACS Calibur cytometer using CellQuest Pro(BDBiosciences) 
software. The CD4+ cell populationwas calculated as the percentage of cells 
positive for CD4 within the total lymphocyte population. The regulator T (Treg) 
cell population was calculated as the percentage of cells positive for CD4, CD25, 
and Foxp3 staining (CD4+CD25+Foxp3+) among the CD4+ lymphocyte population. 
The effectorT (Teff) cell (nonregulatory) population was calculated as the 
percentage of cells that stained positively for CD4 and negatively for Foxp3 
(CD4+Foxp3-) amongCD4+ lymphocytes. 
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Adoptive transfer of murine splenocytes and 1-methyl-4- phenyl-1,2,3,6-
tetrahydropyridine treatment of acceptor mice 
After death, a pool of splenocytes from 5 immunized mice was prepared by 
mixing 2 x 107 cells per mouse for every experimental group. On d 0, each 
mouse was injected intraperitoneally with 107 cells. A total of 5 acceptor mice 
per group were used (n= 5). On d 7, acceptor mice were placed on a 1-methyl-
4-phenyl- 1,2,3,6-tetrahydropyridine (MPTP) treatment to model chronic PD, as 
previously described (Muñoz-Manchado et al. 2013). One month after the end 
of the MPTP treatment, the mice were killed and 500–700 µl of blood was 
extracted for analyses. 
In vitro stimulation of splenocytes 
Splenocytes were isolated from the spleen of immunized mice after killing, as 
previously described. Cells (2 x 106) from each mouse were divided and 
cultured in 2 wells (of a 12-well plate) in RPMI medium (BioWhittaker) with 
10% inactivated foetal bovine serum. Each well was treated either with 
medium alone (control) or with aSyn (20 µg/ml). After incubation for 24 h, the 
supernatant solutions were collected and centrifuged at 500 g for 5 min to 
eliminate any remaining cells and debris, and stored at -80°C for subsequent 
cytokine assaying. 
Antibody determination by ELISA 
Blood samples extracted after death were left for 1 h at 4°C and 1 h at room 
temperature to allow clotting to occur. After clot formation, the samples were 
centrifuged at 21,000 g for 15 min to obtain cell-free serum, and stored at -80°C 
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IgG antibodies were quantified as described previously (Labrador-Garrido et al. 
2014). The values shown [expressed in arbitrary units (AU)] were calculated as 
follows: the values of anti-aSyn result from multiplying the absorbance 
measured in the ELISA assay by the dilution factor of the samples; the values of 
total antibodies result from multiplying the measured absorbance by the 
dilution factor of the samples and by a factor of 1023; finally, the anti-
aSyn/total antibody ratios (AU) were calculated by dividing the absorbance 
values obtained in the corresponding ELISA assays (anti-aSyn antibodies over 
total IgG antibodies, previously multiplied by each dilution factor), and finally 
multiplying by a factor of 105 for simplicity purposes. 
IgG1 and IgG2a isotypes were quantified by following the same procedure as 
for total IgG antibodies, except that Rat monoclonal anti-mouse IgG1 (Abcam) 
and Rat monoclonal antimouse IgG2a (Abcam), respectively, were used as 
detection antibodies. 
Cytokine determination by ELISA 
For quantification of IFN-γ, IL-10, and IL-17 levels from culture supernatants or 
serum, specific ELISA kits, namely mouse IFN-γ and mouse IL-10 BD OptEIATM 
kits (BD Biosciences), and ELISA Development Kit Murine IL17 (PreproTech, 
London, United Kingdom), were used according to the manufacturer’s 
instructions. 
Statistical analyses 
Statistical analysis was performed by using the IBMSPSS Statistics 20 pack 
(Chicago, IL, USA). For all parameters (T-cell populations, antibody 
determinations, and cytokine measurements), the Kruskal-Wallis 1-way ANOVA 
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was first performed to evaluate the existence of significant differences among 
the experimental groups. To determine the differences between groups and to 
obtain the P values, the nonparametric Mann-Whitney U test for 2 independent 
samples was performed. Each group consisted of 5 mice. Statistically significant 
differences were those with P<0.05. 
4. Results 
In vitro screening of a set of chaperone candidates for the selection of 
immunofunctional aSyn/chaperone combinations 
As a first step in identifying promising candidates that could potentially serve to 
immunochaperone aSyn, we first designed and set up an in vitro assay based on 
cultured murine splenocytes to screen a large set of preselected candidates. 
The preselected set consisted of 21 chaperones or co-chaperones (Table 1), all 
of which had either been linked to aSyn or to PD or had been found to display 
immunological activity, according to previous reports.  
Prior to the screening, mixtures of highly purified aSyn and chaperone proteins 
(or the corresponding controls with each protein alone) were prepared as 
described in Materials and Methods. Following a 4 h incubation at room 
temperature, murine splenocytes in culture were stimulated with the various 
aSyn/chaperone combinations and protein controls, previously diluted in PBS to 
their final concentrations (see Materials and Methods) and incubated at 37°C 
for 24 h. Stimulated splenocytes were subsequently labeled to enable detection 
of CD86 and MHC-II surface markers and analysed by flow cytometry (Table 1). 
We then plotted the percentages of CD86+/MHC-II+ cells obtained according to 
the different combination:chaperone ratios vs. the corresponding 
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aSyn and each chaperone, and observed a dispersion of data for the various 
chaperone proteins that we tested (Fig. 1). In addition, the levels of 3 key 
cytokines, namely IFN-γ, IL-10, andIL-17, were assayed in the culture 
supernatants (Table 1) and plotted in an analogous manner (Figs. 1B–D). We 
designed our screening procedure to favour highly immunogenic 
chaperone/aSyn combinations with a diversity of modulatory profiles while 
relegating those with extreme IL-17 responses, which may promote cytotoxic 
Th17 cell-mediated effects (Reynolds et al. 2010; Zhang et al. 2013). Based on 
this, we identified chaperones that showed the highest signal ratios along one 
or both axes in the plots representing MHC-II+/CD86+ expression, and IL- 10 
and IFN-γ cytokine levels, while a negative selection criterion was applied for IL-
17 cytokine (Fig. 1 and Table 1). Three chaperones, Grp94/Gp96 (HSPC4), 
Hsp105, and peptidyl-prolyl cis-trans isomerase FKBP4 (or FKBP52/59), were 
found to produce the largest changes of CD86+/MHCII+ cells after splenocyte 
stimulation (Fig. 1A). The highest signal ratios for IFN-γ were observed for 
Cyp40, Pin1, Grp94/Gp96, FKBP4/52, Rab11A, Hsp40, and Hsp105. On the other 
hand, the highest signal ratios for IL-10 were observed for Grp94/Gp96, 
FKBP4/52, clusterin, and Hsp105 (Table 1). And, finally, the highest signal ratios 
for IL-17 were observed for 14-3-3ε, 14-3-3τ, and Hsp90β. Next, the chaperones 
that exhibited the largest values in combination with aSyn for the first 3 
parameters measured and that did not stand out in the IL-17 assay were 
identified (Table 1). Based on these analyses, Grp94/Gp96 and FKBP4/52 were 













(%) IFN (pg/ml) 
Protein 
name 
Altern.name Syn Chap. Comb. Syn Chap. Comb. 
HSPA1A Hsp70 3.5±0.55 8.45±0.14 9.9±0.13 31.8±8.9 27.3±8.8 50.5±3.8 
HSPA8 Hsc70 11.8±2.37 15.5±2. 
7 
20.1±3.8 708±42.1 565±68 
HSPA9 Grp75  
 
1.6±0.1 




HSP90B Hsp90β 5.32±0.29 4.1±0.4 20. 6±1.9 43.4±6.6 
STUB1 CHIP 14.2±0.13 13.5±0. 
5 
1691±201 1842±59 
Cyp40  3.5±0.27 5.7±0.11 41±17.3 730±148 
FKBP1A FKBP12 2.8±0.5 4.8±0.30 5.9±0.6 18.4±1.5 18.1±2.1 57±14 
CypA  3. 9±0.16 6.3±0.03 23.5±12.3 16.6±4.0 
PARK7 DJ- 1 2.2±0.12 4.7±0.18 5.2±0.2 43.4±8.7 1393±96 1363±103 
PIN1 Pin1 2.8±0.5 3.32±0.03 4.8±0.4 12. 8±1.4 189±29.6 
HSPC4 Grp94/Gp96 2.4±0.3 7.6±0.8 15.1±0.5 20.3±3.75 490±55 1093±12 
14-3-3γ  2.4±0.55 1.68±0.06 2.5±0.3  
34.2±3.8 
14.3±0. 6 23.2±8.8 
14-3-3ε  1.4±0.2 1.35±0.06 1.7±0.07 11.9±0.1 31.7±4.2 
14-3-3t  1.54±0.05 1.9±0.5 15.0±0.4 24.8±2.7 
ST13 Hip 2.2±0.1 5.8±0.22 5.8±0.1 47.3±7.7 40.7±4.9 43. 6±4.2 
Apo-J Clusterin 1.5±0.16 2.2±0.3 23.7±2. 7 60.0±4.4 
HSPB1 Hsp27 0.8±0.06 
 
0.78±0.09 1.6±0.1 16.7±2.3 13.6±0.2 40.0±5.7 
FKBP4 FKBP52/59 12.9±0.1 12.3±0.1  
12.8±2.37 
6080±318 6430±124 
RAB11A  2.3±0.2 12.7±4.5 7.7±0.2 4476±18 4493±27 
DNAJB1 Hsp40 3.5±0.30 2.7±0.97 1909±163 3008±85 
HSPH1 Hsp105 2.8±0.02 6.1±0.33 12.4±2.1 259±36 417±12.0 
 
TABLE 1. In vitro screening of chaperone/aSyn combinations on stimulated murine 
splenocytes in culture. Assayed parameters were MCH-II+/CD86+ cells percentage as 
analysed by flow cytometry, and IFN-γ, IL-10, and IL-17 cytokine levels as determined 
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Chaperones     
                                              





Syn Chap. Comb. Syn Chap. Comb. 
HSPA1A Hsp70 10.1±0.12 21.0±1.3 27.1±0.6 15.3±0.1 19.8±0.8 23.7±4.2 
HSPA8 Hsc70 24±8.0 322±18 293±20 31.5±0.1 29.0±0.1 
HSPA9 Grp75  
 
56.4±1.5 
113±3.5 99. 8±7.2  
 
10.2±0.1 
12.1±0. 6 13.5±0.8 
HSP90B Hsp90β 27. 7±2.7 25.4±4.9 16.4±0.8 20.4±1. 9 
STUB1 CHIP 91±10.7 103.5±4.9 11.9±0.01 15.2±1.3 
Cyp40  29±3.6 31.0±0.5 14.2±0.4 15.1±0.3 
FKBP1A FKBP12 34±8.0 16.7±0.9 32±11.7  
10.7±0.3 
10.5±0.1 10.6±0.4 
CypA  14.0±1. 6 18.4±0. 8 14.4±1.0 14.9±0.7 
PARK7 DJ- 1 21±7.9 24.5±1.9 20.5±3. 5 10.5±0.01 12.7±0.1 
PIN1 Pin1 14.8±0.95 24.0±2.2 25.5±0. 9 21.9±1.5 22.1±1.2 
HSPC4 Grp94/Gp96 10.0±1.1 61. 8±4.0 108.6±3.3 13.8±0.3 20.2±3.2 20.7±1.5 
14-3-3γ  11.9±0.1 8.8±0.05 12.8±2.0 14.9±2.8 17.6±5.0 20.1±3.3 
14-3-3ε  23±8.0 20.6±0.47 28.6±2.7 14.0±0.1 11.5±0.9 19.6±1.9 
14-3-3t  14±0.1 16.2±0.39 19. 5±0.1 12.7±1.5 19.0±1.9 
ST13 Hip 24.3±1.3 17.1±0.04 30±10.6 25.6±0.3 30.0±2.2 36.6±0.4 
Apo-J Clusterin 21.2±2.1 12.6±1.35 32.3±3.0 22.3±0.7 22.4±0. 9 
HSPB1 Hsp27 27±2.2 17.6±0.03 40±7.7  
30.0±3.0 
18.5±0.1 19.4±0.01 
FKBP4  FKBP52/59 277±3.5 347.9±2.5 32.5±0.5 37.4±2.0 
RAB11A  11.0±0.1 115.4±1.9 103±7.1 25.1±2.9 21.1±2.6 
DNAJB1 Hsp40 27.2±2.2 28.9±1.2 53.8±3.3 42±10.6 28.9±7.9 
HSPH1 Hsp105 61±4.5 99.0±2.5 11.4±0.1 11.1±0.1 
 
representative experiment. Altern., alternate; Chap., chaperone; Comb., combination. 
Previously identified chaperones based on results shown in Fig. 1 are highlighted in 
grey. Selected chaperones are indicated in dark grey. 
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Figure 1. In vitro screening of a set of 21 chaperone candidates and the corresponding 
chaperone/aSyn mixtures for selection of immunoactive combinations. Murine 
splenocytes in culture at 1 x 106 cells/well were stimulated with the various 
aSyn/chaperone combinations (at a 1:1 molar ratio, at the nanomolar level; see 
Materials and Methods for details), or with aSyn or the chaperones alone at the same 
concentrations used as controls and incubated at 37°C for 24 h. Splenocytes were then 
labeled for detection of CD86 and MCH-II surface markers and analysed by flow 
cytometry. The contents (percent) of double-positive cells for all the samples were 
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combination/chaperone vs. the same combination/aSyn (A). The levels of IFN-γ (B), IL-
10 (C), and IL-17 (D) cytokines in the supernatants of cultured splenoctyes were 
assayed (Table 1), and the values obtained were plotted in an analogous manner. As a 
first selection step, chaperones that fell within the top triangle in the plot were 
identified (Table 1). In a second round, previously identified chaperones that showed 
the highest measured values in combination with aSyn for CD86+/MHC-II+, IFN-γ, and IL-
10, but not for IL-17, were singled out (Table 1). Based on this analysis, Grp94/Gp96 
(red) and FKBP4/52 (green) chaperones were chosen for subsequent immunization 
studies. Other chaperones that showed extreme values in either plot are shown in 
color: Cyp40 (pink), 14-3-3ε (blue), Hsp105 (yellow), clusterin (brown), and Hsp90β 
(white). 
Specific response elicited by chaperoned aSyn as compared with a 
nonrelevant client protein 
To assess the specificity of the immune responses observed in the screening, 
we carried out a set of assays to compare the effect of Grp94, FKBP4, and 
Hsp70 (as a previously studied model chaperone) on the response elicited by 
aSyn or BSA as a nonrelevant client protein. For this purpose, we first 
quantified the uptake by cultured murine splenocytes of fluorescently labeled 
client protein (aSyn or BSA), alone or in the presence of either chaperone, by 
flow cytometry (Supplemental Fig. 1A). Our results show that although the 
proportion of MHC-II+/aSyn+ cells is higher in the presence of all 3 chaperones 
as compared with the non-chaperoned aSyn, the percentage of MHC-II+/BSA+ 
cells is lower or remains essentially unaltered in the presence of the 
chaperones, as compared with nonchaperoned BSA. Next, we quantified the 
cytokine release levels from stimulated splenocytes with the same protein 
mixtures after incubation for 24 h (Supplemental Fig. 1B, C). These results, 
which are in good agreement with those observed in the screening step, 
showed that all 3 chaperones affect the cytokine release profile elicited by aSyn 
and BSA in a differential manner and that the immune response is specific for 
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each client protein. Furthermore, we used Hsp70 as a previously studied 
chaperone to test the specificity of the immune response elicited by 
chaperoned aSyn or BSA in C57/BL6 mice, as a result of immunization with the 
different protein mixtures. According to the measured cytokine levels in serum 
from immunized mice, although immunization with Hsp70/aSyn caused a 7-fold 
higher IL-10:IFN-γ ratio as compared with aSyn, immunization with Hsp70/BSA 
did not change the IL-10:IFN-g ratio as compared with BSA, indicating that the 
chaperone affects the immune response differentially when comparing aSyn 
with a nonrelevant client protein (Supplemental Fig. 1D). Thus, our results 
indicate that the changes observed in the immune response generated in the 
presence of these chaperones depend on the identity of the accompanying 
client protein, and therefore that the immune regulation in subsequent 
experiments that combine these chaperones and aSyn can be anticipated to be 
aSyn dependent.  
Altered reactivity of splenocytes of mice immunized with Grp94- or FKBP4-
chaperoned MaSyn 
To test and compare the immunogenic activity of both selected chaperones in 
vivo, we first applied an immunization protocol with each chaperone in 
conjunction with MaSyn. Mice were immunized with 1:1 molar ratios of 
chaperone:MaSyn preincubated mixtures or the corresponding controls, 
according to protocols 1 or 2 as described in Materials and Methods, as follows: 
with either Grp94, MaSyn (lower concentration), Grp94/MaSyn, or buffer 
alone/vehicle (protocol 1), or with FKBP4 MaSyn (higher concentration), 
FKBP4/MaSyn, or buffer alone/vehicle (protocol 2).One week after the booster 
injection, the mice were killed, and their spleens and whole blood were 
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Suppl. Figure 1. Assessing the specificity of the immune response elicited by 
chaperoned aSyn. Uptake of AF647-labeled client proteins (CP) aSyn and BSA by mouse 
splenocytes after 1 hr incubation in the presence or absence of Hsp70, Grp94 or FKBP4 
chaperones (1:1 molar ratio), as measured by flow cytometry (a). Shown values are the 
fold-change of cells with MHC-II-positive signal and internalized proteins (MHC-II+/CP+ 
cells) as compared to non-chaperoned CP, for each aSyn and BSA. Cytokine release 
profiles (IFN-γ and IL-10) of cultured murine splenocytes after a 24 h-incubation with 






















































































































































































































































141 CHAPTER 2: A. LABRADOR-GARRIDO ET AL  FASEBJ 2015 
molar ratio) (b). Pre-incubation mixtures with aSyn or BSA and the chaperones (or 
buffer control) were prepared in all cases. Shown values correspond to the ratio of 
‘chaperone-CP mixture’ over the ‘chaperone’, signals (left panels) and to the 
‘chaperone-CP mixture’ over the ‘CP’, signals (right panels). Results shown are 
representative of two independent experiments. IFN-γ levels for non-chaperoned aSyn 
and BSA were 4.5±1.8 pg/ml and 7.4±1.6 pg/ml , respectively. IL-10 levels were 5.0±2.7 
pg/ml and 6.4±4.3 pg/ml. 
Serum cytokine profile of C57/BL6 mice immunized with Hsp70/γSyn or Hsp70/BSA 
combinations at a 1:1 molar ratio (and the corresponding controls with either protein 
alone or buffer/vehicle) by using Hsp70 chaperone as a model. Immunizations were 
performed in the absence of added adjuvant, as previously described in the Materials 
and Methods section (c). Shown values are means ± S.E.M. (N = 5 for ‘vehicle’, ‘Hsp70’, 
‘aSyn’ and ‘Hsp70/aSyn’ groups; N=3 for ‘BSA’ and ‘Hsp70/BSA’ groups). Asterisks 
indicate statistically significant differences between a particular group and the ‘vehicle’ 
group. ** P<0.01. 
 
Figure 2. Cytokine secretion profiles from aSyn-stimulated splenocytes of mice 
immunized with Grp94- (A) or FKBP4-(B) chaperoned MaSyn. IFN-γ (y axis), IL-10 (z 
axis), and IL-17 (z axis) levels were measured by ELISA in the supernatants of cultured 
splenocytes from immunized mice, 24 h after treatment with aSyn (20 µg/ml). Values 
are means ± SEM (n = 5). Asterisks indicate statistically significant differences between 
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To explore possible aSyn-specific hyper-/hypoimmune responses, we measured 
cytokine release profiles of cultured splenocytes isolated from immunized mice. 
To this end, cultured cells from the different experimental groups were pulsed 
with 20µg/ml aSyn (or with medium alone as a control). Levels of IFN-γ and IL-
17 (which are involved in the helper T-cell–mediated Th1/Th17 responses) as 
well as IL-10 were measured in the culture supernatants collected after 24 h of 
incubation (Fig. 2A, B). The data obtained showed an increase in the secretion 
of IFN-γ as a result of immunization with MaSyn/Grp94 (175 ± 37 vs. 75.2 ± 7.9 
pg/ml) and of IL-17 as a result of immunization with Grp94 (10.3 ± 1.7 pg/ml) 
and with the MaSyn/ Grp94 combination (7.9 ± 0.3 pg/ml) as compared with 
the control (5.1 ± 0.6 pg/ml), which indicates a higher Th1/Th17 response to 
aSyn challenge in the case of MaSyn/Grp94 (Fig. 2A). On the other hand, 
splenocytes from mice immunized with the highest concentration of MaSyn 
and with the MaSyn/FKBP4 combination produced higher IFN-γ levels (365 ± 81 
and 269 ± 51 pg/ml, respectively) than the control (87 ± 16.3 pg/ml) when 
stimulatedin vitro with aSyn (Fig. 2B), indicative of a higher Th1 aSyn-specific 
response. 
Because of the key role of CD4+Tcells in the development of synucleinopathies 
and other misfolding diseases associated with chronic neuro inflammation, we 
analysed theCD4+ T-cell population within splenocytes by flow cytometry, which 
allowed the detection of lower levels of CD4+ cells in the groups immunized 
with the lowest concentration of MaSyn (23.8 ± 0.3%), with Grp94 (22.8 ± 
0.2%), and with the MaSyn/Grp94 combination (23.7 ± 1.1%) relative to the 
control group (28.5 ± 0.8%) (Supplemental Fig. 2A). However, no significant 
alterations in the CD4+ T-cell population were observed for the groups 
immunized with the highest concentration of MaSyn, with FKBP4, or with the 
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(Teff) cell population levels for either experimental group (Supplemental Fig. 
2A). Thus, we observed alterations in the cytokine response of the splenocytes 
to a challenge with aSyn that are apparently not related to changes in the Treg or 
Teff cellular contents. 
 
Suppl. Figure 2. CD4+, Treg and Teff cell populations in splenocytes from mice 
immunized with Grp94- or FKBP4- chaperoned MaSyn. Percentage of CD4+ cells (from 
total splenocytes, left), and Treg (CD4+CD25+Foxp3+) and Teff (CD4+Foxp3-) cells 
(right), in isolated splenocytes from mice immunized with MaSyn (lower dose), Grp94, 
or the MaSyn/Grp94 combination (a), and with MaSyn (higher dose), FKBP4, or the 
M Syn/FKBP4 combination (b). The Treg (c) and Teff (d) cell populations were 
calculated as the CD4+CD25+Foxp3+ stained cells and the CD4+Foxp3- stained cells, 
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S.E.M. (N = 5). Asterisks correspond to statistically significant differences between one 
particular group and the ‘vehicle’ group. *P<0.05, ** P<0.01. Plots are from one 
representative mouse sample for each analysis. 
Immunization with Grp94- or FKBP4-chaperoned MaSyn produces a 
differential antigen-specific antibody response 
To analyse the antigen-specific humoral response in the different experimental 
groups as a result of immunization, total and aSyn-specific IgM and IgG levels 
were assayed by ELISA in serum obtained 1 wk after the booster injection (Fig. 
3 and Supplemental Fig. 3). Although no significant changes in absolute IgM or 
IgG levels were observed for either experimental group (Supplemental Fig. 3A, 
B), a significant increase in the anti-aSyn/total IgG content was produced by 
immunization with the MaSyn/Grp94 combination (28.7 ± 3.4 vs. 18.6 ± 2.9 AU) 
(Fig. 3A and Supplemental Fig. 3C). On the other hand, the slight increments in 
anti-aSyn/total IgM contents seen for groups immunized with the highest 
concentration of MaSyn and with FKBP4 (15.6 ± 1.6 and 15.3 ± 1.0 AU, 
respectively) as compared with the control (11.2 ± 0.7AU) was suppressed by 
the MaSyn/FKBP4 combination (14.4 ± 1.4 AU) (Fig. 3B), although no 
differences were observed in the aSyn-specific IgG contents in this group (Fig. 
3B and Supplemental Fig. 3D). Furthermore, no significant shifts in the aSyn-
specific IgG isotype ratios were detected for either experimental group (Fig. 3C, 
D). Overall, our results indicated that immunization with Grp94/MaSyn 
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Figure 3. aSyn-specific humoral response in mice immunized with Grp94- or FKBP4-
chaperoned MaSyn. Relative anti-aSyn IgM and IgG levels in serum from mice 
immunized with MaSyn (lower dose), Grp94, or MaSyn/Grp94 (A) and with MaSyn 
(higher dose), FKBP4, or MaSyn/FKBP4 (B). The relative content of specific anti-aSyn 
IgM and anti-aSyn IgG antibodies were calculated by dividing the levels of anti-aSyn IgM 
or anti-aSyn IgG antibodies by the total IgM or IgG antibody levels, respectively, for 
each mouse. Data are shown for anti-aSyn IgG1 and IgG2a, levels in serum after 
immunization with MaSyn (lower dose), Grp94, or MaSyn/Grp94 (C) and with MaSyn 
(higher dose), FKBP4, or MaSyn/FKBP4 (D). AU values relate only to the internal control 
(vehicle). The values shown are means ± SEM (n = 5). Asterisks indicate statistically 
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Suppl. Figure 3. Humoral response in mice immunized with Grp94- or FKBP4- 
chaperoned MaSyn. Anti-aSyn IgM and total IgM levels in serum from mice immunized 
with MaSyn (lower dose), Grp94, or MaSyn/Grp94 (a), and with MaSyn (higher dose), 
FKBP4, or MaSyn/FKBP4 (b), were determined by ELISA. Anti-aSyn IgG and total IgG 
levels in serum from mice immunized with MaSyn (lower dose), Grp94, or 
MaSyn/Grp94 (c), and with MaSyn (higher dose), FKBP4, or MaSyn/FKBP4 (d). AU: 
arbitrary units; values relate only to the internal control (vehicle). Represented values 
are mean ± S.E.M. (N = 5). Asterisks correspond to statistically significant differences 
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Grp94- and FKBP4-chaperoned MaSyn produce differential immunologic 
phenotypes in the peripheral immunity 
To characterize further and compare the peripheral immune response elicited 
by immunization with both chaperone/aSyn combinations, we analysed the 
IgG1/IgG2 profile of the humoral response by measuring the IgG1 and IgG2 
total antibody levels, as well as the calculated pairwise IgG1:IgG2a ratio for 
each experimental animal (Fig. 4A, B). Interestingly, the aSyn/Grp94 
combination produced an ~2.5-fold increase in the IgG1:IgG2a ratio (26.8 ± 3.7 
vs. 12.3 ± 2.4 AU), suggesting a Th2 skewing of the peripheral response (Fig. 4A, 
inset). Given that the relative levels of IFN-γ and IL-10 are believed to be 
important in determining the balance between Th1/Th2 cells (Katsikis et al. 
1995)—which in turn determines the direction of activation of the cell 
mediated or the humoral immune responses—we measured the levels of these 
2 key cytokines in serum and calculated the pairwise IL-10:IFN-γ ratio for each 
mouse (Fig. 4C, D). Interestingly, although no changes were detected for the 
Grp94 and MaSyn/Grp94 groups (Fig. 4C), some changes were observed for the 
highest MaSyn and MaSyn/FKBP4 experimental groups, namely an increase in 
the IFN-γ levels (36.3 ± 2.6 and 39.2 ± 8.1 pg/ml, respectively) relative to the 
control group (26.5 ± 0.5 pg/ml), and concomitant reductions in the pairwise IL-
10:IFN-γ ratios (1.05 ± 0.07 and 0.89 ± 0.1) as compared with the control group 
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Figure 4. Th1/Th2 profiling in serum from mice immunized with Grp94- or FKBP4-
chaperoned MaSyn. Total IgG1 and IgG2a antibody levels in serum from mice 
immunized with MaSyn (lower dose), Grp94, or MaSyn/Grp94 (A) and with MaSyn 
(higher dose), FKBP4, or MaSyn/FKBP4 (B) were determined by ELISA. Pairwise 
IgG1:IgG2a ratios in each case (A, B, inset) were calculated by dividing the measured 
IgG1 level by the measured IgG2a level for each mouse. AU values relate to the internal 
control (vehicle). IFN-γ and IL-10 levels were measured in sera from immunized mice by 
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IL-10 cytokine level by the measured IFN-γ cytokine level for each mouse for Grp94 and 
FKBP4, experimental groups (C, D). The values shown are means ± SEM (n = 5). 
Asterisks indicate statistically significant differences between a particular group and the 
vehicle group. *P , 0.05. 
Grp94- and FKBP4-chaperoned OaSyn result in differential Th2-like responses 
As the aggregated form of aSyn is believed to be crucially involved in the 
pathogenesis of PD and other synucleinopathies, we decided also to investigate 
the response generated by immunizing mice with combinations of Grp94 or 
FKBP52 chaperones and OaSyn. To this end, we prepared aSyn oligomers (see 
Materials and Methods) and used them to immunize mice in the absence of 
added adjuvant, with the aSyn/chaperone combinations or the proteins alone 
(see immunization protocol 3 in Materials and Methods), after which analysis of 
isolated splenocytes from immunized mice by flow cytometry was carried out. 
In agreement with the findings of the previous experiments, a slight reduction 
in CD4+ cell content was observed for the Grp94 group(21.4 ± 0.9% vs. 23.0 ± 
0.4% for the control), in addition to the OaSyn/Grp94 group (21.5 ± 0.6%), even 
though the differences were not statistically significant. On the other hand, 
both the Treg and Teff cell content remained unchanged in the various groups as 
compared with the control (data not shown). As before, splenocytes were 
cultured and stimulated in vitro with 20 µg/ml aSyn (or with medium alone), 
and after 24 h, the culture supernatants were recovered and used for IFN-γ, IL-
10, and IL-17 cytokine assays using ELISA (Fig. 5). Remarkably, a clear reduction 
of secreted IFN-γ levels (40 ± 23 pg/ml) as compared with the control group 
(168 ± 19 pg/ml) was measured for mice immunized with OaSyn/Grp94, 
suggesting a reduction in the Th1 response linked to aSyn stimulation. On the 
other hand, no significant changes were observed for either IL-10 or IL-17 levels 
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Figure 5. Cytokine secretion profile from aSyn-stimulated splenocytes from mice 
immunized with Grp94- or FKBP4- chaperoned OaSyn. IFN-γ (y axis), IL-10 (z axis), and 
IL-17 (z axis), levels were measured by ELISA in supernatants from cultured splenocytes 
from immunized mice 24 h after treatment with aSyn (20 µg/ml). The values shown are 
means ± SEM (n = 5). Asterisks indicate statistically significant differences between a 
particular group and the vehicle group. *P < 0.05. 
We next assayed the humoral response elicited by immunization with OaSyn 
and chaperones for the different mice groups. The results showed that OaSyn 
produced approximately 2-fold higher levels, as compared with the vehicle, of 
both absolute (23.9 ± 2.3 vs. 10.3 ± 1.5 AU) and relative (53.8 ± 5.5 vs. 27.5 ± 
4.7 AU) anti-aSyn IgM antibodies (Fig. 6A). This increase was potentiated by 
Grp94 within the OaSyn/Grp94 combination (34.9 ± 6.3 and 71.9 ± 5.7 AU, 
respectively), despite this effect not being observed with the chaperone alone 
(Fig. 6A). Moreover, a more significant increase was also observed in the anti-
aSyn IgG levels for the OaSyn/Grp94 group, with an approximately 4-fold 
increase in absolute levels (35.5 ± 11.8 vs. 8.4 ± 0.6 AU for the control group), 
and an approximately 6-fold increment in relative anti-aSyn IgG (60.5 ± 19.5 vs. 
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16.6 ± 3.3 AU for the control group) (Fig. 6B). Immunization with OaSyn/FKBP4 
caused a similar albeit milder effect on the anti-aSyn IgM and IgG response. 
Interestingly, such higher aSyn-specific IgG titers were largely caused by an 
increase in IgG1 antibodies rather than in IgG2a antibodies (Fig. 6C, D), 
although an increase trend for the IgG2a isotype was seen for the OaSyn/FKBP4 
experimental group. These observations suggest that immunization with OaSyn 
elicits an aSyn-specific Th2 type of humoral response, which is potentiated by its 
combination with theGrp94 chaperone. Remarkably, this phenotype was well 
reproduced in MPTP-treated (PD model) mice that had previously received 
splenocytes from immunized animals by adoptive transfer (AT), in which higher 
IgG1 and IgG2a titers of anti-aSyn antibodies were specifically measured for the 
OaSyn/Grp94 and OaSyn/FKBP4 groups, respectively (Fig. 6E, F). Of note, such 
an effect was detected 4 mo after the AT had been performed. These results 
strongly suggest that the effects observed upon immunization with chaperoned 
aSyn are robust and stable in time. 
Finally, to analyze the peripheral response generated by the OaSyn-based 
immunization protocol, we assayed the total IgG1/IgG2a levels in serum (Fig. 
7A). Despite higher levels of IgG1measured for the Grp94 group (86.0 ± 11.3 vs. 
45.8 ± 8.8 AU), no significant changes in the pairwise IgG1:IgG2a ratios were 
detected in either experimental group compared with the control. On the other 
hand, based on the serum levels of IFN-γ and IL-10 cytokines measured by 
ELISA, the calculated pairwise serum IL-10:IFN-γ ratio showed approximately 2- 
to 3-fold increases in the OaSyn/Grp94 (1.15 ± 0.09) and OaSyn/FKBP4 (2.0 ± 
0.47) groups as compared with the control (0.71 ± 0.04) (Fig. 7B). This result 
indicates a shift toward a Th2-type phenotype caused by immunization with 
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Figure 6. aSyn-specific humoral response in mice immunized with Grp94- or FKBP4-
chaperoned OaSyn and in adoptively transferred mice. Absolute and relative anti-aSyn 
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IgM (A) and IgG (B) levels in serum from mice immunized with OaSyn, Grp94, 
OaSyn/Grp94, FKBP4, or OaSyn/FKBP4. The relative contents of specific anti-aSyn IgM 
and IgG antibodies were calculated by dividing the levels of anti-aSyn IgM or IgG 
antibodies by the total corresponding antibody levels for each mouse. Anti-aSyn IgG1 
(C) and IgG2a (D) levels in serum of mice immunized with OaSyn, Grp94, OaSyn/Grp94, 
FKBP4, or OaSyn/FKBP4. Anti-aSyn IgG1 (E) and IgG2a (F) levels in serum of (PD model) 
MPTP-treated mice 5 mo after receiving splenocytes through AT from donor mice 
immunized with OaSyn, Grp94, OaSyn/Grp94, FKBP4, or OaSyn/FKBP4. AU values relate 
only to the internal control (vehicle). The values shown are means ± SEM (n = 5). 
Asterisks indicate statistically significant differences between a particular group and the 
vehicle group. Hash signs indicate statistically significant differences between a given 
chaperone/aSyn combination and the corresponding chaperone and aSyn groups. */# 
P< 0.05. 
 
Figure 7. Th1/Th2 profiling in serum from mice immunized with Grp94- or FKBP4-
chaperoned OaSyn. Total IgG1 and IgG2a antibody levels in sera from mice immunized 
with OaSyn, Grp94, OaSyn/Grp94 FKBP4, or OaSyn/FKBP4 were determined by ELISA 
(A). AU values relate only to the internal control (vehicle). Pairwise IgG1:IgG2a ratios 
(A, inset) were calculated by dividing the measured IgG1 level by the measured IgG2a 
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mice by ELISA (Supplemental Fig. 4). Pairwise IL-10:IFN-γ ratios were calculated by 
dividing the measured IL-10 cytokine level by the measured IFN-γ cytokine level for 
each mouse (B). The values shown are means ± SEM (n = 5). Asterisks indicate 
statistically significant differences between a particular group and the vehicle group. 
*P< 0.05. 
5. Discussion 
In addition to the traditional functions of molecular chaperones in assisting 
polypeptide folding and preventing protein misfolding and aggregation, a 
diversity of HSP-mediated immune responses of the innate and adaptive 
system have recently been described for certain HSPs (Binder 2014; Srivastava 
2002; Quintana & Cohen 2011). Such adjuvant activities, also displayed by 
exogenously administered HSPs, have already been used in immunotherapy of 
cancer and infectious and autoimmune diseases (Binder 2014; Srivastava 2005). 
As a result of exploiting the immunofunctional properties and the chaperoning 
activity of human Hsp70, we found that immunization with the aSyn/Hsp70 
complex generated an immunomodulatory phenotype in the peripheral system 
together with limited aSyn-specific antibody/humoral response (Labrador-
Garrido et al. 2014). In the present work, as an approach to explore the 
immunomodulatory capabilities of the chaperome in relation to a misfolding 
protein, and to select suitable chaperones to accompany aSyn for 
immunotherapy of PD, we started out by screening a large set of preselected 
chaperone candidates. For this purpose, we designed and set up an in vitro 
screening procedure with cultured murine splenocytes and tested the immune 
response elicited by the chaperone candidates in combination with aSyn. 
Remarkably, differential immunomodulatory profiles were revealed by the 
screening, indicating that several chaperones including Hsp105, Hsp40, Cyp40, 
Pin1, Grp94/Gp96, FKBP4/52, Rab11A, and Apo-J/clusterin, among others, 
could modify significantly the aSyn-elicited immune response.  
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Based on the screening results, we selected 2 chaperones— Grp94/Gp96 and 
FKBP4/52—as good candidates for subsequent immunization studies. FKBP4/52 
is a member of the immunophilin protein family, whose name reflects a high 
binding affinity toward the natural immunosuppressant drug FK506. Although 
the established physiologic function of FKBP4/52 is that of a cytosolic 
chaperone with peptidyl-prolyl cis/trans isomerase (rotamase) activity (Barik 
2006), 2 studies have reported its participation in the regulation of lymphocyte 
activity via its isomerase activity (Nath & Isakov 2015; Mamane et al. 2000; 
Chambraud et al. 1996). Pathologically, FKBP4/52 has been linked with 
neurodegeneration and was shown to interact with tau and aSyn proteins 
(Gerard et al. 2011; Deleersnijder et al. 2011; Giustiniani et al. 2015). The other 
selected chaperone, Grp94/Gp96, has a typically endoplasmic location and can 
be found in the extracellular space in situations of stress and exposure to 
immunologic danger signals. Following pioneering work by Srivastava et al. 
(Srivastava et al. 1986), a number of studies have demonstrated that its 
immunologic specificity originates from the bound peptides, and several clinical 
trials of immunotherapy in cancer patients based on Grp94/Gp96 preparations 
are currently under way (Randazzo et al. 2012). In addition, altered levels of 
Grp94/Gp96 have been linked to neurodegeneration (Kurzawa-Akanbi et al. 
2012; Di Domenico et al. 2010), and the chaperone has been shown to bind to 
intracellular aSyn in a cellular model of PD (Jin et al. 2007).  
The FKBP4/52 and Grp94/Gp96 chaperones selected in this way were used to 
prepare MaSyn or OaSyn/chaperone mixtures, and the corresponding controls 
of chaperones and aSyn proteins alone or vehicle were chosen to immunize 
C57BL/6 mice in the absence of added adjuvant. Our results from aSyn-
challenged splenocytes showed that immunization with MaSyn/Grp94 
promoted a Th1/Th17 anti-aSyn cellular response, whereas MaSyn/FKBP4 
elicited a higher Th1 response to aSyn stimulation. Interestingly enough, 
immunization with OaSyn/Grp94 produced an attenuation of theTh1 cellular 
immunity, that is, a higher Th2/Th1 response to aSyn stimulation, as compared 




ALPHA-SYNUCLEIN AND IMMUNE SYSTEM CROSSTALK IN PARKINSON'S DISEASE; 
THERAPEUTICAL APPROACHES OF ITS MODULATION BY MOLECULAR CHAPERONES 
In additional experiments, analysis of the anti-aSyn humoral response 
developed in mice immunized with MaSyn showed that only the MaSyn/Grp94 
combination produced an increase in anti-aSyn antibody titers, and it did so 
without modifying the IgG isotype contents. On the other hand, immunization 
of mice with OaSyn by itself increased the IgM and IgG anti-aSyn antibody 
levels, and such an effect was potentiated by Grp94 and, to a lesser extent, by 
FKBP4. Interestingly, such an increase in anti-aSyn IgG titers by Grp94 was 
found to be produced exclusively by higher anti-aSyn IgG1 isotype levels, once 
again indicating a Th2-skewing of the antigen-specific humoral immunity by 
OaSyn/Grp94. Conversely, an increase trend in anti-aSyn IgG2a antibodies was 
seen in mice immunized with OaSyn/FKBP4, suggesting a Th1 skewing of this 
response. Remarkably, this pattern was reproduced in a mouse model of PD 
months after receiving splenocytes by AT from immunized donors, which 
supports the notion that these long-term changes generated by immunization 
with chaperoned aSyn are robust and physiologically relevant. 
The final set of experiments, assessment of the IgG1:IgG2a ratio of total serum 
antibody titers, revealed that immunization with the MaSyn/Grp94 
combination increased this ratio and therefore indicates a skewing of the 
general peripheral immunity toward a Th2-type phenotype, despite the 
observation of a lack of significant change in the IL-10/IFN-γ serum levels. In 
contrast, immunization with the MaSyn/FKBP4 combination produced 
unaltered total IgG1 and IgG2a levels but reduced the IL-10:IFN-γ ratio in the 
serum, consistent with a skewing of the general peripheral immunity toward a 
Th1-type phenotype. Remarkably, this effect was reversed when OaSyn was 
used in the immunization protocol in the OaSyn/FKBP4 combination, which 
generated a considerable increase IL-10:IFN-γ ratio in serum, indicating a 
skewing of the general peripheral immunity toward a Th2-type phenotype. 
Interestingly, our results suggest that immunization with Grp94/Gp96- and 
FKBP4/52-chaperoned aSyn produced responses that dissociate the aSyn-
specific immunity from the general immunologic phenotype.  
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Taken together, our work reveals that a variety of molecular chaperones 
display an array of immunomodulatory activities in vitro. Interestingly, a recent 
study has shown some of these chaperones, or their close homologs, to be part 
of a chaperome subnetwork critically involved in ageing and neurodegenerative 
disease, including PD (Brehme et al. 2014). Indeed, although several studies 
have focused on its essential role as the guardian of proteostasis, the potential 
of the chaperome as a modulator of the immune response has not previously 
been addressed. Even though there is still a clear need to understand further 
the role of Th1/Th2/Th17 imbalances in the development of PD, our results show 
that in addition to Hsp70, Grp94/Gp96 and FKBP4/52 can be used effectively to 
chaperone aSyn and modulate the immune response in diverse ways, 
depending both on the chaperone involved and on the aggregation state of the 
aSyn protein. Based on these first observations, we propose that such 
immunochaperones could potentially act as highly versatile tools to redirect the 
immune response in misfolding diseases at the appropriate time of disease 
progression, both for basic studies of the immune profiles associated with 
neurodegeneration and to serve as a novel immunotherapeutic strategy for PD 
and perhaps other related amyloid disorders. 
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CONCLUSIONS 
3. Immunization of healthy mice with aSyn/Hsp70 produces a shift in the 
peripheral immune system from a pro-inflammatory profile towards an 
immunomodulatory profile. 
4. Several members of the chaperome, including Hsp105, Hsp40, Cyp40, Pin1, 
Grp94/Gp96, FKBP4/52, Rab11A, and Apo-J/clusterin, significantly modify the 
aSyn-elicited immune response of stimulated lymphocytes, in vitro. 
5. Immunization with monomeric aS/Grp94 promotes a Th1/Th17 anti-aSyn 
phenotype coupled to increased antigen-specific humoral response, while 
generating a skewing towards a Th2 peripheral, general immune state. 
6. Immunization with monomeric aS/FKBP4 promotes a Th1 anti--synuclein 
response accompanied by a Th1 peripheral, general immune state. 
7. Immunization with oligomeric aS/Grp94 promotes a skewing towards a Th2 
anti--synuclein phenotype together with increased antigen-specific humoral 
response, while generating a skewing towards a Th2 peripheral, general 
immune state. 
8. Immunization with oligomeric aS/FKBP4 promotes a skewing to a Th1 anti--
synuclein phenotype accompanied by a Th2 peripheral, general immune profile. 
9. Immunization with Grp94/Gp96- and FKBP4/52-chaperoned -synuclein 
drives the dissociation, in the peripheral system, of the -synuclein-specific 
immune responses from the general immune phenotype. 
10. Grp94/Gp96 and FKBP4/52 can be used effectively to chaperone aSyn and 
modulate the immune response, depending both on the chaperone involved 
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11. Immunization via adoptive transfer of splenocytes from mice vaccinated 
with monomeric aS/Grp94 promotes a Th1-skewed anti--synuclein 
phenotype, while generating an immunomodulatory/Th2 peripheral general 
immune state in recipient PD model mice. 
12. Direct vaccination with monomeric aS/Grp94 promotes a Th1/Th17 anti--
synuclein phenotype coupled to increased antigen-specific humoral response, 
while generating a skewing towards a Th2 peripheral, general immune state in 




161 CHAPTER 3 











ALPHA-SYNUCLEIN AND IMMUNE SYSTEM CROSSTALK IN PARKINSON'S DISEASE; 





163 CHAPTER 3.1: ALPHA-SYNUCLEIN AND THE IMMUNE RESPONSE IN PARKINSON’S DISEASE  
Alpha-Synuclein and the Immune Response in         
Parkinson’s Disease 
Cintia Roodveldt1, Adahir Labrador-Garrido1,                                              
Guillermo Izquierdo2 and David Pozo1 
1CABIMER-Andalusian Centre for Molecular Biology & Regenerative Medicine 
CSIC-University of Seville-UPO-Junta de Andalucía, Seville 
2 Clinical Neurosciences Management Unit, Virgen Macarena University 
Hospital, University of Seville Medical School, Seville, Spain 
1. Introduction 
In the last few years, it has become evident that the immunological component 
is of central importance in Parkinson’s Disease (PD) pathogenesis and 
progression. This can also certainly be said about the prominent role that the 
protein α-synuclein (aSyn) is currently believed to play in the pathobiology of 
this neurodegenerative disorder. Moreover, the multiple mechanisms through 
which aSyn might be affecting the immune system appear not to be just a 
consequence of disease progression, but to actively contribute to the delicate 
balance between neuroprotection and neurotoxicity that ultimately underlies a 
given stage of disease.  
PD is a proteinopathy, whose pathological hallmark is the presence of deposits 
of aggregated aSyn in intracellular fibrillar inclusions in neurons of the 
substantia nigra pars compacta (SN) of the brain, known as Lewy bodies (LB) 
(Spillantini et al., 1998; Croisier et al., 2005), and the loss of dopaminergic 
neurons (Braak et al., 2003). Three missense mutations, A53T, A30P and E46K, 
as well as multiple copies of the wild-type (Wt) aSyn gene, are linked to early-
onset, familial PD (Polymeropoulos et al., 1997; Krüger et al., 1998; Zarranz et 
al., 2004; Gasser, 2005). Given that aSyn is the major component of LB in both 
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critical factor in PD aetiology. Currently, the cellular and molecular mechanisms 
underlying the pathological actions of aSyn are poorly understood, and the 
factors contributing to sporadic PD, representing the vast majority of PD cases, 
are not known. 
aSyn, together with β- and γ-synucleins, belong to the family of synucleins, a 
group of closely related, brain-enriched proteins. This 140 aa-residue protein is 
largely located in neuronal presynaptic terminals (Kim, Seo and Suh, 2004) and 
in the nucleus (Yu et al., 2007). In particular, it is found in the neocortex, 
hippocampus and SN (Kim, Seo and Suh, 2004), and in other brain regions, as 
well as within astrocytes, microglia and oligodendroglia (Richter-Landsberg et 
al., 2000; Mori et al., 2002; Austin et al., 2006). It is known to interact with a 
variety of proteins (Jenco et al., 1998; Peng et al., 2005) and lipid membranes 
(Jo et al., 2000). The physiological functions of aSyn are still being established, 
but its interaction with pre-synaptic membranes and lipids suggests a role in 
the regulation of synaptic vesicle pools including dopamine release control 
(Perez and Hastings, 2004) and in lipid metabolism (Cabin et al., 2002; 
Castagnet et al., 2005; Golovko et al., 2009). 
Both in vitro and in vivo in LB, aSyn can self-assemble to form ordered fibrillar 
aggregates, characterized by a cross β-sheet structure, that are morphologically 
similar to the amyloid fibrils found in neuritic plaques in Alzheimer´s disease 
(AD) as well as in deposits associated with other amyloidogenic processes (Chiti 
and Dobson, 2006). The initial phase of the aggregation process is thought to 
involve the formation of intermediate oligomers and protofibrillar species 
which, according to accumulating experimental evidence, can be more toxic to 
cells than the mature fibrils into which they develop (Bucciantini et al., 2002; 
Stefani and Dobson, 2003). These and other findings suggest a common 
structure-linked toxicity among pre-fibrillar species, and propose similar 
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mechanisms contributing to pathogenesis for this group of diseases (Bucciantini 
et al., 2004; Baglioni et al., 2006). Overall, different hypotheses have been 
proposed that postulate that aSyn induces a ‘gain of toxic function’ upon 
aggregation (Bennett, 2005).  
While aSyn is typically considered as an intracellular protein, it has also been 
found to be normally present in extracellular biological fluids, including human 
cerebrospinal fluid (CSF) and blood plasma (Borghi et al., 2000; El-Agnaf et al., 
2003, 2006; Lee et al., 2006; Tokuda et al., 2006). However, aSyn levels have 
been found to be elevated in plasma from PD and multiple system atrophy 
(MSA) patients relative to age-matched controls (Lee et al., 2006), while lower 
levels than normal have been detected in CSF from PD patients (Tokuda et al., 
2006). On the other hand, two studies by El-Agnaf and colleagues showed an 
elevated content of oligomeric aSyn species present in plasma (El-Agnaf et al., 
2006) and post mortem CSF (Tokuda et al., 2010) from PD patients, compared 
to controls, indicating that changes in the levels and characteristics of 
extracellular aSyn are associated with the disease (Lee, 2008). Even though 
membrane permeability from dying cells could be one contributing factor, it 
has been suggested that vesicle-mediated exocytosis from normal cells is 
probably the main source of extracellular aSyn (Lee, 2008). By using brain 
homogenates and neuronal cell cultures, Lee and colleagues (Lee, Patel and 
Lee, 2005) have shown that both monomeric and aggregated aSyn can be 
secreted by an unconventional secretory pathway. On the other hand, 
extracellular aSyn has been shown to be taken up by neuronal and microglial 
cells in culture, although the nature of the mechanism involved is still 
controversial (Lee, 2008). In addition, two recent studies have provided strong 
evidence for a neuron-to-neuron and neuron-to-non-neuronal cell transmission 
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models of PD (Desplats et al., 2009; Danzer et al., 2011), highlighting the 
importance of extracellular aSyn in the pathogenic mechanism of α-
synucleinopathies. 
2. Neuroinflammation in PD 
Another prominent pathological feature of PD brains is the presence of a robust 
inflammatory response mediated by activated microglia and reactive astrocytes 
in affected areas of the SN (Glass et al., 2010). Inflammation is the first 
response of the immune system to pathogens or irritation. In acute conditions, 
it protects tissue against invading agents and promotes healing. However, a 
chronic inflammatory state can turn harmful towards the host´s own tissue 
(Kim and Joh, 2006; Gao and Hong, 2008). Microglia are the resident 
immunocompetent cells in the brain (Aloisi, 2001), capable of antigen 
presentation to lymphocytes (Kreutzberg, 1996) and rapid activation in 
response to immune insults and invading of PD pathogenesis in the central 
nervous system (CNS) (Kim and Joh, 2006). As a result of pathogen invasion or 
tissue damage, microglia switch to an activated phenotype and thereby 
promote an inflammatory response that serves to further engage the immune 
system by recruiting other cells to the site of brain lesion, and initiate tissue 
repair (Glass et al., 2010). However, uncontrolled inflammation may result in 
production of neurotoxic factors that can be highly detrimental (Gao and Hong, 
2008; Glass et al., 2010). Indeed, inflammation in the CNS and sustained 
overactivation of microglia, i.e. reactive microgliosis, are currently believed to 
be actively involved in the pathogenesis of various neurodegenerative diseases 
including PD, AD, multiple sclerosis (MS), and amyotrophic lateral sclerosis 
(ALS) (Kim and Joh, 2006; Gao and Hong, 2008; Long-Smith, Sullivan and Nolan, 
2009; Glass et al., 2010).  
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At present, whether microglial activation ultimately protects or actually 
exacerbates neuronal loss in the context of PD and other related diseases is still 
under debate (Vila et al., 2001; Wu et al., 2002; Wyss-Coray and Mucke, 2002; 
Delgado and Ganea, 2003; Sánchez-Pernaute et al., 2004; Gao and Hong, 2008; 
Halliday and Stevens, 2011), although the current view favours the second 
hypothesis. Evidence of microglial attack in PD is supported by findings from 
epidemiological studies, animal models, and cell culture experiments (McGeer 
and McGeer, 2008). Epidemiological studies have revealed that taking 
ibuprofen anti-inflammatory agent regularly is associated with a 35% lower risk 
of PD (Chen et al., 2003, 2005), supporting the concept that inflammatory 
attack is contributing to dopaminergic neuronal loss. On the other hand, in vivo 
studies show that the specific early up-regulation of SN microglia in PD 
correlates with disease severity and dopamine terminal loss (Orr et al., 2005; 
Ouchi et al., 2005). Overall, studies based on animal models and in vitro cell 
culture, indicate that dopaminergic cells are highly sensitive to inflammatory 
attack (Castaño et al., 1998; Fernagut and Chesselet, 2004) and that microglial 
cells can be strongly activated to mount such an inflammatory response (Austin 
et al., 2006). Moreover, it has been recently reported that treatment with CSF 
from PD patients strongly affects cultured microglial cells, resulting in reduced 
cell growth, morphological changes, as well as increased content and 
aggregation of aSyn (Schiess et al., 2010). This illustrates how microglia itself, 
and not only dopaminergic neurons, can be highly affected by the medium in a 
PD scenario. 
3. αSyn-induced microglial activation 
The results gathered thus far using the different PD animal models have 
substantially increased our understanding of PD’s pathogenesis by usually 
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MPTP mouse model of PD indicates that inflammation in the SN can be self-
propagating and leads to progressive neurodegeneration, the aSyn transgenic 
animal model demonstrates that overexpression of this endogenous protein 
can certainly provide a powerful source of inflammation (McGeer and McGeer, 
2008). Whether microglial activation is essentially caused by the release of 
aberrant aSyn species to the extracellular space, (Zhang et al., 2005; Wersinger 
and Sidhu, 2006; Reynolds, Kadiu, et al., 2008), or otherwise, that neuronal 
death itself drives microglial immune responses in an aSyn-independent 
manner (Giasson et al., 2000; Przedborski et al., 2001; Mandel et al., 2005), is 
still under debate. However, there is ample accumulated evidence pointing at 
aSyn as the main trigger of microglial activation in PD (Roodveldt, 
Christodoulou and Dobson, 2008). For example, several studies have 
demonstrated that extracellular and nigral aSyn- containing aggregates are 
often surrounded by activated microglia or inflammatory mediators in PD 
brains (McGeer et al., 1988; Yamada, McGeer and McGeer, 1992), similarly to 
what has been described for amyloid plaques in AD (Griffin et al., 2006). 
Moreover, the extent of microglial activation in the SN from PD patients has 
been found to be correlated with the degree of aSyn accumulation (Croisier et 
al., 2005) and with increased aSyn levels as evidenced by in vitro (Klegeris et al., 
2008; Kim et al., 2009) and in vivo (Lee, Tran and Tansey, 2009) studies, 
strongly supporting the view that the protein has a major role in phenotypic 
changes of microglia. Up to this point, a considerable number of in vivo studies 
with animal models of PD that directly link aSyn with microglial activation have 
been reported. It has been demonstrated in mice that overexpression of aSyn 
alone (by using adeno-associated virus, AAV) is sufficient to trigger 
neuroinflammation, involving not only classical microglial activation but also 
stimulation of adaptive immunity, preceding the appearance of overt 
neurodegeneration signs (Theodore et al., 2008). In line with this finding, a rat 
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AAV-based model for overexpressing the A53T aSyn variant in the SN revealed 
dramatic changes in cytoskeletal protein levels and activated microglia-
mediated neuroinflammation in the striatum (with increased release levels of 
IL-1β, IFN-γ, and TNF-α proinflammatory cytokines), well before neuronal loss 
was evident (Chung et al., 2009). Another recent study using a AAV rat PD 
model showed that overexpression of Wt aSyn in the SN not only leads to 
persistent microglia activation, but that depending on the degree of aSyn-
induced neurophatology that models either the onset or the late stages of the 
disease, different microglial responses will occur: upon lower aSyn expression 
levels where only neurodegeneration occurs, microglia with antigen-presenting 
capabilities predominate, whereas levels that can induce neuronal cell death 
correlate with long-term induction of macrophagic microglia (Sanchez-Guajardo 
et al., 2010), suggesting that microglia may play different roles during disease 
progression (Sanchez-Guajardo et al., 2010). 
Two recent studies have explored the link between neuroinflammation and 
aSyn dysfunction by lipopolysacharide (LPS) injection in rat (Choi, Zhang and 
Bing, 2010) or mice (Gao et al., 2011), to trigger systemic and brain 
inflammation. In the first study, the authors observed increased microglia 
activation and secretion of proinflammatory cytokines as well as greater 
nitration of proteins including aSyn, in elderly rats, suggesting that an 
exaggerated neuroinflammatory response that occurs naturally with aging 
might contribute to aSyn aggregation and dopaminergic neurodegeneration in 
PD (Choi, Zhang and Bing, 2010). In the second study, the authors evaluated 
dopaminergic neurodegeneration, aSyn pathology and neuroinflammation in 
Wt and transgenic A53T aSyn-overexpressing mice (Gao et al., 2011). They 
observed that, while both models initially displayed acute neuroinflammation, 
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progressive degeneration of nigrostriatal dopamine pathway, accumulation of 
aggregated, nitrated aSyn, and formation of LB (Gao et al., 2011), suggesting 
that genetic factors and environmental exposures act synergistically to 
precipitate the development of PD. On the other hand, microglial cells from 
aSyn-knockout mice have been shown to exhibit a remarkably different 
morphology compared to Wt cells (Austin et al., 2006), displaying elevated 
levels of secreted pro-inflammatory cytokines such as TNF-α and IL-6 after 
activation, indicating that aSyn plays a critical role in modulating the microglial 
activation state. More recently, the authors have found that microglial 
activation in this model is accompanied by increased protein levels of three 
enzymes involved in lipid-mediated signalling, which suggests a broader 
function for aSyn in brain physiology beyond synapsis control (Austin et al., 
2011). 
In the last few years, several in vitro studies have focused on the effects of 
extracellular aSyn on microglial activation. Zhang et al. (Zhang et al., 2005) first 
reported that exogenous, aggregated aSyn cause activation of microglial cells, 
which then become toxic towards cultured dopaminergic neurons. Their results 
indicate that microglial phagocytosis of aSyn and activation of NADPH oxidase, 
are critical in aSyn-induced microglial activation and neurotoxicity. This finding 
is highly relevant considering that aggregated aSyn has been shown to be 
secreted by exocytosis from neuroblastoma and primary neuronal cells (Lee, 
Patel and Lee, 2005; Danzer et al., 2011), and by stressed neurons (Klegeris et 
al., 2008). Moreover, following the discovery that aSyn aggregates can be 
released from neurons and transmitted to neighbouring cells (Desplats et al., 
2009), a study has recently shown that aSyn release by SH-SY5Y neuroglioma 
cells, especially when treated with MPP+ neurotoxin, are able to activate the 
inflammatory response in a microglial cell line (Alvarez-Erviti et al., 2011). 
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Up to this point, research on aSyn-mediated cell response has focused primarily 
on the effects on neuroinflammation (Benner et al., 2008) or microglial 
activation (Zhang et al., 2005, 2007; Thomas et al., 2007; Reynolds, Glanzer, et 
al., 2008; Cookson, 2009) of aSyn in its aggregated form. Interestingly, Reynolds 
and co-workers (Reynolds, Kadiu, et al., 2008) have found that nitrated, 
aggregated aSyn (N-aSyn) has a stronger stimulating effect on microglia than 
that of nitrated but non-aggregated aSyn. In addition, several investigations 
have found that N-aSyn, which has been detected in LB of human brains with 
PD (Giasson et al., 2000) and has been linked to neurodegeneration in PD 
mouse models (Benner et al., 2008; Gao et al., 2008), induces a neurotoxic 
inflammatory microglial phenotype that accelerates dopaminergic neuronal 
loss (Biasini et al., 2004; Zhang et al., 2005; Zhou et al., 2005; Thomas et al., 
2007). By integrating genomic and proteomic techniques, Gendelman and 
colleagues created a fingerprint of microglial cell activation following its 
interactions with aggregated N-aSyn in cell culture (Reynolds, Kadiu, et al., 
2008), indicating that the activation, which was found to be capable of 
mediating dopaminergic neurotoxicity, is mainly mediated by the NF-κB 
pathway (Reynolds, Kadiu, et al., 2008). However, whether extracellular aSyn 
contains the same modifications than the protein found in LB (Giasson et al., 
2000; Hodara et al., 2004; Anderson et al., 2006), which is a typically pro-
oxidative environment, is still uncertain (Lee, 2008). 
Over the last few years, certain differential functions for non-aggregated, 
extracellular aSyn in glia have been reported. It has been observed that, in 
contrast to the aggregated form, monomeric aSyn enhances microglial 
phagocytosis (Park et al., 2008). A few investigations that explore the effects of 
non-aggregated aSyn on the cytokine release profile of potentially relevant cells 




ALPHA-SYNUCLEIN AND IMMUNE SYSTEM CROSSTALK IN PARKINSON'S DISEASE; 
THERAPEUTICAL APPROACHES OF ITS MODULATION BY MOLECULAR CHAPERONES                 
 
 
(Lee et al., 2009) cell lines, and primary astrocyte (Klegeris et al., 2006) or 
microglial (Su et al., 2008; Su, Federoff and Maguire-Zeiss, 2009; Roodveldt et 
al., 2010) cultures. Indeed, we have observed a strong innate immune response 
in primary glial and microglial cell cultures elicited by exogenous, non-
aggregated aSyn (Roodveldt et al., 2010). Interestingly, a comparative study 
using unmodified aSyn has recently shown that exogenous non-aggregated 
aSyn induces higher TNF-α, IL-1β and ROS release levels than aggregated aSyn 
in microglia (Lee et al., 2010). These and other recent findings point at the 
importance of exploring the effects on the immune response of aggregated as 
well as non-aggregated aSyn. 
Even though a study using monocytic THP-1 cell line (Klegeris et al., 2008) had 
shown modest increases in IL-1β and TNF-α secretion levels after stimulation 
with A30P, A53T, or E46K aSyn mutants compared to the Wt protein, there is a 
lack of a comprehensive study of the effect exerted by non-aggregated aSyn, 
performed with primary cell cultures. With this in mind, we analysed the 
cytokine release profile of primary microglial cultures ―which represents a 
more comparable physiological environment― after stimulation with Wt or the 
PD-linked aSyn mutants (Roodveldt et al., 2010). Indeed, we found remarkable 
differences between the aSyn variants in the interleukin and chemokine release 
profiles and significant effects on the microglial phagocytic capacity (Roodveldt 
et al., 2010). In particular, we observed marked differences in IL-6 and IL-1β 
pro-inflammtory cytokines, IL-10 immunoregulatory cytokine, as well as IP-
10/CXCL10, RANTES/CCL5, MCP-1/CCL2 and MIP-1α/CCL3 chemokines release 
levels. Our results indicate that extracellular, non-aggregated Wt aSyn produces 
a moderate to low pro-inflammatory response in glia, together with a reduction 
of the immunoregulatory response, and a moderate stimulation of Th1 
chemokine secretion. The A30P and E46K pathological variants, on the other 
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hand, can induce strong pro-inflammatory and immunoregulatory responses, 
together with marked increases in chemokine release levels. This exacerbated 
innate immune response might explain the earlier onset and more rapid 
evolution of these two genetic cases of PD as compared to the sporadic kind. 
Intriguingly, our results from the pathologically-linked A53T variant showed not 
to provoke a significant innate immune response, which might suggest that 
other neurodegeneration mechanisms contributing to the pathogenesis of PD, 
probably involving the adaptive immune response, might exist in this case. 
Combined with the effect on microglial phagocytosis, our results indicate that 
these aSyn-induced phenotypes might reflect either a classical (A30P and E36K) 
or an alternative (A53T) microglial activation state, or a hybrid phenotype (Wt), 
which could probably explain the different disease progression modes that can 
occur in PD. Alternative activation of macrophages and microglia is a response 
to tissue injury that is thought to be involved in tissue repair and restoration 
(Ponomarev et al., 2007), and has been suggested to play a role in repair and 
extracellular matrix remodelling in AD (Colton et al., 2006). Currently, there is 
no other indication that such an activation mode could be operating in the 
context of PD.  
Upon activation, microglia and astrocytes start secreting inflammatory 
cytokines in order to communicate and mount the immune response to 
counteract disease or injury. The cytokines TNF-α, IL-1β, IL-2, IL-4, IL-6, TGF-α, 
TGF-β1, TGF-β2 have all been reported to be increased in the nigrostriatal 
region and CSF of patients with PD or DLB (Croisier and Graeber, 2006). As a 
result of aSyn-induced activation of microglia in vitro, a few cytokines and 
metabolites have been shown to be significantly up-regulated (reviewed in 
(Roodveldt et al., 2008)): IL-6, IL-1β, ICAM-1, TNF-α, IFN-γ, MCP-1, O2-, iROS, 
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stronger effect on cytokines release than does the Wt protein. Interestingly, 
analysis of the microglia transcriptome by Gendelman and co-workers 
(Reynolds, Glanzer, et al., 2008) after stimulation with aggregated N-aSyn, 
revealed a significant up-regulation of the toll-like receptor 2 (TLR-2) gene. TLRs 
are known to sense the molecular signatures of microbial pathogens, and play a 
fundamental role in innate immune responses, inducing the expression of 
diverse inflammatory genes (Kawai and Akira, 2007). Therefore, it seems 
plausible that cells challenged with aSyn, or with certain forms of aSyn, could 
become hyper-responsive to inflammatory signals. 
Activated microglia can also produce substantial amounts of superoxide 
radicals, which may be the major source of the oxidative stress thought to be 
largely responsible for dopaminergic cell death in PD. The generation of ROS by 
microglia activated by aSyn (Thomas et al., 2007) can result in oxidation and 
nitration of proteins, DNA modifications, and lipid peroxidation, leading to 
neurotoxicity (Zhang et al., 2005). Oxidation (Ko et al., 2000; Souza et al., 2000) 
and nitration (Giasson et al., 2000; Souza et al., 2000) of aSyn, in turn, can lead 
to the formation of more aggregates, which could result in increased cytotoxic 
effects. Consistent with this, Kelly et al. have shown that high levels of oxidized 
cholesterol metabolites in brains from PD and dementia with LB patients, 
accelerate aSyn fibrillation (Bosco et al., 2006). On the other hand, McGeer and 
colleagues (Klegeris et al., 2007) have reported that aSyn-stimulated microglia, 
in combination with IFN-γ, produce and increase in the toxicity on human 
monocytic cells exerted by neurotoxic secretions (Klegeris et al., 2007). 
Interestingly, this toxicity can be diminished with specific ligands for ryanodine 
receptors (Klegeris et al., 2007), which are known to help mediate the efflux of 
Ca2+ ions from intracellular stores and avoid uncontrolled increases in [Ca2+]i 
that may lead to cell death (Giorgi et al., 2008). 
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Further insight into the mechanism of pathogenesis might derive from the 
findings that several proteins which are thought to be linked to PD are up-
regulated as a result of aSyn-induced microglial activation. Gendelman and co-
workers, by determining the activated microglia proteome profile (Reynolds, 
Glanzer, et al., 2008), found that aggregated N-aSyn activation of microglia 
results in differential expression of several proteins. These range from proteins 
involved in oxidative stress, cell adhesion, glycolysis, growth control, and 
migration, to cytoskeletal proteins. It is worth noting that two of those proteins 
found to be most up-regulated, calmodulin and ubiquitin, have been shown to 
interact with aSyn with possible functional consequences. Calmodulin has been 
shown, in vitro, to bind to aSyn in a Ca2+-dependent manner (Lee et al., 2002) 
and to inhibit aSyn fibrillation (Martinez et al., 2003). On the other hand, a 
fraction of aSyn found in LB is mono-ubiquitinated (Hasegawa et al., 2002; 
Tofaris et al., 2003), but the role of this modification remains unclear. Recently, 
it has been demonstrated that the ubiquitin-protein isopeptide ligase, seven in 
absentia homolog (SIAH), directly interacts with and monoubiquitinates aSyn, 
promoting its aggregation (Lee et al., 2008; Rott et al., 2008) and apoptosis (Lee 
et al., 2008). In addition, there is also evidence implicating a role for the 
ubiquitin-proteasome system (UPS) in PD (reviewed in (Lim and Tan, 2007). 
Also of interest are the elevated levels of Hsp70 observed upon microglial 
activation. This central chaperone has been demonstrated to inhibit aSyn 
aggregation in vitro (Dedmon et al., 2005; Huang et al., 2006; Roodveldt et al., 
2009), in neuroglioma cells (Klucken et al., 2004) as well as in fly (Auluck et al., 
2002) and mouse (Klucken et al., 2004) models of PD, protecting cells from the 
cytotoxic effects of aggregates.  
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Together with microglial cells, astrocytes and oligodendrocytes are part of glia, 
which normally serve neuroprotective functions but, given adverse stimulation 
as discussed before, they may contribute to develop chronic 
neuroinflammation (McGeer and McGeer, 2008; Halliday and Stevens, 2011). 
Compared to microglia, the functions of astrocytes are poorly understood. 
Because they have been shown to produce both pro-inflammatory and anti-
inflammatory agents, these cells are thought to have a dual role (McGeer and 
McGeer, 2008). Many ICAM-1-positive astrocytes are seen in the SN of PD 
brains and this may attract reactive microglia to the area since microglia carry 
the counter receptor LFA-1 (Miklossy et al., 2006). Indeed, aSyn has been 
shown to be capable of both of activating microglia and stimulating astrocytes 
to produce IL-6 and ICAM-1 (Klegeris et al., 2006). On the other hand, 
astrocytes have been shown to secrete a number of neurotrophic factors that 
protect dopaminergic neurons in some models of PD (McGeer and McGeer, 
2008), but the mechanisms underlying most of these functions are not yet 
known. Astrocytes have been shown to express aSyn (Tanji et al., 2001). 
Interestingly, the presence of aSyn-containing inclusion bodies in astrocytes of 
sporadic PD brains has been observed (Wakabayashi et al., 2000; Terada et al., 
2003; Braak, Sastre and Del Tredici, 2007). Finally, a recent study showed that 
astrocyte expression of A53T aSyn leads to the development of progressed 
paralysis, strong microglial activation, and neurodegeneration (Gu et al., 2010). 
There is still little data on the role of oligodendrocytes in PD. aSyn-containing 
inclusions have been detected in this cell type in MSA, in DLB, and in PD 
(Wakabayashi et al., 2000; Campbell et al., 2001). McGeer and colleagues have 
reported the presence of complement-activated oligodendrocytes in the SN of 
PD cases (Yamada, McGeer and McGeer, 1992). Intriguingly, transgenic mice 
overexpressing Wt aSyn in oligodendrocytes have been observed to develop 
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severe neurological alterations and neurodegeneration (Shults et al., 2005; 
Yazawa et al., 2005), drawing the attention to a possible role of these glial cells 
in PD. 
5. Expression of aSyn by immunocompetent cells 
Given that aSyn expression has been reported also in non-neuronal cells, it is 
currently thought to play a role besides dopamine release control. While 
searching for a link between the CNS and peripheral immune system in PD, Kim 
et al. (Kim et al., 2004) found that aSyn was up-regulated in peripheral blood 
mononuclear cells (PBMC) at the gene level, in idiopathic PD vs. non-PD 
controls. Moreover, by in vitro transfection with Wt, A30P and A53T aSyn 
genes, they found that aSyn expression is correlated to glucocorticoid-sensitive 
apoptosis, possibly caused by the enhanced expression of glucocorticoid 
receptor (GR), caspase activation, CD95 (Fas) up-regulation, and ROS 
production. However, the increase in ROS production by overexpression of the 
aSyn mutants was markedly greater than for Wt aSyn. aSyn expression has also 
been found in cultured human macrophages (Tanji et al., 2002) and its 
expression levels have been reported to increase by stimulation with 
proinflammatory cytokine IL-1β or LPS (Tanji et al., 2002), further supporting a 
role for aSyn in the inflammatory process. Finally, expression of aSyn in 
cultured human T cells, B cells, natural killer (NK) cells and in 
monocytes/macrophages, have been reported (Shin et al., 2000). Currently, it is 
not known whether expression or aggregation, of aSyn in T cells can be 
regulated by ligand activation of the T cell. This may be relevant as it could 
represent a key link between regulation of the adaptive immunity and aSyn 
expression levels. 
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In the last few years, mounting evidence has pointed at a possible participation 
of the adaptive immune system in PD pathogenesis. However, whether this 
immune response actually contributes to neurodegeneration, and in that case 
by which mechanism, remains unknown. The initial observations in PD patients 
that a small amount of CD8+ T lymphocytes occur in proximity to degenerating 
nigral neurons (McGeer et al., 1988), and the occurrence in LB of components 
of the classical or antibody-triggered complement cascade (Yamada, McGeer 
and McGeer, 1992) had suggested a possible involvement of the adaptive 
immunity in the PD process. More recently, the finding of accumulated IgG in 
the SN of PD patients and increased expression of IgG-binding receptors on 
activated microglia (Orr et al., 2005), and the detection of anti-aSyn 
autoantibodies (AAb) in blood serum of PD patients (Papachroni et al., 2007), 
suggest that the pathological process may involve adaptive immune-mediated 
mechanisms. In addition, the observation that humoral immune mechanisms 
can trigger microglial-mediated neuronal injury in animal models of PD (He, Le 
and Appel, 2002), and the finding by Standaert and colleagues of IgG deposition 
in mouse brains following AAV-mediated aSyn overexpression in the SN 
(Theodore et al., 2008), further support a role of the adaptive immune system 
in disease progression. 
A possible consequence of the initial microglial activation in the affected 
regions of PD brains is the local permeabilization of the blood-brain barrier 
(BBB), leading to infiltration to the affected regions by B- and/or T-lymphocytes 
(Racke et al., 2000). Indeed, a remarkable T- and B-cell infiltration into the SN 
linked to aSyn overexpression was observed at the early stages, i.e. before the 
appearance of significant dopaminergic neuronal loss, reaching levels in the SN 
of up to 10-fold and 5-fold compared to controls (Theodore et al., 2008). A 
recent study by Hunot and colleagues (Brochard et al., 2009) has shown that 
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CD8+ and CD4+ T-cells, but not B-cells, had invaded the brain in PD patients and 
in MPTP-treated mice during the course of neural degeneration. Furthermore, 
based on these results the authors propose that T-cell dependant toxicity is 
essentially mediated by CD4+ T-cells and requires the expression of FasL 
(Brochard et al., 2009). Given that the FasL pathway had been shown to 
produce proinflammatory cytokine responses in macrophages (Park et al., 
2003), the authors speculate that the CD4+ Th FasL-mediated activation of 
microglia could participate in neuroinflammation and neurodegeneration 
processes in PD (Brochard et al., 2009). 
Based on results obtained with an MPTP murine model of the disease, 
Gendelman and colleagues (Reynolds et al., 2010) have suggested that the 
aSyn-specific regulatory T-cells (Treg cells), which are regulatory components of 
the adaptive immunity, might be able to counteract the autoaggresive effector 
T-cell responses that exacerbate neuroinflammation (Benner et al., 2008), and 
therefore contribute to attenuate neurodegeneration in PD. Indeed, the same 
group has reported that microglial cells stimulated with N-aSyn are susceptible 
of essentially opposing immune regulatory responses by Treg cells (CD4+, 
CD245+) and effector T-cells (CD4+, CD25-) in culture (A. D. Reynolds et al., 
2009). By analysing an array of cytokines released by treated microglia, the 
authors found that, while the effector T-cell subset exacerbates microglial-
mediated inflammation and may induce neurotoxic responses, Treg cells are 
able to suppress N-aSyn microglial-induced reactive-oxygen species (ROS) and 
NF-κB activation and are proposed to be neuroprotective (A. D. Reynolds et al., 
2009). Furthermore, the study indicates that Treg cells can regulate microglial 
inflammation by inducing Fas-FasL-mediated apoptosis of N-aSyn-stimulated 
microglial cells (A. D. Reynolds et al., 2009). By using a proteomic analysis, the 
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microglial protein expression profile for certain proteins linked to cell 
metabolism, migration, protein transport and degradation, redox biology, and 
cytoskeletal and bioenergetics metabolism, to presumably attenuate the 
neurotoxic phenotype caused by N-aSyn stimulation (Ashley D. Reynolds et al., 
2009). 
Thus far, accumulated data demonstrate that in the MPTP model of PD, 
misfolded and aggregated aSyn are secreted from neurons, which promotes 
pro-inflammatory M1-type microglia and cytotoxic T-cells, therefore amplifying 
neuronal damage. In sporadic human PD, it is currently unkown which factor 
triggers disease onset, but it has been proposed that under certain 
circumstances, a similar set of temporal and mechanistic events could 
transform neuroprotective microglia and T cells into cytotoxic cells, thereby 
accelerating disease progression (Appel, Beers and Henkel, 2010). This way, 
activated microglia and the cytokine milieu that they generate might promote 
T-cell differentiation into different cell subsets in the context of PD (Appel, 
Beers and Henkel, 2010). Indeed, it has been shown that M1 (pro-
inflammatory) cells promote, whereas M2 (non-inflammatory) cells reduce, 
CD4+ Th1 cell proliferation and function (Verreck et al., 2004), but also that, 
conversely, T-cells can dictate microglial pro- or anti-inflammatory phenotypes 
(Giuliani et al., 2003; Kebir et al., 2007; Mount et al., 2007). Whether microglia 
dictate the specific T-cell phenotype or otherwise, that T-cells dictate the 
specific microglial phenotype (i.e. M1 vs. M2), is still unknown (Appel, Beers 
and Henkel, 2010). But overall, the communication established between 
microglia, T cells and neurons seem to indicate that the immune response is not 
only a consequence of injury, but that it actively contributes to the balance 
between neuroprotection and neurotoxicity (Stone et al., 2009; Appel, Beers 
and Henkel, 2010). 
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To analyse the possibility that humoral immunity may play a role in initiating or 
regulating inflammation, Orr et al. (Orr et al., 2005) analysed the association 
between nigral degeneration and humoral immune markers in brain tissue of 
patients with idiopathic or genetic PD and controls. All the patients with PD 
revealed IgG, but not IgM, binding on dopamine neurons. Moreover, the 
proportion of IgG-immunopositive neurons showed a negative correlation with 
the degree of cell loss in the SN, and positive correlation with the number of 
activated microglia. IgG was found to be concentrated at the cell surface of 
neurons, but also on their LB, and was shown to co-localize with aSyn. These 
results, in combination with their finding that activated microglia express high-
affinity IgG receptors (FcγRI) in both idiopathic and genetic forms of PD, might 
suggest that the activation of microglia may be induced by neuronal IgG (Orr et 
al., 2005). 
The question regarding the functional importance of antibodies against 
antigen-specific, disease-associated neuronal proteins still needs to be 
addressed. It has been demonstrated that an IgG fraction purified from serum 
of PD patients causes death of dopaminergic neurons in vivo following 
stereotaxic injection in the SN of experimental animals (Chen et al., 1998), and 
the presence of immunoglobulins in PD brain tissue have been proposed to 
lead to the targeting of dopaminergic nigral neurons for destruction (Orr et al., 
2005). Currently, it remains unknown whether these anti-aSyn AAb are 
neurotoxic, or on the contrary, they actually have a neuroprotective role, as has 
been shown in a human aSyn transgenic mouse model of PD (Masliah et al., 
2005). 
A recent study has assessed the presence of auto-antibodies (AAb) against all 
three synucleins in the peripheral blood serum of PD patients and healthy 
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Syn showed no association with PD, multi-epitopic AAb against aSyn were 
detected in 65% of all patients, with a strong correlation with the inherited 
mode of the disease. In addition, a recent study based on measuring AAb levels 
against monomeric, oligomeric, and fibrillar aSyn in serum from PD patients 
(Gruden et al., 2011), showed that all three AAb specificities reached the 
highest values after 5-year of disease duration, and subsided in 10-year 
sufferers. Intriguingly, there was a ca. 15-fold increase in AAb titre values 
relative to monomeric aSyn (72% of patients), and a ca. 4-fold increase for aSyn 
oligomers (56% of patients). Moreover, the authors also found a decline in 
CD3+, CD4+ and CD8+ T-lymphocyte and B-lymphocyte subsets. Based on these 
results, they suggest that aSyn toxicity elimination by AAb in early PD pathology 
might be linked with the decline of lymphocyte subsets reflecting the influence 
of inflammatory and oxidative stress processes (Gruden et al., 2011). 
Despite their potential involvement in PD pathogenesis and progression, the 
role of NK cells in PD has hardly been explored. NK cells are active members of 
the innate immune system that act as a first-line defence, and also mediate 
between the innate and adaptive immune systems (Salazar-Mather, Ishikawa 
and Biron, 1996; Su et al., 2001). Interestingly, a recent study using blood 
samples from PD patiens indicates that the NK activity increases as the disease 
advances (Mihara et al., 2008). Moreover, the study also showed that the NK 
cell content among the total lymphocytes of the PD group was higher than in 
the control group (Mihara et al., 2008). 
7. Prospects for aSyn-based immunotherapy in PD 
In addition to its well-known importance in the pathogenesis of PD, aSyn is 
becoming a primary target for preventing or controlling the process of PD. In 
the late few years, vaccination for treating some neurodegenerative disorders 
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has emerged as a potentially useful approach. Thus far, this avenue has been 
scarcely explored for PD. Importantly, immunization with aSyn was shown to 
generate a humoral response in a mouse model of PD (Masliah et al., 2005), 
producing beneficial albeit modest results on histopathological markers of the 
disease. On the contrary, using N-aSyn as the immunogen proved to elicit 
strong antigen-specific effector T cell responses in MPTP-intoxicated mice that 
caused exacerbated neuroinflammation and neurodegeneration (Benner et al., 
2008). This response was further shown to be largely mediated by Th17 cells 
and causing Treg dysfunction (Reynolds et al., 2010). In addition, the authors 
demonstrated that Treg cells from mice treated with the neuropeptide VIP, 
known to promote Treg responses (Delgado et al., 2005; Gonzalez-Rey et al., 
2006), can efficiently modulate N-aSyn-generated immunity in MPTP mice and 
confer neuroprotection (Reynolds et al., 2010), suggesting a possible novel 
therapeutic avenue for PD. 
Given that microglial activation can maintain or even aggravate the disease 
process, blocking inflammation or shifting the balance between pro-
inflammatory and anti-inflammatory states in a controlled manner, offers one 
of the most promising strategies for developing palliative (and maybe 
preventive) therapies for PD and related disorders. Epidemiological data have 
identified the non-steroidal anti-inflammatory drug (NSAID) ibuprofen as 
neuroprotective for PD (Klegeris, McGeer and McGeer, 2007). NSAIDs are 
thought to act on dopamine quinone formation and activation by aSyn of both 
astrocytes and microglia. On the other hand, Gendelman and colleagues 
demonstrated that T cells from mice immunized with Copolymer-1 (Cop-1), are 
able to attenuate microglial responses and lead to neuroprotection in a MPTP 
mouse model of PD (Benner et al., 2004). This neuroprotective effect was later 
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involvement of Treg cells (Laurie et al., 2007). Later work by the same group 
confirmed this hypothesis by showing that passive transfer to MPTP mice of 
activated Treg cells, but not effector T cells, efficiently suppressed microglial 
activation and afforded neuroprotection (Reynolds et al., 2007), suggesting that 
the immunomodulating abilities of Treg cells could potentially be utilized as a 
therapeutic approach against PD (Stone et al., 2009). 
Fig. 1. Links between aSyn and the immune response in PD. Continuous arrows with 
filled tips: positive effect; continuous arrows with open tips: cell transformation; 
discontinuous arrows: secretion of cellular factors. APC, Antigen-processing cell; BBB, 
Blood-brain barrier; CKs, Chemokines; IL, Interleukin; IFN-γ, Interferon γ; LB, Lewy 
bodies; ROS, Reactive oxygen species; RNS, Reactive nitrogen species; TGF-β, Tumor 
growth factor β. 
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8. Conclusion 
It is well established that PD onset and progression are characterized by 
sustained activation of microglia, linked to significant dopaminergic neuron loss 
in the SN of the brain. Over the last protein, is linked to neurotoxicity through 
various proposed mechanisms, and may be one of the primary causes of the 
immunological abnormalities observed in PD. Recent studies with cellular and 
in vivo models of the disease indicate that increased levels of extracellular 
aSyn, both in its aggregated and non-aggregated forms, are found in a PD 
scenario. 
Accumulated evidence has now established that aggregated extracellular aSyn 
is able to trigger the activation of microglia, inducing a highly detrimental 
cascade of neuroinflammation and neuronal demise. In addition, recent studies 
have have demonstrated that non-aggregated aSyn can also have a substantial 
impact on microglial phenotype and cytokine release profile, especially in the 
cases of familial PD aSyn mutants. By releasing toxic factors, or by 
phagocytosing neighbouring cells, activated microglia and astrocytes are 
believed to form a self-perpetuating neuronal degeneration cycle. On the other 
hand, recent findings point at a possible role of the adaptive immune system 
involving aSyn, and the pathological process in PD. Clearly, further studies in 
this direction are necessary to help understand the complex immunological 
mechanisms underlying PD and the key, and possibly multiple, links between 
aSyn and the immune response in relation to in relation to pathogenesis (Figure 
1). 
In addition to trying to develop effective tools to prevent aSyn aggregation, 
modulating the innate immune response by intervening microglial activation, 
promoting a selective aSyn-specific humoral response, and manipulating the 
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considered as highly promising therapeutic approaches for the treatment of PD 
and other synucleinopathies.  
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1. Introduction 
Several neurodegenerative diseases are associated with a build up of misfolded 
or abnormal proteins and the formation of distinct aggregates, resulting in a 
putative pathological protein load on the nervous system (Chiti & Dobson 
2006). This aberrant accumulation of amyloid or amyloid-like aggregates occurs 
in Parkinson’s (PD), Alzheimer’s (AD), and Huntington’s (HD) diseases, 
amyotrophic lateral sclerosis, and frontotemporal dementia, among others. A 
broad array of cellular defence mechanisms operate to counteract this effect, 
including antioxidant proteins, the stress-inducible response and, in particular, 
molecular chaperones (Morimoto 2008; Voisine et al. 2010). Molecular 
chaperones are responsible for maintaining normal protein homeostasis within 
the cell by assisting protein folding, inhibiting protein aggregation, and 
modulating protein degradation pathways (Hartl & Hayer-Hartl 2009). 
Currently, there is substantial evidence supporting the involvement of these 
protein aggregational processes and a role of molecular chaperones, and 
especially of Hsp70, in PD pathogenesis (Bandopadhyay & de Belleroche 2010; 
Broadley & Hartl 2009; Witt 2010). Firstly, extensive colocalization of Hsp70 
with α- synuclein (aSyn), the major component of Lewy bodies (LBs) (Spillantini 
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demonstrated ( uluck et al. 2002; McLean et al. 2002). Secondly, patients with 
PD show highly perturbed expression of different members of the Hsp70 family 
in the substantia nigra pars compacta (SN) of the brain, which is precisely the 
target of neurodegeneration (Grünblatt et al. 2001; Hauser et al. 2005). Finally, 
there is a considerable amount of data derived from studies performed in vitro, 
in cell culture and with animal models of PD (Arawaka et al. 2010; Witt 2010), 
that support the protective effects of Hsp70 against aSyn aggregation and 
toxicity, considered to be central in the aetiology of the disease. 
The discovery within the last few years of three different missense mutations 
(A30P, E46K and A53T) in the aSyn gene as causative of early onset PD 
unambiguously linked this protein to disease onset and progression (Krüger et 
al. 1998; Polymeropoulos et al. 1997; Zarranz et al. 2004). Additionally, a locus 
triplication causing an increased dosage of the wild-type (Wt) aSyn gene has 
been found to potentiate neurodegeneration (Singleton et al. 2003). Finally, as 
mentioned above, aSyn is the major component of intracellular protein rich 
aggregates found in the brain of post-mortem patients of PD, the LBs and Lewy 
neurites (LNs). The appealing hypothesis for LBs formation is that aSyn 
monomers combine to form oligomers (or protofibrils), which coalesce into 
fibrils and then co-aggregate with other proteins into (intracellular) inclusions 
(Conway et al. 1998; Wood et al. 1999). While the monomers and oligomers of 
aSyn are soluble, the fibrils and LBs are insoluble in the neuronal cytoplasm. 
Some controversy arises, however, from the roles of the various physical forms 
or species of aSyn in PD pathogenesis. LBs have been proposed to be both 
neurotoxic (El-Agnaf et al. 1998), and protective (Mouradian 2002; Rochet et al. 
2000). Other hypotheses state that the pre-fibrillar intermediates, composed of 
aSyn oligomers, are the main toxic species towards dopaminergic neurons 
(Conway et al. 2000; Volles & Lansbury 2003). Lansbury and co-workers have 
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shown that aSyn oligomers can form annular, elliptical, or circular amyloid 
pores in cell membranes (Lashuel, Hartley, et al. 2002; Volles & Lansbury 2003), 
and cell culture studies have demonstrated that aSyn oligomers reduce cell 
viability, disrupt lysosomes and induce Golgi fragmentation (Gosavi et al. 2002), 
as well as toxicity in animal models (Karpinar et al. 2009). In line with these 
findings, the more neurotoxic A30P and A53T mutants of aSyn share an 
increased tendency to form soluble oligomeric intermediates, whereas the 
E46K and A53T mutants fibrillate faster than the wild-type protein (Conway et 
al. 2000; Choi et al. 2004). 
The heat-shock-protein 70 (Hsp70) family of chaperones (Mayer & Bukau 2005; 
Young 2010) is well conserved from bacteria to higher eukaryotes (where it is 
found within different organelles), having critical roles in a range of cellular 
processes such as promoting the folding of newly synthesized proteins and 
assisting the rescue of misfolded aggregated proteins. Hsp70 is highly relevant 
in the context of protein conformational diseases given that stress-induced 
cytosolic Hsp70 can prevent protein aggregation and enables the cell to avoid 
the accumulation of potentially toxic aggregates (Hartl 1996). 
The structures of several Hsp70 homologues are similar and consist of an actin-
like ATPase domain (nucleotide-binding domain, NBD) and a C-terminal 
substrate-binding domain (SBD), which are connected by a short linker region 
(Mayer & Bukau 2005). The substrate binding pocket recognizes and binds to 
unstructured or partially folded stretches within polypeptides (Bukau & 
Horwich 1998), with the current view that Hsp70s could prevent misfolding by 
binding to certain patterns in the polypeptide chain of the substrate that are 
highly enriched in hydrophobic residues (Maeda et al. 2007; Rüdiger et al. 
1997). Even though most of our current understanding of the Hsp70 molecular 
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orthologue (DnaK), the outlines of the mechanism appear conserved (Hartl & 
Hayer-Hartl 2002; Young 2010). The ATPase cycle of Hsp70 involves alternation 
between an ATP-bound state which has low affinity and fast exchange rates for 
peptide substrates (‘open’ state), and an ADP-bound state with high affinity 
and low exchange rates for substrates (‘closed’ state) (Mayer & Bukau 2005). 
This alternation is achieved by a bidirectional structural communication 
between the NBD and the SBD domains, driven by a complex allosteric 
mechanism (Mayer & Bukau 2005; Young 2010). 
The ATPase cycle is typically modulated by several co-chaperones, most notably 
the ‘Jdomain’ protein Hsp40/DNAJB1 (or DnaJ, the bacterial orthologue), 
resulting in increase of the ATPase activity (Bukau & Horwich 1998; Mayer & 
Bukau 2005; Minami et al. 1996), and the BAG family of proteins which function 
as nucleotide-exchange factors (NEFs) and promote the ADP release from the 
the Hsp70 NBD (Takayama et al. 1999; Young 2010). In addition to acting as 
enhancer of the basal ATPase rate of Hsp70, the Hsp40 family of co-chaperones 
has a key role in the canonical model of the Hsp70 machinery mechanism, 
given the ability of some of them to also recognize and bind to unfolded client 
proteins and ‘deliver’ them to Hsp70 (Kampinga & Craig 2010). Other important 
co-chaperones are Hop, which binds to the C-termini of Hsp70 and Hsp90 and 
assists substrate transfer between the two chaperones (Scheufler et al. 2000), 
and Hip (ST13) which has been shown to specifically bind to and stabilize, the 
ADP-bound state of Hsp70 (Höhfeld et al. 1995; Prapapanich et al. 1996), and 
has been suggested to increase the half-life of Hsp70-substrate complexes 
(Höhfeld et al. 1995). Finally, CHIP (Ballinger et al. 1999) acts as an E3-ubiquitin 
ligase that ubiquitinates HSPA8/Hsc70/Hsp73 (i.e. the constitutive cytosolic 
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2. Links between Hsp70 and the pathogenesis of PD 
PD is currently thought to involve different pathogenic mechanisms that 
eventually lead to neurodegeneration, as discussed elsewhere in this book 
series. There is substantial evidence supporting a prominent role in PD-related 
cell death of aSyn toxic oligomers. One hypothesis postulates that certain aSyn 
species can affect the homeostasis of cell membranes (Gupta et al. 2008; 
Lashuel, Petre, et al. 2002; Volles & Lansbury 2002), and produce ER and 
oxidative stress, UPS and mitochondrial dysfunction (Gupta et al. 2008; Jellinger 
2010), as well as neuroinflammation (Jellinger 2010; Roodveldt et al. 2008) 
processes, all of which have been linked, to a lower or larger extent, to the 
amyloid-like aggregation of aSyn. As will be described below, the Hsp70 system 
has been found to be a key player in counteracting most of these processes, 
not only by physically interacting with aSyn, but also by promoting aggregation 
clearance  
 Fig. 1. Links between Hsp70 and the multiple aSyn-mediated processes in PD 
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system; LB: Lewy bodies; LN: Lewy neurites. Discontinuous lines depict the possible 
‘sequestration’ of certain chaperones by aSyn aggregating species 
2.1  Hsp70 in modulation of aSyn aggregation and cytotoxicity 
Heat-shock proteins (HSPs) prevent and reverse the misfolding and aggregation 
of proteins, and the Hsp70 family in particular is known to play important roles 
in protecting neurons from protein aggregation-derived stress (Lu et al. 2010). 
Therefore, it might not seem surprising that Hsp70 has been found to be linked 
to several neurodegenerative processes and ‘conformational’ disorders, 
including PD (Witt 2010). Notably, Hsp70 has been shown to colocalize with 
aggregated aSyn within LBs in brains from PD patients (Auluck et al. 2002),  
strongly suggesting a role for this chaperone in managing aSyn aggregates in 
the context of PD (Figure 1). It is then that a substantial portion of the research 
in the field has focused on the effects of this major cytosolic chaperone on aSyn 
aggregation and cytotoxicity. Following the discovery that Hsp70 can abrogate 
the neurotoxicity of abnormal polyglutamine proteins (Warrick et al. 1999), it 
was shown that Hsp70 can also prevent dopaminergic neuronal loss associated 
with aSyn in a Drosophila PD model (Auluck et al. 2002). Numerous studies that 
followed have reported that over-expression of Hsp70 is able to reduce aSyn 
aggregation and/or toxicity in various cellular models (Danzer et al. 2011; 
Klucken, Shin, Masliah, et al. 2004; McLean et al. 2004; Opazo et al. 2008; 
Outeiro et al. 2008; Zhou et al. 2004). In particular, McLean and co-workers 
(Outeiro et al. 2008) have found that Hsp70 rescues aSyn-linked toxicity by 
promoting the cellular clearance of aSyn oligomers, rather than monomers. 
Another study (Opazo et al. 2008) found that Hsp70 manages aSyn intracellular 
aggregation by increasing the clearing of aggregates primarily through the 
aggresome, and the subsequent removal of small aggregates and aggresomes 
from the cytosol. An interesting study by McLean and colleagues (Danzer et al. 
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2011) has recently shown that Hsp70 can also inhibit the formation of 
extracellular aSyn oligomers and rescue the cytotoxicity produced by such 
secreted oligomers, in a cellular model. Moreover, their data also indicates that 
Hsp70 is released to the extracellular medium together with secreted aSyn, 
adding to the accumulating evidence that Hsp70 can be released from cells by 
an active mechanism, with functionally relevant consequences. 
Intriguingly, while it was found that over-expression of Hsp70 can prevent aSyn 
aggregation in a Wt aSyn transgenic mouse model (Klucken, Shin, Masliah, et al. 
2004), a recent work based on A53T-aSyn transgenic mice has failed to observe 
this effect (Shimshek et al. 2010), seeding some controversy. Could these 
findings reflect a difference in the nature of the aggregates generated by Wt 
and mutant aSyn, and therefore a differential ability of Hsp70 to cope with 
those aggregates? Even though there is compelling evidence demonstrating the 
important role of Hsp70 under physiological and pathological scenarios in 
modulating fibril formation based on in vivo and cellular models, the molecular 
mechanism underlying such anti-aggregation properties in the context of PD, is 
still not fully understood. 
Unlike the many research works performed with PD cellular and animal models 
that have contributed to our understanding on Hsp70 function under 
physiological or pathological conditions, only a handful of studies have focused 
on the molecular mechanism and interactions that underlie the modulation of 
aSyn aggregation exerted by Hsp70. An in-cell fluorescence resonance energy 
transfer (FRET) study indicated that Hsp70 alters the conformation of aSyn, 
inducing it to adopt a more ‘open’ conformation, without affecting the aSyn-
aSyn intermolecular interactions (Klucken et al. 2006). Similarly to what had 
been found in vitro for Hsp70 and the HD-related huntingtin protein 
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shown that Hsp70 is able to suppress aSyn fibril assembly. In this case, a variety 
of in vitro studies have shown that this efficient inhibition of amyloid assembly 
can occur in the absence of collaborating co-chaperones and in an ATP-
independent manner (Ahmad 2010; Dedmon et al. 2005; Huang et al. 2006; Luk 
et al. 2008; Roodveldt et al. 2009), while promoting formation of small 
oligomeric species of moderate toxicity (Roodveldt et al. 2009). However, our 
recent study demonstrates that, even though Hsp70 is indeed able to control 
aSyn fibrillation and its associated toxicity in an ATP-independent manner, it 
does so more efficiently in the presence of ATP (Roodveldt et al. 2009), 
consistent with the results obtained with a cellular model (Klucken, Shin, 
Hyman, et al. 2004). Nevertheless, this ATP-dependent activity was found to 
require Hip co-chaperone activity, and not Hsp40 as observed in the case of 
mutant huntingtin protein (Lotz et al. 2010), suggesting that Hsp70 can function 
through different molecular mechanisms, depending on the nature of the 
aggregating client protein. 
Interestingly, our study also showed that Hsp70 in the presence of ATP is prone 
to coaggregate with aggregating aSyn, presumably caused by the formation of a 
highly insoluble (ADP)Hsp70/aSyn complex. Surprisingly, this co-aggregation 
can be prevented by the addition of the co-chaperone Hip (St13), which had 
been found to be under-expressed in serum of PD patients since the early 
stages of the disease (Scherzer et al. 2007). The relevance of Hip in assisting the 
suppression of aSyn aggregation in an Hsp70-dependent manner was further 
supported by a study we performed in a C. elegans model of PD (Roodveldt et 
al. 2009), in which knock-down of Hip produced a much stronger PD phenotype 
than knock-down of Hsp70, shown by higher levels of aSyn aggregation in the 
former condition. This finding indicates that Hip co-chaperone could be 
important not only in modulating the chaperone’s molecular mechanism, but 
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also in guarding the functionality and availability of Hsp70 under certain 
conditions. 
One relevant question relates to the nature of the species along the 
aggregation pathway of aSyn that are specifically recognized and targeted by 
Hsp70. Initially, Hsp70 was reported to bind to aSyn filaments in vitro 
(Lindersson et al. 2004). However, it is currently understood that Hsp70 does 
not disaggregate or alter the structural properties of mature aSyn fibrils 
(Dedmon et al. 2005), but rather inhibits fibril formation via interactions with 
soluble pre-fibrillar forms of aSyn. A few studies performed with cell extracts 
(Zhou et al. 2004) and with live cells (Klucken et al. 2006), in addition to 
experiments with purified proteins (Dedmon et al. 2005; Huang et al. 2006; 
Roodveldt et al. 2009), demonstrate the existence of molecular interactions 
between Hsp70 and aSyn oligomeric species. Even though previous attempts to 
isolate such complexes by co-immunoprecipitation or pulldown experiments 
had failed (Luk et al. 2008), we have been able to probe the formation of a 
complex between Hsp70 and aSyn oligomeric species by FRET (Roodveldt et al. 
2009), suggesting that these interactions are transient (Luk et al. 2008; 
Roodveldt et al. 2009), besides being highly dynamic (Luk et al. 2008; Roodveldt 
et al. 2009). 
In addition, we have recently shown by FRET and nuclear magnetic resonance 
(NMR) analyses that, contrary to what was previously thought, Hsp70 can also 
interact with aSyn monomeric species (Roodveldt et al. 2009) with an affinity 
constant lying within the low micromolar range. Moreover, the fluorimetric 
study revealed the existence of diverse Hsp70/aSyn complexes that are formed 
depending on the nucleotide state of the chaperone, either nucleotide-free, or 
ATP- or ADP-bound, that are sampled along the ATPase cycle. Based on these 
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complex in the ADP-state of Hsp70 that arises during the aggregation process of 
aSyn, leads to Hsp70 being entrapped or sequestered by the oligomers. 
However, we propose that this compact complex can be stabilized by the Hip 
co-chaperone and therefore the co-aggregation of the chaperone, and 
ultimately the formation of aSyn fibrils, can be prevented (Roodveldt et al., 
2009). In other words, our findings indicated that a decreased expression of Hip 
could facilitate depletion of Hsp70 by amyloidogenic polypeptides, impairing 
chaperone proteostasis. Interestingly, another case of chaperoneinhibition/ 
depletion by aSyn oligomers, but not by unstructured monomers, was recently 
reported for the Hsp70/Hsp40 system (Hinault et al. 2010). In this case, the 
authors found that the inhibition of the chaperone system was predominantly 
caused by the sequestration or incapacitation, by off-pathway aSyn oligomers, 
of the J-domain (Hsp40) co-chaperone (Hinault et al. 2010). 
What is the region on the aSyn molecule thought to be recognized and bound 
by Hsp70? One study mapped this region as the broad segment between 
residues 21 and 110 (Luk et al. 2008). Based on a predictive algorithm for 
Hsp70-binding regions (Rüdiger et al. 1997) and FRET analyses to probe Hsp70-
aSyn interactions (Roodveldt et al. 2009), our results indicate that Hsp70 can 
bind to the N-terminus and the central NAC region of the protein. The first 
binding region is involved in functional lipid interactions, while the second one 
comprises the stretch of hydrophobic residues that readily forms fibrils in vitro 
and is generally assumed to be involved in initiating the fibrillation process 
(Giasson et al. 2001). In addition, our results suggest that Hsp70 also interacts 
with the negatively charged C-terminus of the aSyn molecule, especially in the 
nucleotide-free state. Taken together, the studies carried out thus far 
demonstrate that Hsp70 modulates aSyn aggregation by interacting with the 
protein at different stages of aggregation, by recognizing essentially two or 
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three regions in the aSyn molecule, and forming different transient complexes 
with the substrate. The strong binding versatility displayed by Hsp70 with 
aggregating aSyn might be possible thanks to the large structural flexibility 
conferred by the lid subdomain within the SBD, that has been recently 
described by Mayer and colleagues (Schlecht et al. 2011). 
2.2 Cooperation of Hsp70 with the ubiquitin-proteasome system 
(UPS). 
2.2.1 Involvement of the ubiquitin-proteasome system in PD. 
The ubiquitin-proteasome system (UPS) is responsible for the degradation of 
vital regulatory proteins that control almost every cellular function (Hershko & 
Ciechanover 1998). The UPS system is composed of three classes of 
ubiquitinating enzymes (E1, E2 and E3) that activate, transfer and attach the 
small protein ubiquitin to the Lys residues of proteins that are targeted for 
degradation. Conjugation of at least four ubiquitin moieties acts as the 
degradation signal in a process that is initiated by the recognition of the 
ubiquitin linkage by the proteasome, which first catalyzes the unfolding and 
then the proteolysis of the targeted protein function (Hershko & Ciechanover 
1998). 
Impairment in the UPS has been linked to many neurodegenerative disorders 
and indeed to contribute to disease progression in PD (Ciechanover & Brundin 
2003; Cook & Petrucelli 2009; McNaught et al. 2001). The involvement of UPS 
in PD arouse major interest with the identification of mutations in the E3 
ubiquitin ligase parkin protein as a cause of autosomal recessive PD (Kitada et 
al. 1998). Both the loss of E3 activity and the possibility of incomplete or 
aberrant ubiquitination are proposed as causes of parkin-related PD (Giasson & 
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terminal hydrolase-L1 (UCH-L1), and mutations in the uchl-1 gene cause 
dysfunction of this enzyme and lead to accumulation of toxic products (Leroy et 
al. 1998). 
Beyond the clear genetic association between the UPS and PD, several studies 
have demonstrated a reduced proteolytic activity in the SN of PD patients when 
compared with aged-matched controls (McNaught et al. 2003; McNaught & 
Jenner 2001; McNaught & Olanow 2006). In culture of rat primary neurons, 
treatment with proteasomal inhibitors has shown to lead to the formation of 
aSyn- and ubiquitin- positive proteinaceous inclusions, analogous to LBs found 
in PD patients (McNaught, Mytilineou, et al. 2002; Rideout et al. 2005). 
Moreover, systemic administration of proteasomal inhibitors in rats produced a 
behavioural and pathological phenotype strongly reminiscent of PD (McNaught 
et al. 2004), although recently some controversy arose in this matter (Manning-
Boğ et al. 2006). Further support to the active role played by proteasomal 
impairment in PD progression originated from studies with pesticides, such as 
rotenone and paraquat (Cook & Petrucelli 2009). Mice treated with such 
environmental toxins display a strong reduction in proteolytic activity that is 
dependent on the presence of aSyn (Fornai et al. 2005). All together, these data 
undoubtedly link aSyn aggregation with impairment of the UPS in PD 
progression. 
In relation to protein misfolding and aggregation, it has been proposed that 
failure of the UPS to adequately remove misfolded or abnormal proteins may 
underlie demise of nigral cells in sporadic PD (McNaught et al. 2001). 
Furthermore, deficits in the 26/20S proteasome pathways are accompanied by 
protein accumulation and aggregation, which may also cause 
neurodegeneration (Chung et al. 2001), in line with recent findings that general 
intracellular aggregation of proteins into aggresomes can inhibit the UPS 
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(Bence et al. 2001). Moreover, chaperones of the heat-shock families, including 
HSP27, 40, 70, 60, 90, and 110, as well as components of the UPS, such as 
ubiquitin, UCH-L1 and parkin, are found in LBs extracted from PD patients post 
mortem (Shults 2006). These combined pieces of evidence have attracted much 
attention lately as they imply that LBs could originate from ubiquitin-rich 
aggresomes that the proteasomal components may not be able to process 
(McNaught, Shashidharan, et al. 2002). One plausible mechanism would involve 
aSyn adopting abnormal protein conformations and overwhelming the cellular 
protein degradation systems (Wong & Cuervo 2010), whereas deficits in the 
UPS machinery would challenge the cell’s ability to detect and degrade 
misfolded proteins that can result in the formation of toxic early aggregates 
(McNaught, Shashidharan, et al. 2002). The common outcome of this failure at 
different levels is thus expected to be a cellular build-up of unwanted toxic 
species that should have been cleared in otherwise healthy conditions. Minimal 
defects in the crucial protein turnover machinery may suffice to cause a slow 
demise of dopaminergic neurons, which may explain the relentless, progressive 
nature of the disease (Vila & Przedborski 2003). 
Alpha-synuclein extracted from LBs in PD brains has been found to be mono- 
and di-ubiquitinated (Hasegawa et al. 2002), while soluble aSyn is mono-
ubiquitinated by SIAH-1 and -2, but not by parkin (Liani et al. 2004; Rott et al. 
2008). Instead, a modified, Oglycosylated, version of aSyn is a substrate for 
parkin-induced ubiquitination (Shimura et al. 2001), and it was shown that 
interaction of parkin with aSyn is mediated by synphilin-1 (Chung et al. 2001) as 
well as by the protein 14-3-3-η (Sato et al. 2006). Importantly, parkin has been 
shown to be able to rescue primary neurons from the toxic effects of aSyn 
(Petrucelli et al. 2002), suggesting that the two proteins share a common 
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addition, UCH-L1 may be involved in regulating the cytoplasmic abundance of 
aSyn, as it displays unexpected ubiquitin ligase activity that is also able to poly-
ubiquitinate mono- and di-ubiquitinated aSyn (Liu et al. 2002). Since 
attachment of at least four ubiquitin molecules is known to be required for 
protein degradation via the UPS (Hershko & Ciechanover 1998), it is likely that 
mono-, di-, and aberrant poly-ubiquitinated aSyn could have a pathogenic 
impact (Rott et al. 2008; Sun & Chen 2004). 
2.2.2 Role of the C-terminus Hsp70-interacting protein (CHIP) in 
PD 
Hsp70 and Hsp90 family members as well as small HSPs all take part in the 
degradation of protein substrate and are able to cooperate with the UPS 
towards this goal (Patterson & Hohfeld, 2006). Notably, protein homeostasis 
thus appears to be tightly controlled by interplay between the protein folding 
and protein degradation systems. Hsp70 takes part in the degradation of 
immature and aberrant forms of certain proteins, particularly ER-bound 
membrane proteins (Taxis et al. 2003), but also some cytosolic and nuclear 
proteins (Bercovich et al. 1997). For example, Hsp70 assists in the folding of the 
aggregation prone cystic fibrosis transmembrane conductance regulator (CFTR); 
however, Hsp70 is also able to present CFTR to the UPS and thus control 
precisely the abundance of this protein known to accumulate in aggregosomes 
and to cause cystic fibrosis (Zhang et al. 2001). Indeed, Hsp70 is actively 
recruited to aggregosomes and it has been proposed that this chaperone can 
reduce aggregosome formation by stimulating proteasomal degradation of 
misfolded proteins (Dul et al. 2001; García-Mata et al. 1999). The proposed 
mechanism for chaperone-UPS cooperation is that both systems compete for 
the same misfolded and aggregation-prone substrate proteins, and that the 
efficiency of chaperones in maintaining these proteins in solution increments 
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the probability of the UPS to degrade aberrant polypeptides. Alternatively, 
failure of chaperones to keep misfolded proteins in a soluble state gives rise to 
aggregates that are not efficiently degraded by the UPS and, moreover, may 
inhibit UPS activity towards other protein targets, altering protein homeostasis 
(Figure 1). 
Insights into the mechanism that enables the cooperation of protein 
chaperones with the UPS have been obtained from the identification and 
functional characterization of the C-terminal Hsp70 interacting protein (CHIP) 
co-chaperone (Ballinger et al. 1999; Höhfeld et al. 2001; McDonough & 
Patterson 2003). CHIP contains three tetratricopeptide repeat domains (TPR) 
that recognize and bind the EEVD motif in both Hsp70 and Hsp90 (Ballinger et 
al. 1999). CHIP-complexed Hsp70 displays reduced ATP hydrolysis in vitro, 
suggesting that the co-chaperone diminishes the on-rate of binding and release 
cycles in Hsp70 (Ballinger et al. 1999). In its C-terminus, CHIP possesses an 
ubiquitin ligase domain (U box) that is capable of targeting proteins to 
degradation, in a homologous manner to RING finger domains found in E3 
ubiquitin ligase enzymes (Connell et al. 2001; Meacham et al. 2001). 
CHIP has been shown to efficiently act as E3 ligase for several Hsp70 and Hsp90 
substrates, such as the glucocorticoid receptor and Erb2 (Dickey et al. 2007; 
McDonough & Patterson 2003; Murata et al. 2001). Proteins ubiquitinated by 
CHIP are efficiently targeted to the proteasome and subsequently degraded. 
Notably, the UbcH4/UbcH5 proteins are E2 conjugating enzymes (Demand et al. 
2001) that are stress-activated, suggesting that upon stress CHIP furnishes the 
cell with chaperone-dependent ubiquitin ligases capable of ubiquitinating 
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The ubiquitinating activity of CHIP is regulated by two co-chaperones, BAG-1, 
which is an enhancer, and the Hsp70 binding protein 1 (HspBP1), which acts as 
a repressor. The co-chaperone BAG-1 associates with the ATPase domain of 
Hsp70 and, in addition, possesses a ubiquitin-like domain that is efficiently 
recognized and bound by the proteasome (Lüders et al. 2000). Thus, BAG-1 
provides the proteasome with the capability to recruit Hsp70 and consequently 
degrade its cargo clients. A ternary complex involving BAG-1, Hsp70 and CHIP 
has been isolated, and BAG-1 is capable of stimulating CHIP mediated 
degradation of some proteins (Alberti et al. 2002). The co-chaperone HspBP1, 
in turn, competes with BAG-1 for binding to the ATPase domain of Hsp70 
(Alberti et al. 2004). Notably, when in complex with HspBP1 bound Hsp70, CHIP 
shows a much reduced ubiquitin ligase activity and chaperone substrates are 
no longer ubiquitinated and target to the UPS (Alberti et al. 2004). 
In the context of neurodegeneration, CHIP has been shown to intervene in the 
degradation of misfolded aggregation-prone proteins associated with AD, PD 
and HD, as well as with spinocerebellar ataxia and spinal bulbar muscle atrophy 
(Adachi et al. 2007; Al-Ramahi et al. 2006; Hatakeyama et al. 2004; Shin et al. 
2005; Urushitani et al. 2004). Indeed, CHIP plays an active role in modulating 
aSyn aggregation and degradation (Kalia et al. 2011; Shin et al. 2005; Tetzlaff et 
al. 2008). It was shown that CHIP interacts with both soluble and aggregated 
aSyn, and its over-expression reduces aSyn abundance and aggregation (Shin et 
al. 2005). Interestingly, CHIP induces aSyn clearance via two alternative 
pathways, one involving Hsp70 and proteasomal degradation, and another 
Hsp70-independent route that targets aSyn to lysosomes (Shin et al. 2005). A 
fluorescence-complementation assay demonstrated that CHIP reduced 
significantly the abundance of aSyn toxic oligomers in cell culture, suggesting 
that this aberrant species is preferentially recognized by the co-chaperone 
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(Tetzlaff et al. 2008). More recently, it was discovered that CHIP is an E3 
ubiquitin ligase of aSyn since it efficiently conjugates ubiquitin moieties to this 
protein (Kalia et al. 2011). CHIP-catalyzed ubiquitinated forms of aSyn include 
mono- and poly-ubiquitinated species, and the activity of CHIP depends on the 
presence of Hsp70 and the co-chaperone BAG5. Contrary to the enhancer 
activity reported for BAG1, BAG5 reduces the ability of CHIP to ubiquitinate 
aSyn in and Hsp70-dependent manner (Kalia et al. 2011). 
Additional pathogenic mechanisms in PD that involve the activity of CHIP relate 
to the ubiquitin ligase activity of parkin and the kinase activity of the leucine-
rich repeat kinase-2 (LRRK2). It has been found that CHIP, Hsp70 and parkin 
form a ternary complex that promotes ubiquitination and degradation of the 
Pael receptor, a protein localized in the ER and whose accumulation has been 
linked to dopaminergic neuronal death (Imai et al. 2002). CHIP is proposed to 
enhance the activity of parkin, even in the absence of Hsp70 (Imai et al. 2002). 
Concerning LRRK2, CHIP regulates the ubiquitination, degradation, and toxicity 
mediated by pathogenic mutations of this kinase (Ko et al. 2009). CHIP binds 
LRRK2 via its TPR motifs and formation of this complex is protective in cell 
culture models, while in the presence of mutant LRKK2, knock-down of CHIP 
leads to cell death (Ko et al. 2009). 
2.3 Hsp70 in chaperone-mediated autophagy (CMA) 
Macroautophay and chaperone-mediated autophagy (CMA) are the two main 
lysosomal proteolytic systems in mammalian cells for the degradation of 
intracellular proteins (Xilouri & Stefanis 2011). CMA is the process of 
degradation of intracellular components by lysosomes which selectively 
degrades cytotolic proteins containing a KFERQ-like motif (Koga & Cuervo 
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cytosolic Hsp70 (Hsc70) and co-chaperones (including Hsp40, Hip, Hsp90 and 
BAG1) to substrate proteins, and their subsequent targeting to lysosomes via 
the lysosomal surface receptor LAMP-2A (Xilouri & Stefanis 2011). The 
substrate protein is subsequently degraded after unfolding and translocation 
into the lysosomal lumen, in a process involving lysosomal Hsc70 (Figure 1). It 
has been estimated that about 30% of cytosolic proteins could be subjected to 
degradation via CMA (Dice 2007), and furthermore, this pathway  may be a 
major route by which aSyn is degraded in neurons (Witt 2010). Even though it is 
currently accepted that dysregulation of autophagy plays a role in 
neurodegeneration (Bandhyopadhyay & Cuervo 2007; Nixon 2006; Rubinsztein 
2006; Xilouri & Stefanis 2011), including the PD neurodegenerative process 
(Martinez-Vicente et al. 2008; Yang et al. 2009), the mechanism by which CMA 
modulates neuronal survival or death, is still unclear. 
Given that pathologic accumulation of aSyn is a hallmark of PD, several recent 
studies have addressed the possible link between aSyn degradation, CMA 
dysfunction and the neurodegenerative process. Indeed, aSyn, which contains a 
pentapeptide sequence (95VKKDQ99) consistent with Hsc70 binding (Dice 1990), 
has been shown to be degraded via CMA using isolated lysosomal preparations 
(Cuervo et al. 2004) and neuronal cells (Alvarez-Erviti et al. 2010; Martinez-
Vicente et al. 2010; Vogiatzi et al. 2008). On the contrary, the A30P and A53T 
aSyn variants were observed to bind strongly to LAMP-2A receptors but were 
not internalized, thus inhibiting the CMA degradation of other substrates 
(Cuervo et al. 2004). This CMA dysfunction was later shown to mediate aSyn 
toxicity in cellular models (Xilouri et al. 2009). Moreover, a recent study using 
both aSyn transgenic- and paraquat- PD mouse models (Mak et al. 2010), has 
shown that aSyn can be degraded in the lysosome through CMA, in vivo. The 
study also revealed an up-regulation of LAMP-2A and lysosomal Hsc70 and an 
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increase in Hsc70-aSyn interactions in brain lysosomes, relative to controls. On 
the other hand, a recent work showed a significant reduction of both LAMP-2A 
and Hsc70 levels in the SN and amygdala of PD brains, relative to age-matched 
Alzheimer’s disease (AD) and healthy, brain controls (Alvarez-Erviti et al. 2010). 
Even though their results might initially appear contradictory, these findings 
support a key role for Hsc70 and the CMA system in maintaining intracellular 
general proteostasis, especially within the aSyn-overload scenario that is 
typically associated to PD and other α-synucleinopathies. 
2.4 Emerging links between the Hsp70 system and 
neurodegeneration in PD 
2.4.1 The CSPα-Hsc70-SGT complex and neurodegeneration in PD 
Cysteine-string protein α (CSPα) is an abundant protein localized in synaptic 
vesicles that maeliorates neurodegeneration in cellular and animal models 
(Johnson et al. 2010). It contains a Dna-J domain and has been shown to 
interact with Hsc70 and to increase its ATPase activity (Braun et al. 1996). CSPα 
has been shown to assemble into an enzymatically active ternary complex with 
Hsc70 and SGT (small glutamine-rich tetratricopeptide repeat domain protein) 
with a likely regulatory function in secretory vesicles (Tobaben et al. 2001). 
CSPα has also been reported to interact with other chaperones, including 
Hsp90 (Sakisaka et al. 2002), Hip, Hop (Rosales-Hernandez et al. 2009), and 
Hsp40 (Gibbs et al. 2009). 
CSPα dysfunction has been implicated in various pathologies, including memory 
impairment, type-2 diabetes, cystic fibrosis, and HD (reviewed in (Johnson et al. 
2010)). A few years ago, a link between CSPα and PD was also established 
(Chandra et al. 2005). The results of this study, performed using a transgenic 
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neurodegeneration (Chandra et al. 2005). In a recent study (Sharma et al. 
2011), the CSPα-Hsc70-SGT complex was found to bind to monomeric SNAP-25, 
a pre-synaptic SNARE protein, and prevent its aggregation, thus promoting the 
formation of the SNARE complex involved in neuronal synapse. Interestingly, 
another recent study using a transgenic mouse model of aSyn aggregation with 
associated neurodegeneration, has shown that SNAP-25 is redistributed within 
synaptic terminals and the protein was found to colocalize with aSyn within 
intraneuronal aggregates (Garcia-Reitböck et al. 2010).  These data raise the 
question whether aggregating aSyn might actually be sequestering CSPα 
involved in the CSPα-Hsc70-SGT complex, analogously to what was observed 
for aggregating huntingtin (Miller et al. 2003), and therefore enabling the 
aggregation of SNAP25 in a PD scenario. 
2.4.2 The unfolded protein response (UPR) in PD 
The unfolded protein response (UPR) is a mechanism activated within the cell 
when the endoplasmic reticulum (ER) function is impaired and, as a result, 
unfolded proteins accumulate in the ER lumen (a process called ‘ER stress’). The 
ER-resident Hsp70 family member GRP74/BiP recognizes and binds such 
unfolded proteins, which causes the release UPR activating factors (Rutkowski 
& Kaufman 2004). To restore ER function, the UPR reduces protein translation 
and enhances folding and processing capacity within ER. However, if the stress 
overwhelms the cell restoring capacity, the UPR induces apoptosis (Paschen & 
Mengesdorf 2005). A few years ago, a mutation in the parkin gene was found to 
be related to familiar PD due to the impairment of its ubiquitin ligase function 
which results in protein accumulation within the ER lumen and leads to ER 
stress and apoptosis (Imai et al. 2001). More recently, a strong correlation 
between UPR activation and PD pathogenesis in PD patients was established 
(Hoozemans et al. 2007), with results that might suggest a functional 
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connection between aSyn and ER stress. In addition, it was found that 
overexpression of Wt aSyn triggers UPR in yeast (Cooper et al. 2006). A recent 
study has shown that aSyn is also found aggregated and accumulated within 
the ER lumen and induces UPR by binding to GRP78/BiP in cells, which could 
lead to apoptosis (Bellucci et al. 2011). Clearly, supplementary investigations 
are needed to determine the exact role of the UPR in the pathophysiology of 
PD. 
2.4.3 Mitochondrial dysfunction in PD 
In both familial and sporadic forms of PD, several mitochondrial alterations and 
increase of oxidative species are well recorded (Jellinger 2010). The important 
role of mitochondrial pathology in PD is reflected by the specific and selective 
loss of mitochondrial complex I activity in the SN of PD patients (Valente et al. 
2004). Results from a study with neuronal cell cultures indicated that this 
impairment was dependent on aSyn mitochondrial import and accumulation 
(Devi et al. 2008). Interestingly, a recent proteomic study revealed that 
expression of mortalin (mtHSP70/GRP75), a mitochondrial stress protein and 
member of the Hsp70 chaperone family which binds to DJ-1 and aSyn (Jin et al. 
2007), is significantly decreased in PD brains (De Mena et al. 2009; Jin et al. 
2006) as well as in a cellular model of PD (Jin et al. 2006). Moreover, specific 
coding mutational variants of the mortalin gene have been recently discovered 
in a few PD patients (Burbulla et al. 2010; De Mena et al. 2009). Finally, 
differential levels of mitochondrial mortalin were measured in Wt and A53T 
cellular models of PD (Pennington et al. 2010), suggesting a possible 
involvement of aSyn aggregation in PD-related mitochondrial dysfunction (Xie 
et al. 2010). 
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A biomarker is a naturally occurring molecule, gene, or characteristic by which a 
particular medical condition, disease, etc. can be identified. Despite the current 
relevance of identifying a biomarker for early diagnosis of PD and/or to follow 
up its progression, up to date there is no reliable biomarker available (Morgan 
et al. 2010; Nyhlén et al. 2010). Therefore, certain key proteins that are tightly 
linked to PD pathogenesis or progression, such as the members of the Hsp70 
machinery discussed above, which could manifest changes in their expression 
levels in body fluids cells or alter their presence in body fluids in a PD scenario, 
could represent potential markers of disease development or predisposition. 
 Nowadays the most promising biomarkers for PD in cerebrospinal fluidic (CSF) 
are aSyn, DJ-1, amyloid β, and the tau protein. These are the principal targets in 
the Parkinson’s Progression Markers Initiative, a public-private, large-scale 
study project that aims to identify biological markers of disease progression 
spearheaded by the Michael J. Fox Foundation (www.PPMI-info.org). DJ-1, 
which is the only chaperone to be included in this study, is a mitochondrial 
chaperone which has been one of the most studied proteins for its potential 
use as a PD biomarker. However, results published thus far from measurements 
of DJ-1 in CSF (Hong et al. 2010) and serum from PD patients (Hong et al. 2010; 
Shi et al. 2010; Waragai et al. 2007) are somewhat controversial or 
inconsistent, which could probably be explained by the high DJ-1 protein level 
present in blood cells (Shi et al. 2010). 
Currently, it is well established that certain proteins, including members of the 
Hsp70 family such as Hsp701A and 1B, display perturbed expression levels in 
the SN of PD brains (Hauser et al. 2005); however, changes in tissue expression 
levels are in principle not useful for an application as biomarkers. Recently, a 
significant decrease in whole blood mRNA levels of St13/Hip co-chaperone was 
reported for early PD patients, but not for AD patients or healthy controls 
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(Scherzer et al. 2007). A second group later found differences in HSPA8 (Hsc70) 
and HIP2 expression levels between PD patients and controls (Grünblatt et al. 
2010). However, a third study reported no significant differences in the 
expression pattern of ST13 in early-stage PD patients, as compared to controls 
(Shadrina et al. 2010). This discrepancy could be attributed, at least in part, to 
heterogeneity in the criteria of diagnosing and classifying the individuals into 
groups and to the difficulty in establishing the actual onset of the disease. 
Other members of the Hsp70 machinery are known to change their expression 
patterns in PD patients compared to healthy controls (Hauser et al. 2005). 
Unfortunately, these changes appear not specific or sufficient to differentiate 
between PD and other related neurodegenerative disorders (Hauser et al. 
2005). This is probably due to the fact that the Hsp70 machinery plays a central 
role in maintaining cell proteostasis, which is perturbed in a variety of 
neurodegenerative diseases. 
Considering that PD is a complex pathology that involves several systems such 
as the stress response, the UPS, the immune system, etc., a unique biomarker 
might not be enough as a tool for diagnosis or follow-up of disease progression. 
Instead, there is general consensus that the use of a set of distinct parameters, 
such as protein expression profiles, age, symptoms and others, would probably 
be the best approach (Fasano et al. 2008; Grünblatt et al. 2010; Scherzer et al. 
2007). 
4. The Hsp70 system as a therapeutic tool for PD 
As described in this chapter, in the last few years it has become evident that 
HSPs play an important role in the initiation and progression of PD and other 
neurodegenerative diseases. This cumulative evidence has prompted the 
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strategies have been tested to manipulate Hsp70 as a therapeutic 
approximation for PD and related neurodegenerative diseases (reviewed in 
(Kalia et al. 2010)). Three general approaches have been explored, namely, to 
increase the intracellular activity of Hsp70, to overexpress Hsp70 and/or other 
co-chaperones, and to deliver chaperones or regulatory factors using cell-
penetrating peptides (CPPs). 
4.1 Increasing the intracelular activity of Hsp70 
Theoretically, it should be feasible to control the activity of the cellular 
chaperone machinery by using different types of drugs. The mechanism of most 
of such chemical compounds is based on activating HSF-1, a key transcriptional 
regulator of the heat shock response (HSR) that activates the gene expression 
of inducible HSPs. One way of activating HSF-1 is by inhibiting Hsp90 activity; as 
a result, HSF-1 becomes active and increases the expression of inducible 
chaperones like HSPA1A/Hsp72 and others. Geldanamycin (GA) and its 
derivative 17-allylamino-17-demethoxygeldanamycin (17-AAG) are antibiotics 
with high affinity for the ATPase domain of Hsp90, which blocks its interaction 
with HSF-1 and subsequently allows its activation (Waza et al. 2006; Zou et al. 
1998). GA prevents aSyn induced dopaminergic cell loss in cell culture (McLean 
et al. 2004) and in animal models of PD (Auluck et al. 2005; Shen et al. 2005), 
while the less toxic 17-AAG has also proven to be neuroprotective in PD cellular 
models (Danzer et al. 2011; Riedel et al. 2010) and in two animal models of PD-
related neurodegenerative diseases (Fujikake et al. 2008; Waza et al. 2005). 
Even though 17-AAG is currently under phase-II clinical trials as an anti-tumour 
drug (Pacey et al. 2012; Richardson et al. 2010; Solit et al. 2008), its use in 
patients with neurodegenerative diseases could be hampered by its toxicity and 
unavailability for oral administration (Pacey et al. 2012). Another family of 
inhibitors of Hsp90 activity is SNX- 2112 and its analogues, which are orally 
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available and present improved blood brain barrier (BBB) permeability. In 
particular, SNX-0723 was shown to prevent aSyn oligomer formation and aSyn-
induced toxicity in cell culture (Putcha et al. 2010), and preclinical studies for 
cancer therapy are proving their safety (Zhai et al. 2011), although similar 
studies in neurodegenerative animal models are still needed. 
Other drugs are able to activate HSF-1 without inhibiting Hsp90 activity, which 
could represent a less toxic approximation for neurodegenerative pathologies. 
Arimoclomol, for example, has already been tested in phase I- and IIa-clinical 
trials for treating ALS, and shown to be safe and tolerable (Cudkowicz et al. 
2008; Phukan 2010). Another example is HSF-1A (Neef et al. 2010), shown to 
upregulate Hsp70 expression and to reduce poly-Q cytotoxicity in cell and fly 
models of poly-Q neurodegenerative disorders (Neef et al. 2010). Celastrol, yet 
a similar drug, and some structural relatives, appear as promising drugs due to 
their rapid kinetics and low EC50 (Westerheide et al. 2004), although further 
studies are needed.  
Besides these approaches, HSF-1 co-inducers could represent more tolerable 
drugs for therapy. These are molecules that partially activate HSF-1, reducing 
its activation threshold and often working in conjunction with secondary stress 
signals to fully induce HSR. Non-steroidal anti- inflammatory drugs (NSAIDs) are 
well known co-inducers of HSR. For example, Sodium salicylate and 
Indomethacin induce HSF-1 DNA binding and reduce the temperature required 
for triggering the HSR (Jurivich et al. 1995; Lee et al. 1995). The association of 
NSAIDs use with a lower risk of common neurodegenerative diseases such as 
AD and PD has been analysed in several studies (Etminan et al. 2008; Gagne & 
Power 2010). According to one hypothesis, this negative correlation could be 
due to continuous up-regulation of HSR and consequently continued 
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4.2 Overexpression of Hsp70 and/or related co-chaperones 
In principle, it should be possible to design a gene therapy approach for the 
treatment of PD and other conformational neurodegenerative diseases based 
on HSPs, considering the substantial number of reports having characterized 
the molecular pathways by which Hsp70 acts in the context of disease. 
Intriguingly, even though overexpression of Hsp70 has been shown to be 
protective in animal models of PD (Dong et al. 2005; Jung et al. 2008), a recent 
study in mouse indicates otherwise (Shimshek et al. 2010). Up to date, one 
phase-I study in PD patients using recombinant Adeno-Associated Virus (AAV) 
to deliver aromatic aminoacid decarboxylase enzyme into the putamen, 
supports the proof-of-principle for the use of gene therapy in PD (Christine et 
al. 2009). With this precedent, gene therapy could potentially be employed to 
overexpress other chaperones and co-chaperones that may improve Hsp70 
function and its neuroprotective properties. Indeed, recombinant AAV has been 
already used to transduce Hsp104 (Vashist et al. 2010), a non-mammalian 
chaperone, in a rat model of PD and proven to be neuroprotective by 
disaggregating protein inclusions and synergizing with endogenous Hsp70 (Lo 
Bianco et al. 2008). 
Given that co-chaperone BAG-5 is known as a negative regulator of Hsp70, 
downregulation of its expression has been tested in a mouse model of PD. In 
this study, direct expression in the SN by recombinant AAV delivery of BAG-
5(DARA), a BAG-5 mutant which inhibits wild-type BAG-5 activity, resulted in 
increased dopaminergic neuron survival (Kalia et al. 2004). Another possible 
approach to increase Hsp70 function by using gene therapy techniques could 
be gene silencing by RNA interference to knockdown Hsp70 downregulators. 
Although these techniques have not been extensively tested for 
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neurodegenerative therapy, they remain a potentially useful tool (Manfredsson 
et al. 2006). 
4.3 Chaperones or regulatory factors delivery using CPPs 
Cell penetrating peptides (CPPs) are the most recent approximation that shows 
promise towards increasing Hsp70 activity within cells. These are peptide 
motifs that allow cell transduction of macromolecules including functional full-
length proteins. The basic domain of the trans-activator of transcription (TAT) 
from HIV-1 is the best known among CPPs and it has been shown that fusion 
with TAT allows proteins to penetrate cell membranes of several cell types and 
even to cross the BBB (Fawell et al. 1994; Schwarze et al. 1999). In the last few 
years, TAT-Hsp70 transduction has been reported to be neuroprotective 
against different kinds of stress in cell models (Lai et al. 2005; Nagel et al. 2008) 
as well as in a MPTP mouse model of PD (Nagel et al. 2008). In addition, 
transduction of TAT-Hsp40 has also been shown to be cytoprotective against 
oxidative stress in cells (Kim et al. 2008). Finally, transduction of HSF-1(+)-TAT, 
an HSF-1 mutant fused to TAT, capable of activating HSR by itself, was 
demonstrated to induce to induce Hsp70 expression and to protect cells against 
heat stress in vitro (Hou & Zou 2009). Although further investigation is needed, 
CPPs tagging could prove a powerful tool in therapy against neurodegenerative 
diseases by allowing the efficient transduction of cytoprotective proteins and 
factors. 
5. Conclusions 
There is strong experimental support to propose the Hsp70 chaperone system 
as a key player in pathogenesis and progression of PD. This central role seems 
to be especially linked to aSyn, although alternative connections between the 
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exist. Up to this point, there is substantial evidence supporting an active role of 
Hsp70 in well-established PD-related processes. First, in the inhibition or 
modulation of aSyn aggregation pathway that results in the formation of LBs 
and the suppression of aSyn-mediated toxicity to cells that leads to 
neurodegeneration. Second, a prominent role in the control of the activity of 
the UPS machinery, the general protein degradation and disposal system in the 
cell. And third, a central role in CMA, which handles the lysosomal degradation 
of selected cytosolic proteins, including aSyn. In addition, emerging 
mechanisms for Hsp70 in relation to PD include its participation in the CSPα-
Hsc70-SGT complex in the neuron, and the increasing attention paid to the UPR 
and mitochondrial dysfunction processes in PD, both of which rely on Hsp70. 
The accumulated studies thus far suggest that Hsp70 chaperone is a highly 
versatile protein whose anti-aggregation activity seems to involve different 
interactions and the formation of transient and highly dynamic complexes with 
various aSyn species, presumably early oligomers and probably monomers, 
along the aggregation pathway. This activity can be certainly modulated by the 
presence of nucleotides and by certain co-chaperones, in particular, Hip. 
Clearly, further in vitro and in cell studies with Hsp70 and co-chaperones, to 
better understand the full molecular mechanism of mammalian Hsp70 in 
managing aSyn aggregation, are needed. 
As a biomarker of PD, Hsp70 seems not to represent a good candidate itself, 
probably due to its central role in maintaining cellular proteostasis which is 
perturbed in several amyloidoses and related diseases. However, the Hsp70 co-
chaperone Hip might represent a potentially useful biomarker for early 
diagnosis of PD, although more studies are needed in this direction. Given that 
PD is a complex disease, a ‘complex biomarker’ (i.e. composed of various 
markers) appears to be the only reliable option. Finally, the Hsp70 machinery 
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can be indirectly enhanced by HSF-1 pharmacological activation, which 
represents one of the most promising therapeutic approaches for treating this 
complex and highly debilitating disease. 
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